US20010018422A1 - Dolastatin 15 derivatives - Google Patents
Dolastatin 15 derivatives Download PDFInfo
- Publication number
- US20010018422A1 US20010018422A1 US09/756,593 US75659301A US2001018422A1 US 20010018422 A1 US20010018422 A1 US 20010018422A1 US 75659301 A US75659301 A US 75659301A US 2001018422 A1 US2001018422 A1 US 2001018422A1
- Authority
- US
- United States
- Prior art keywords
- group
- alkyl
- formula
- substituted
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1CN([RaH])C(C)(C=O)C1 Chemical compound *C1CN([RaH])C(C)(C=O)C1 0.000 description 21
- BRUFPYLQOUGUSL-UHFFFAOYSA-N C=C1C2=C(C=CC=C2)C2=C1/C=C\C=C/2.C=C1C2=CC=CC=C2CC2=C1C=CC=C2.C=C1C2=CC=CC=C2CCC2=C1C=CC=C2.C=C1C2=CC=CC=C2OC2=C1C=CC=C2.C=C1CCCC1.C=C1CCCC2=C1C=CC=C2.C=C1CCCCC1.C=C1CCNCC1.C=C1CCOCC1 Chemical compound C=C1C2=C(C=CC=C2)C2=C1/C=C\C=C/2.C=C1C2=CC=CC=C2CC2=C1C=CC=C2.C=C1C2=CC=CC=C2CCC2=C1C=CC=C2.C=C1C2=CC=CC=C2OC2=C1C=CC=C2.C=C1CCCC1.C=C1CCCC2=C1C=CC=C2.C=C1CCCCC1.C=C1CCNCC1.C=C1CCOCC1 BRUFPYLQOUGUSL-UHFFFAOYSA-N 0.000 description 2
- OKLUTIDHARRSIC-UHFFFAOYSA-N CC(C)(N)C=O Chemical compound CC(C)(N)C=O OKLUTIDHARRSIC-UHFFFAOYSA-N 0.000 description 2
- NCXUNZWLEYGQAH-UHFFFAOYSA-N CC(O)CN(C)C Chemical compound CC(O)CN(C)C NCXUNZWLEYGQAH-UHFFFAOYSA-N 0.000 description 2
- IOBXDYSETZRMKB-UHFFFAOYSA-N CC1(C)CC(C)(C)C(C)(C=O)N1[RaH] Chemical compound CC1(C)CC(C)(C)C(C)(C=O)N1[RaH] IOBXDYSETZRMKB-UHFFFAOYSA-N 0.000 description 2
- WAJYNXUEQIFBGO-UHFFFAOYSA-N CC1(C)CNC(C)(C=O)C1(C)C Chemical compound CC1(C)CNC(C)(C=O)C1(C)C WAJYNXUEQIFBGO-UHFFFAOYSA-N 0.000 description 2
- OJIGOQHXBPXSHU-UHFFFAOYSA-N CC1(C)SC(C)(C)C(C)(C=O)N1[RaH] Chemical compound CC1(C)SC(C)(C)C(C)(C=O)N1[RaH] OJIGOQHXBPXSHU-UHFFFAOYSA-N 0.000 description 2
- BXGWRQBTCNAOGM-UHFFFAOYSA-N CC1(C=O)CCCC1.CN[Re] Chemical compound CC1(C=O)CCCC1.CN[Re] BXGWRQBTCNAOGM-UHFFFAOYSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N CCC(C)C Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- XWAKKPDDQPWGAQ-UHFFFAOYSA-N CCC=CN(C)C Chemical compound CCC=CN(C)C XWAKKPDDQPWGAQ-UHFFFAOYSA-N 0.000 description 2
- PMDCZENCAXMSOU-UHFFFAOYSA-N CCNC(C)=O Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 2
- ZIBVCHCLEDSEON-UHFFFAOYSA-N CN([RaH])C(C)(C)C=O Chemical compound CN([RaH])C(C)(C)C=O ZIBVCHCLEDSEON-UHFFFAOYSA-N 0.000 description 2
- CLUCYKDATQSXLY-UHFFFAOYSA-N CN([RaH])C1(C=O)CC2=C(C=CC=C2)C1 Chemical compound CN([RaH])C1(C=O)CC2=C(C=CC=C2)C1 CLUCYKDATQSXLY-UHFFFAOYSA-N 0.000 description 2
- JPSGNSVOMBKVMW-UHFFFAOYSA-N CN1CC2=CC=CC=C2C1C=O Chemical compound CN1CC2=CC=CC=C2C1C=O JPSGNSVOMBKVMW-UHFFFAOYSA-N 0.000 description 2
- FHJGOJSYFDDBAA-UHFFFAOYSA-N COC1OC(C)C(OC)C(OC)C1OC Chemical compound COC1OC(C)C(OC)C(OC)C1OC FHJGOJSYFDDBAA-UHFFFAOYSA-N 0.000 description 2
- CTMZNQYLQVLUMT-UHFFFAOYSA-N O=CC1C2CCC(C2)N1[RaH] Chemical compound O=CC1C2CCC(C2)N1[RaH] CTMZNQYLQVLUMT-UHFFFAOYSA-N 0.000 description 2
- NIIPNAJXERMYOG-UHFFFAOYSA-N [H]N(C)N(C)C Chemical compound [H]N(C)N(C)C NIIPNAJXERMYOG-UHFFFAOYSA-N 0.000 description 2
- MDXHNHJIFOKDNC-UHFFFAOYSA-N C.C#C=N.C#C=NC(=O)C1=CC=CC=C1.C#C=NC(=O)C1=CC=CC=C1.C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].O=C(Cl)C1=CC=CC=C1.O=C(O)C1=CC=CC=C1.O=S(Cl)Cl Chemical compound C.C#C=N.C#C=NC(=O)C1=CC=CC=C1.C#C=NC(=O)C1=CC=CC=C1.C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].C[N+](=O)[O-].O=C(Cl)C1=CC=CC=C1.O=C(O)C1=CC=CC=C1.O=S(Cl)Cl MDXHNHJIFOKDNC-UHFFFAOYSA-N 0.000 description 1
- KHRIPQMMFOGLOF-UHFFFAOYSA-N C.CN(C)C Chemical compound C.CN(C)C KHRIPQMMFOGLOF-UHFFFAOYSA-N 0.000 description 1
- BGDMZUXSPMVPGF-UHFFFAOYSA-N C.CN([RaH])C1(C=O)CCC2=C1C=CC=C2 Chemical compound C.CN([RaH])C1(C=O)CCC2=C1C=CC=C2 BGDMZUXSPMVPGF-UHFFFAOYSA-N 0.000 description 1
- ITLZZPNJGAKDET-UHFFFAOYSA-N C.CON(C)C(=O)C1=CC=CC=C1N.CON(C)C(=O)C1=CC=CC=C1NC(=O)OC(C)(C)C.Cl Chemical compound C.CON(C)C(=O)C1=CC=CC=C1N.CON(C)C(=O)C1=CC=CC=C1NC(=O)OC(C)(C)C.Cl ITLZZPNJGAKDET-UHFFFAOYSA-N 0.000 description 1
- MNAICHNLMACOFK-UHFFFAOYSA-N CC(C(C(C1ON)ON)ON)OC1ON Chemical compound CC(C(C(C1ON)ON)ON)OC1ON MNAICHNLMACOFK-UHFFFAOYSA-N 0.000 description 1
- QLOQZGCJXPOXET-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1=CC=CC=C1C(=O)O.CON(C)C(=O)C1=CC=CC=C1NC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NC1=CC=CC=C1C(=O)O.CON(C)C(=O)C1=CC=CC=C1NC(=O)OC(C)(C)C QLOQZGCJXPOXET-UHFFFAOYSA-N 0.000 description 1
- QMMOXUPEWRXHJS-UHFFFAOYSA-N CC=CCC Chemical compound CC=CCC QMMOXUPEWRXHJS-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N CCC Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N CCCC Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N CN(C)C Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- HCYUOPTYSPYJCC-GXPVXACCSA-N CN(C)C(=O)C1=C(N)C=CC=C1.[H]N(C(=O)[C@H](C(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1=C(C(=O)N(C)C)C=CC=C1)C(C)C)C(C)C.[H]N(C(=O)[C@H](C(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C Chemical compound CN(C)C(=O)C1=C(N)C=CC=C1.[H]N(C(=O)[C@H](C(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1=C(C(=O)N(C)C)C=CC=C1)C(C)C)C(C)C.[H]N(C(=O)[C@H](C(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C HCYUOPTYSPYJCC-GXPVXACCSA-N 0.000 description 1
- XNDHAQYFGQZWFP-UHFFFAOYSA-N CN(C)C(=O)C1=CC=CC=C1N.CN(C)C(=O)C1=CC=CC=C1[N+](=O)[O-] Chemical compound CN(C)C(=O)C1=CC=CC=C1N.CN(C)C(=O)C1=CC=CC=C1[N+](=O)[O-] XNDHAQYFGQZWFP-UHFFFAOYSA-N 0.000 description 1
- FXCVLPILDIBLRM-UHFFFAOYSA-N CN(C)C(=O)C1=CC=CC=C1[N+](=O)[O-].O=C(O)C1=CC=CC=C1[N+](=O)[O-] Chemical compound CN(C)C(=O)C1=CC=CC=C1[N+](=O)[O-].O=C(O)C1=CC=CC=C1[N+](=O)[O-] FXCVLPILDIBLRM-UHFFFAOYSA-N 0.000 description 1
- WMFFCWYIWLXMLT-UHFFFAOYSA-N CN([RaH])C1(C=O)CCC1 Chemical compound CN([RaH])C1(C=O)CCC1 WMFFCWYIWLXMLT-UHFFFAOYSA-N 0.000 description 1
- ZYKFANXTSSLFOF-UHFFFAOYSA-N CN([RaH])C1(C=O)CCC2=C1C=CC=C2 Chemical compound CN([RaH])C1(C=O)CCC2=C1C=CC=C2 ZYKFANXTSSLFOF-UHFFFAOYSA-N 0.000 description 1
- VMQLNNMPLRNNGE-FFVYQDKPSA-N Cl.[H][C@]1(C)CCC[C@@]1([H])C.[H][C@]1(C)CCC[C@@]1([H])NC Chemical compound Cl.[H][C@]1(C)CCC[C@@]1([H])C.[H][C@]1(C)CCC[C@@]1([H])NC VMQLNNMPLRNNGE-FFVYQDKPSA-N 0.000 description 1
- DTENSCWZNHGNKW-OVVSMXPMSA-N N.[H]C1(CON)CCCC1([H])C(=O)O.[H][C@]12CCC[C@@]1([H])C(=O)OC2=O Chemical compound N.[H]C1(CON)CCCC1([H])C(=O)O.[H][C@]12CCC[C@@]1([H])C(=O)OC2=O DTENSCWZNHGNKW-OVVSMXPMSA-N 0.000 description 1
- FFCSNNIHTZZCHA-LBWYZESNSA-N O=C(O)C1CCCC1COO.O=[Ac][Ac].[H][C@]12CCC[C@@]1([H])C(=O)OC2=O Chemical compound O=C(O)C1CCCC1COO.O=[Ac][Ac].[H][C@]12CCC[C@@]1([H])C(=O)OC2=O FFCSNNIHTZZCHA-LBWYZESNSA-N 0.000 description 1
- LWQZKOLFOUYADS-ZSMNRQTQSA-N [H]C1(C)CCCC1([H])N.[H]N(C(=O)[C@H](C(C)C)N(C)C)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1CCCC1/C(O)=N(/[H])CC1=CC=CC=C1)C(C)C)C(C)C.[H]N(C(=O)[C@H](C(C)C)N(C)C)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C Chemical compound [H]C1(C)CCCC1([H])N.[H]N(C(=O)[C@H](C(C)C)N(C)C)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1CCCC1/C(O)=N(/[H])CC1=CC=CC=C1)C(C)C)C(C)C.[H]N(C(=O)[C@H](C(C)C)N(C)C)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C LWQZKOLFOUYADS-ZSMNRQTQSA-N 0.000 description 1
- WOQUVZDPZRPDIP-UHFFFAOYSA-N [H]C1(CON)CCCC1([H])C(=O)O.[H]C1(N)CCCC1([H])C(=O)O Chemical compound [H]C1(CON)CCCC1([H])C(=O)O.[H]C1(N)CCCC1([H])C(=O)O WOQUVZDPZRPDIP-UHFFFAOYSA-N 0.000 description 1
- LFFCXOCGHLOIJF-UHFFFAOYSA-N [H]C1(N)CCCC1([H])C(=O)O.[H]C1(NC)CCCC1([H])C(=O)NBr Chemical compound [H]C1(N)CCCC1([H])C(=O)O.[H]C1(NC)CCCC1([H])C(=O)NBr LFFCXOCGHLOIJF-UHFFFAOYSA-N 0.000 description 1
- OTBRWEQHKJPXDG-LCCVNLTRSA-N [H]N(C(=O)[C@H](C(C)C)N(C)C)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1=C(C(=O)N(C)C)C=CC=C1)C(C)C)C(C)C.[H]N(C(=O)[C@H](C(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1=C(C(=O)N(C)C)C=CC=C1)C(C)C)C(C)C Chemical compound [H]N(C(=O)[C@H](C(C)C)N(C)C)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1=C(C(=O)N(C)C)C=CC=C1)C(C)C)C(C)C.[H]N(C(=O)[C@H](C(C)C)N([H])C(=O)OCC1=CC=CC=C1)C(C(=O)N(C)[C@H](C(=O)N1CCC[C@H]1C(=O)NC1=C(C(=O)N(C)C)C=CC=C1)C(C)C)C(C)C OTBRWEQHKJPXDG-LCCVNLTRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Compounds of the present invention include cell growth inhibitors which are peptides of Formula I
- A, D, and E are ⁇ -amino acid residues
- B is an ⁇ -amino acid residue
- F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue
- G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a ⁇ -hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone.
- compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.
- An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
- the present invention provides compounds with antineoplastic activity as well as increased metabolic stability relative to Dolastatin 15.
- the present invention relates to peptides having antineoplastic activity. It also includes pharmaceutical compositions comprising these compounds and methods for treating cancer in a mammal, including a human, by administration of these compositions to the mammal.
- the invention is based on the discovery that Dolastatin 15, a peptide isolated from the sea hare Dolabella auricularia, is a potent inhibitor of cell growth. This compound, however, is present in trace quantities in the sea hare, and is, thus, difficult to isolate and expensive to synthesize and suffers from poor aqueous solubility. As shown herein, however, Dolastatin 15 can serve as a starting point for the development of compounds which overcome these disadvantages while retaining antineoplastic activity or exhibiting greater antineoplastic activity than the natural product.
- Dolastatin 15 provides compounds with a surprisingly improved therapeutic potential for the treatment of neoplastic diseases as compared to Dolastatins-10 and -15.
- the Dolastatin-15 derivatives exhibit activity even in multiple drug-resistant tumor systems and an unpredicted high solubility in aqueous solvents.
- the compounds of the present invention can be conveniently synthesized, as described below in detail.
- the term “monovalent radical” is intended to mean an electrically neutral molecular fragment capable of forming one covalent bond with a second neutral molecular fragment.
- Monovalent radicals include the hydrogen atom, alkyl groups, such as methyl, ethyl and propyl groups, halogen atoms, such as fluorine, chlorine and bromine atoms, aryl groups, such as phenyl and naphthyl groups, and alkoxy groups, such as methoxy and ethoxy groups.
- Two monovalent radicals on adjacent sigma-bonded atoms can also together form a pi bond between the adjacent atoms.
- Two monovalent radicals may also be linked together, for example, by a polymethylene unit, to form a cyclic structure.
- R and R′ are each a monovalent radical, and can, together with the nitrogen atom, form a heterocyclic ring.
- two monovalent radicals bonded to the same atom can also together form a divalent radical, such as an alkylidene group, for example, a propylidene group, or an oxygen atom.
- the term “residue” refers to the molecular fragment remaining after the removal of the elements of a water molecule (one oxygen atom, two hydrogen atoms) from a molecule, such as an amino acid or a hydroxy acid.
- normal alkyl refers to an unbranched, or straight chain, alkyl group, for example, normal propyl (n-propyl, —CH 2 CH 2 CH 3 ).
- A, D and E are ⁇ -amino acid residues;
- B is an ⁇ -amino acid residue or an ⁇ -hydroxy acid residue;
- F is an aminobenzoic acid residue, or an aminocycloalkanecarboxylic acid residue, such as an aminocyclobutanecarboxylic acid residue, an aminocylopentanecarboxylic acid residue, or an aminocyclohexanecarboxylic acid residue;
- G is a monovalent radical.
- the peptides of Formula I are generally composed of L-amino acids but they can contain one or more D-amino acids. They can also be present as salts with physiologically-compatible acids, including hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.
- physiologically-compatible acids including hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic
- A is an amino acid derivative of Formula II a ,
- n a is an integer, preferably 0, 1, 2, or 3.
- R a is a monovalent radical, such as a hydrogen atom or a C 1 -C 3 -alkyl group which can be normal, branched or cyclic and can be substituted by one or more, preferably 1 to about 3, fluorine atoms; suitable examples include methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-2-fluoroethyl, 1-fluoromethyl-2-fluoroethyl or cyclopropyl; methyl, ethyl or isopropyl are preferred;
- R 1 a is a monovalent radical, such as a hydrogen atom or a methyl, ethyl, propyl or phenyl group.
- the phenyl group can be substituted; suitable substituents include one or more halogen atoms, with fluorine, chlorine and bromine being preferred, C 1 -C 4 -alkyl groups, methoxy, ethoxy, trifluoromethyl or nitro groups.
- R 2 a , R 3 a , R 4 a and R 5 a are each, independently, a monovalent radical, such as a hydrogen atom or a methyl group.
- R a and R 1 a together can also form a propylene bridge.
- A is an amino acid derivative of Formula III a .
- R 1 a is a monovalent radical, for example, a hydrogen atom or a lower alkyl group, preferably a methyl, ethyl or propyl group.
- R 6 a is a monovalent radical, such as a hydrogen atom, a normal or branched C 1 -C 8 -alkyl group, which can he substituted by one or more halogen, preferably fluorine, atoms, or a C 3 -C 8 -cycloalkyl or C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group, a C 1 -C 4 -oxoalkyl group such as a methoxymethyl, 1-methoxyethyl or 1,1-dimethylhydroxymethyl group, a C 2 -C 5 alkenyl group, such as a vinyl or 1-methylvinyl group, or a substituted or unsubstituted phenyl group.
- halogen preferably fluorine, atoms
- Suitable phenyl substituents include one or more halogen atoms, preferably fluorine, chlorine or bromine atoms, and alkyl, methoxy, ethoxy, trifluoromethyl, or nitro groups.
- R 7 a is a monovalent radical, preferably a methyl group or an ethyl group.
- A is an amino acid residue of Formula IV a ,
- m a is an integer, preferably 1 or 2.
- R a and R 7 a have the meanings stated for R a and R 7 a in Formula III a .
- A is an amino acid residue of Formula V a .
- R a and R 7 a have the meanings stated for R a and R 7 a in Formula III a .
- A is a substituted proline derivative of Formula VI a ,
- R a and R 1 a have the meanings stated for R a and R 1 a in Formula II a
- X a is a monovalent radical, preferably a hydroxyl, methoxy or ethoxy group or a fluorine atom.
- A is a thiaprolyl derivative of Formula VII a ,
- R a , R 1 a , R 2 a , R 3 a , R 4 a and R 5 a have the meanings stated for these variables in Formula II a .
- A is a 1,3-dihydroisoindole derivative of Formula VIII a ,
- R a has the meaning stated for R a in Formula II a .
- A is a 2-azabicyclo[2.2.1]heptane-3-carboxylic acid derivative of Formula IX a ,
- Z a is a single or double bond and R a has the meaning stated for this variable in Formula II a .
- the 3-carbonyl substituent can have either the exo or endo orientation.
- B is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2-tert-butylglycyl or 2-ethylglycyl residue.
- B can also be a carboxylic acid derivative of Formula II b ,
- R 1 b and R 2 b are each a monovalent radical.
- R 1 b is, preferably, a hydrogen atom and R 2 b is, for example, a cyclopropyl group, a normal or branched butyl, preferably tertiary-butyl, group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group.
- R 1 b and R 2 b together can be an isopropylidene group.
- D is an N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkyl-2-tert-butylglycyl, N-alkyl-norleucyl, N-alkyl-isoleucyl, N-alkyl-allo-isoleucyl or N-alkyl-norvalyl residue, where the alkyl group is preferably methyl or ethyl.
- D is an ⁇ -amino carboxylic acid derivative of Formula II d ,
- R d has the meaning stated for R a in Formula III a
- R 1 d is a monovalent radical, preferably a hydrogen atom
- R 2 is a monovalent radical such as a cyclopropyl group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group.
- R 1 d and R 2 d together can form an isopropylidene group.
- D can be a proline derivative of Formula III d ,
- n d is an integer, for example, 1 or 2.
- R 3 d has the meaning stated for R 1 a in Formula III a .
- X d is a monovalent radical, preferably a hydrogen atom, and, in the case where n d equals 1, can also be a hydroxyl, methoxy or ethoxy group or a fluorine atom.
- E is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl or hydroxyprolyl residue, or a cyclic ⁇ -amino carboxylic acid residue of Formula II e ,
- n e is an integer, preferably 0, 1 or 2.
- R 1 e has the meaning stated for R 1 a in Formula III a .
- R 2 e and R 3 e are each a monovalent radical, and can be, independently, a hydrogen atom or a methyl group.
- R 4 e is a monovalent radical, preferably a hydrogen atom, a hydroxyl, methoxy or ethoxy group or a fluorine atom.
- R 5 e is a monovalent radical, preferably a hydrogen atom.
- R 3 e and R 4 e together can form a double bond or R 4 e and R 5 e can together be a double-bonded oxygen radical.
- R 1 e and R 2 e can together form a double bond.
- E is a 2- or 3-amino-cyclopentanecarboxylic acid residue of Formula III e ,
- R e is a monovalent radical, such as a methyl or ethyl group and R 1 e has the meaning stated for R 1 a in Formula III a .
- F is an aminobenzoyl derivative of Formula II f ,
- R f is a hydrogen atom or an alkyl group, preferably a methyl, ethyl or propyl group.
- the carbonyl group can be in position 1 (ortho), 2 (meta), or 3 (para) of the phenyl ring relative to the nitrogen atom.
- R 1 f and R 2 f are each, independently, a hydrogen atom; a halogen atom, for example, a fluorine, chlorine, bromine, or iodine atom; a C 1 -C 4 -alkyl group; a methoxy, ethoxy, trifluoromethyl, nitro, cyano, amino or dimethyalmino group.
- R 1 f and R 2 f can together form a dioxymethylene group.
- F is an aminocycloalkanecarboxylic acid residue of Formula III f ,
- R f is a monovalent radical, such as a hydrogen atom or a lower alkyl group, preferably a methyl, ethyl or propyl group.
- a f is an integer, for example, 0, 1 or 2.
- the carbonyl group is in position 2 or position 3 of the cycloalkane ring relative to the nitrogen atom at position 1.
- the stereogenic centers can be, independently of each other, R or S.
- the combinations R1,S2 and S1,R2 would be referred to as cis-pentacin derivatives, while the combinations R1,R2 and S1,S2 are trans-pentacin derivatives.
- G is an amino or substituted amino group of Formula II g ,
- R 1 l is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated C 1 -C 18 -alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryl-C 1 -C 6 -alkoxy group, or a substituted or unsubstituted aryloxy-C 1 -C 6 -alkoxy or heteroaryl-C 1 -C 6 -alkoxy group.
- the aryl group is preferably a phenyl or naphthyl group.
- the heteroaryl group is a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system, such as, for example, imidazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, pyrazolyl, thiophenyl, furanyl, pyrrolyl, 1,2,4- or 1,2,3-triazolyl, pyrazinyl, indolyl, benzofuranyl, benzothiophenyl, isoindolyl, indazolyl, quinolinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzopyranyl, benzothiazolyl, oxadiazolyl, thiadiazolyl or pyridinyl group.
- Suitable aryl or heteroaryl substituents include one or more halogen atoms, preferably fluorine, bromine or chlorine; C 1 -C 4 -alkyl groups; methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group or a nitro group.
- R 2 l is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated C 1 -C 18 -alkyl group, a C 3 -C 10 -cycloalkyl group, a substituted or unsubstituted aryl group, where aryl is preferably phenyl or naphthyl.
- Suitable aryl substituents include one or more halogen, preferably fluorine, chlorine or bromine, atoms, C 1 -C 4 -alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group, nitro or cyano groups, a C 1 -C 7 -alkoxycarbonyl group, a C 1 -C 7 -alkylsulfonyl group, an amino or C 1 -C 7 -dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle, or an unsubstituted or substituted heteroaryl group.
- the heteroaryl group can be a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system which can be fused to a benzene ring, such as, for example, imidazolyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, oxazolyl, pyrazolyl, 1,2,4- or 1,2,3-triazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzopyranyl, indolyl, isoindolyl, indazolyl or quinolinyl group, with preferred substituents being C 1 -C 6 -alkyl groups, or hydroxyl or
- R 2 l can additionally be of Formula II l ,
- a l is an integer, preferably 0, 1, 2, 3, 4, or 5.
- R 3 l is a monovalent radical, such as a lower alkyl group, for example, a methyl, ethyl, propyl or isopropyl group.
- R 4 l is a saturated or partially unsaturated carbocyclic group containing from 3 to about 10 carbon atoms, or a substituted or unsubstituted aryl or heteroaryl group, where the preferred aryl and heteroaryl groups and suitable substituents are as stated for R 2 l in Formula II g .
- R 2 l can also be a monovalent radical of Formula III l ,
- W l is an oxygen or sulfur atom or an N—R 6 l group.
- R 5 l is a monovalent radical, such as a hydrogen atom, a C 1 -C 4 -alkyl or C 3 -C 7 -cycloalkyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R 2 l from Formula II g .
- R 6 l is a monovalent radical, preferably a hydrogen atom, a C 1 -C 4 -alkyl group or a C 3 -C 7 -cycloalkyl group, a C 1 -C 18 -alkanoyl group, a benzoyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R 2 l in Formula II g ,
- R 2 l can alternately be a substituent of Formula IV l ,
- b l is an integer, preferably 2, 3 or 4.
- Z l is a monovalent radical, such as a formyl, aminocarbonyl or hydrazinocarbonyl group, or a cyclic or acyclic acetal or thioacetal group.
- R 2 l can also be a substituent of Formula V l ,
- R 7 l is a monovalent radical, such as a glycol oligomer of the formula
- d l is an integer, preferably in the range from about 2 to about 4 or from about 40 to about 90.
- R 2 l can further be a carbohydrate of Formula VI l ,
- R 8 l is a monovalent radical, such as a hydrogen atom, a C 1 -C 4 -alkanoyl or alkyl group, a benzoyl group or a benzyl group.
- G is an ⁇ -hydroxy amine of Formula III g ,
- R 9 l is a monovalent radical such as a hydrogen atom, a C 1 -C 6 -alkyl group or a substituted or unsubstituted aryl group, with aryl and its preferred substituents having the meaning stated for R 2 l in Formula II g .
- R 10 l is a monovalent radical, preferably a hydrogen atom, alkyl, for example, methyl, or a phenyl group.
- Another subclass of compounds of this invention includes peptides of Formula I wherein G is a hydrazido group of Formula IV g ,
- R 11 l and R 12 l are each, independently, a monovalent radical such as a hydrogen atom, a normal or branched C 1 -C 8 -alkyl group, a C 3 -C 8 - cycloalkyl group, a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group or a substituted or unsubstituted aryl, heteroaryl, aryl-C 1 -C 4 -alkyl or heteroaryl-C 1 -C 4 -alkyl group, where aryl, heteroaryl and their preferred substituents can be selected from among the options listed for R 2 1 in Formula II g .
- R 11 l and R 12 l can also together form a propylene or butylene bridge.
- G is a monovalent radical of the formula —O—R 13 l or —S—R 13 l , where R 13 l is a monovalent radical, such as a C 3 -C 10 -cycloalkyl group, a normal or branched C 2 -C 16 -alkenylmethyl group or a C 1 -C 16 -alkyl group which can be substituted by from 1 to about 5 halogen, preferably fluorine, atoms.
- R 13 l is a monovalent radical, such as a C 3 -C 10 -cycloalkyl group, a normal or branched C 2 -C 16 -alkenylmethyl group or a C 1 -C 16 -alkyl group which can be substituted by from 1 to about 5 halogen, preferably fluorine, atoms.
- R 13 l can also be the radical —(CH 2 ) el —R 14 l where e l is an integer, preferably 1, 2 or 3.
- R 14 l is a monovalent radical, preferably a saturated or partially unsaturated C 3 -C 10 -carbocycle.
- R 13 l can further be the radical
- f l is an integer, preferably 1, 2, 3 or 4.
- R 13 l can also be the radical
- g l is an integer, preferably from about 2 to about 4, or from about 40 to about 90.
- R 13 l can also be the radical
- aryl and heteroaryl can also be substituted and, along with their preferred substituents, can be selected from the group listed for R 2 l in Formula II g .
- h l is an integer, preferably 0, 1, 2 or 3.
- R 13 l can further be the radical
- Another subclass of compounds of this invention includes peptides of Formula I in which G is an aminoxy group of the formula
- R 15 l and R 16 l are each a monovalent radical, and can independently be a hydrogen atom, a normal or branched C 1 -C 8 -alkyl group, which can be substituted by halogen, preferably fluorine, atoms, a C 3 -C 8 -cycloalkyl group, a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group, a substituted or unsubstituted aryl or heteroaryl group or a substituted or unsubstituted aryl-C 1 -C 4 -alkyl group.
- Aryl and heteroaryl groups and the preferred substituents thereof can be selected from the options listed for R 2 l in Formula II g . Additionally, R 15 l and R 16 l can together form a 5-, 6- or 7-membered heterocycle.
- Another subclass of compounds of this invention includes peptides of Formula I wherein G is an oximato group of the formula
- R 15 l and R 16 l are selected from among the options listed above and, additionally, can together form a cyclic system comprising, preferably, from about 3 to about 7 ring atoms.
- This cyclic system can additionally be fused to one or more aromatic rings. Particularly preferred cyclic systems are shown below.
- a further subclass of compounds of this invention includes peptides of Formula I wherein G is a hydrogen atom, a normal or branched C 1 -C 8 -alkyl group, which can be substituted by up to six halogen, preferably fluorine, atoms, a C 3 -C 8 -cycloalkyl group or a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group.
- G can also be an arylalkyl, heteroarylalkyl, aryl or heteroaryl group of Formula V g ,
- R 17 l is a substituted or unsubstituted aryl or heteroaryl group.
- Preferred aryl groups include phenyl and naphthyl groups.
- Suitable aryl substituents include halogen, preferably fluorine, bromine or chlorine, atoms, C 1 -C 4 -alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group, a nitro or cyano group, a C 1 -C 7 -alkoxycarbonyl group, a C 1 -C 7 - alkylsulfonyl group, an amino group or a C 1 -C 6 -dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
- R 17 l can also be a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system which can be fused to a benzene ring.
- Suitable heteroaryl groups include imidazolyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, oxazolyl, pyrazolyl, 1,2,4- or 1,2,3-triazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzopyranyl, indolyl, isoindolyl, indazolyl and quinolinyl groups.
- Preferred heteroaryl substituents are C 1 -C 6 -alkyl
- Another subclass of compounds of this invention includes compounds of Formula I wherein G is a monovalent radical of Formula VI g ,
- R 18 l is a monovalent radical, such as a hydrogen atom, a straight-chain or branched C 1 -C 8 -alkyl group which can be substituted by halogen, preferably fluorine, atoms, especially a CF 2 -moiety, a C 3 -C 8 -cycloalkyl group, a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl, group.
- Suitable aryl substituents are halogen, preferably fluorine, bromine or chlorine, atoms, C 1 -C 4 -alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C 1 -C 7 -alkoxycarbonyl moiety, a C 1 -C 7 -alkylsulfonyl moiety, an amino group or a C 1 -C 6 -dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
- G can also be a monovalent radical of Formula VII g
- R 19 l and R 20 l are each, independently, a monovalent radical, such as a hydrogen atom, a straight-chain or branched C 1 -C 8 -alkyl group, which can further be substituted by halogen, preferably fluorine, atoms, especially a CF 2 -moiety, a C 3 -C 8 -cycloalkyl group, a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl group.
- Suitable aryl substituents include one or more halogen, referably fluorine, bromine or chlorine, atoms, C 1 -C 4 -alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C 1 -C 7 -alkoxycarbonyl moiety, a C 1 -C 7 -alkylsulfonyl group, an amino group or a C 1 -C 6 -dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
- N(R 19 l )R 20 l can additionally form a ring system of the formula N(CH 2 ) fg , where f g is an integer selected from among 4, 5 or 6.
- Another subclass of compounds of this invention includes peptides of Formula I, wherein G is a monovalent radical of Formula VIII g ,
- R 21 l is a monovalent radical, preferably a methyl group, a trifluoromethyl group, an ethyl group or a phenyl group.
- G can also be an alkyl- or arylcarbonylalkyl group of Formula IX g ,
- R 22 l is a monovalent radical, such as a hydrogen atom, a straight-chain or branched C 1 -C 8 -alkyl group which can be substituted by up to six halogen, preferably fluorine, atoms, especially a CF 2 -moiety, a C 3 -C 8 -cycloalkyl group, a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl, group.
- halogen preferably fluorine, atoms, especially a CF 2 -moiety
- C 3 -C 8 -cycloalkyl group a C 3 -C 8 -cycloalkyl-C 1 -C 4 -alkyl group
- a substituted or unsubstituted aryl preferably phenyl or naphthyl, group.
- Suitable aryl substituents are halogen, preferably fluorine, bromine or chlorine, atoms, C 1 -C 4 -alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C 1 -C 7 -alkoxycarbonyl moiety, a C 1 -C 7 -alkylsulfonyl moiety, an amino group or a C 1 -C 6 -dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
- the compounds of the present invention can be prepared by known methods of peptide synthesis.
- the peptides can be assembled sequentially from individual amino acids or by linking suitable small peptide fragments.
- sequential assemblage the peptide chain is extended stepwise, starting at the C-terminus, by one amino acid per step.
- fragment coupling fragments of different lengths can be linked together, and the fragments in turn can be obtained by sequential assembly from amino acids or by fragment coupling of still shorter peptides.
- Preferred methods include the azide method, the symmetric and mixed anhydride method, the use of in situ generated or preformed active esters, the use of urethane protected N-carboxy anhydrides of amino acids and the formation of the amide linkage using coupling reagents, such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloyl chloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propane-phosphonic anhydride (PPA), N,N-bis(2-oxo-oxazolidinyl)imido-phosphoryl chloride (BOP-Cl), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop
- the coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.
- DMAP N,N-dimethyl-4-aminopyridine
- HOBt N-hydroxy-benzotriazole
- HOOBt N-hydroxybenzotriazine
- HOSu N-hydroxysuccinimide
- 2-hydroxypyridine 2-hydroxypyridine
- the units employed for assembling the peptide chain can be reacted in solution, in suspension or by a method similar to that described by Merrifield ( J. Am. Chem. Soc. 85: 2149 (1963)). Particularly preferred methods are those in which peptides are assembled sequentially or by fragment coupling using the Z, Boc or Fmoc protective group technique, with one of the reactants in the said Merrifield technique being bonded to an insoluble polymeric support (also called resin hereinafter). This typically entails assembling the peptide sequentially on the polymeric support using the Boc or Fmoc protective group technique, with the growing peptide chain covalently bonded at the C terminus to the insoluble resin particles. This procedure allows the removal of reagents and byproducts by filtration, eliminating the need to recrystallize intermediates.
- the protected amino acids can be linked to any suitable polymer, which must be insoluble in the solvents used and have a stable physical form which permits filtration.
- the polymer must contain a functional group to which the first protected amino acid can be covalently attached.
- a wide variety of polymers are suitable for this purpose, including cellulose, polyvinyl alcohol, polymethacrylate, sulfonated polystyrene, chloromethylated styrene/divinylbenzene copolymer (Merrifield resin), 4-methylbenzhydrylamine resin (MBHA-resin), phenylacetamidomethyl resin (Pam-resin), p-benzyloxy-benzyl-alcohol-resin, benzhydryl-amine-resin (BHA-resin), 4-(hydroxymethyl)-benzoyl-oxymethyl-resin, the resin of Breipohl et al.
- Solvents suitable for peptide synthesis include any solvent which is inert under the reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of these solvents.
- solvents suitable for peptide synthesis include any solvent which is inert under the reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of these solvents.
- DMF N,N-dimethylformamide
- DMSO dimethyl sulfoxide
- NMP N-methyl-2
- Peptide synthesis on the polymeric support can be carried out in a suitable inert organic solvent in which the amino acid derivatives starting materials are soluble.
- preferred solvents additionally have resin-swelling properties and include DMF, DCM, NMP, acetonitrile, DMSO, and mixtures of these solvents.
- the peptide is removed from the polymeric support. The conditions under which this cleavage is accomplished for various resin types are disclosed in the literature.
- the cleavage reactions most commonly used are acid- or palladium-catalyzed, the former being conducted in, for example, liquid anhydrous hydrogen fluoride, anhydrous trifluoromethanesulfonic acid, dilute or concentrated trifluoroacetic acid, and acetic acid/dichloromethane/trifluoroethanol mixtures.
- the latter can be carried out in THF or THF-DCM-mixtures in the presence of a weak base such as morpholine. Certain protecting groups are also cleaved off under these conditions.
- Partial deprotection of the peptide may also be necessary prior to certain derivatization reactions.
- peptides dialkylated at the N-terminus can be prepared either by coupling the appropriate N,N-di-alkylamino acid to the peptide in solution or on the polymeric support or by reductive alkylation of the resin-bound peptide in DMF/1% acetic acid with NaCNBH 3 and the appropriate aldehyde.
- the N-terminal protected tetrapeptide A′-B-D-E-OH is coupled with an amino-derivative F-G to give an intermediate compound A′-B-D-E-F-G using the methods for peptide coupling as described above. Then, the N-protecting group is removed by conventional methods as described above. The groups R A and R 7 A can then be attached to the amino terminus via reductive alkylation as described above.
- nitrophenyl ketones are then reduced to the corresponding amino-phenyl-ketones either by hydrogenation in presence of a palladium catalyst, such as palladium on carbon, or by metal salts in presence of acids such as the combination of tin(II)chloride and hydrochloric acid (Nunn et al., J. Chem. Soc. 1952: 583-588).
- a palladium catalyst such as palladium on carbon
- metal salts in presence of acids such as the combination of tin(II)chloride and hydrochloric acid
- a more direct route is the reaction of nitrobenzoyl chlorides with an organometallic reagent such as a lithium or Grignard reagent (Fürstner et al., Tetrahedron 51, 773-786 (1995)).
- organometallic reagent such as a lithium or Grignard reagent
- 2-Amino-phenyl ketones can be obtained by reaction of the corresponding 2-fluorophenyl-ketone with sodium azide in a polar solvent, such as N,N-dimethylformamide, and subsequent reduction of the intermediate benzisoxazole (see scheme III.3).
- a polar solvent such as N,N-dimethylformamide
- 2-aminophenyl-(4-pyridazinyl)-ketone has been described by N. Haider et al. ( Arch. Pharm. 325: 119-122 (1992)).
- nitrobenzoic acids or substituted nitrobenzoic acids are coupled with primary or secondary amines (HNR 1 R 2 ) by using coupling reagents.
- Preferred method is the use of coupling reagents such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloylchloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propane-phosphonic anhydride (PPA), N,N-bis(2-oxo-3oxazolidinyl)-imidophosphoryl chloride (BOP-Cl), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (DCC), diisopropylcarbodiimide (
- the coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), azabenzotriazole, N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.
- DMAP N,N-dimethyl-4-aminopyridine
- HOBt N-hydroxy-benzotriazole
- HOOBt N-hydroxybenzotriazine
- azabenzotriazole N-hydroxysuccinimide
- 2-hydroxypyridine 2-hydroxypyridine
- the corresponding nitro-benzoyl chloride can be used. These are either commercially available or could be synthesized from the corresponding acids with thionyl chloride.
- the amines react with the nitrobenzoylchlorides in the presence of a base such as pyridine, which can also be used as the solvent (N. S. Cho et al., J. Heterocycl. Chem. 33, 1201-1206 (1996)).
- the nitro-benzamides are then reduced to the corresponding amino-benzamides by reducing agents such as metal salts in presence of hydrochloride acids or by metal-catalysed hydrogenation using palladium on a solid such as palladium on charcoal as catalyst. This route is described in Example 1.
- Another method involves transforming the amine to the trifluoroacetamide by treatment with trifluoroacetic anhydride.
- the amide is deprotonated with a base such as sodium hydride or potassium t-butanolate and then treated with the corresponding alkyl halide such as methyl iodide, ethyl iodide or isopropyl iodide.
- the trifluoroacetamide is easily cleaved in basic alcoholic solution such as potassium carbonate in methanol.
- the starting materials for the synthesis of amino-benzamides are the N-protected aminobenzoic acids. Different protecting groups for the nitrogen are compatible such as the above mentioned Z-, Boc- or Fmoc-protecting groups.
- the N-protected amino-benzoic acids are coupled with amines as described above for the nitro-benzoic acids using the above mentioned coupling conditions. This route is exemplified in Example 2.
- Another route to enantiomerically pure cis-(1R, 2S)-2-amino-cyclopentylcarboxylic acid is the addition of chiral lithium (S)-(-methylbenzyl)benzylamide to t-butyl-1-cyclopentene-1-carboxylate with subsequent removal of the benzyl groups by hydogenation and removal of the t-butyl group by acid treatment (Davies et al., Synlett 1993, p. 461).
- the corresponding trans-epimer could be obtained by isomerisation with a base such as potassium t-butoxide.
- Amides of Boc-protected 2-aminocyclopentylcarboxylic acid can be obtained by coupling the acid with the corresponding amine using the standard procedures as described above for the coupling of nitrobenzoic acid with amines or as described in D. Nöteberg et al., Tetrahedron 53: 7975 (1997).
- Deprotection of the amine function can be achieved by using Lewis acids, for example, a mineral acid such as hydrochloric acid in ether or dioxane or an organic acid, such as trifluoroacetic acid in methylene chloride.
- the present invention comprises a method for partially or totally inhibiting formation of, or otherwise treating (e.g., reversing or inhibiting the further development of) solid tumors (e.g., tumors of the lung, breast, colon, prostate, bladder, rectum, or endometrial tumors) or hematological malignancies (e.g., leukemias, lymphomas) in a mammal, for example, a human, by administering to the mammal a therapeutically effective amount of a compound or a combination of compounds of Formula I.
- the agent may be administered alone or in a pharmaceutical composition comprising the agent and an acceptable carrier or diluent.
- Administration may be by any of the means which are conventional for pharmaceutical, preferably oncological, agents, including oral and parenteral means such as subcutaneously, intravenously, intramuscularly and intraperitoneally, nasally or rectally.
- the compounds may be administered alone or in the form of pharmaceutical compositions containing a compound of Formula I together with a pharmaceutically accepted carrier appropriate for the desired route of administration.
- Such pharmaceutical compositions may be combination products, i.e., they may also contain other therapeutically active ingredients.
- the dosage to be administered to the mammal will contain a therapeutically effective amount of a compound described herein.
- therapeutically effective amount is an amount sufficient to inhibit (partially or totally) formation of a tumor or a hematological malignancy or to reverse development of a solid tumor or other malignancy or prevent or reduce its further progression.
- the dosage is determined empirically, using known methods, and will depend upon factors such as the biological activity of the particular compound employed; the means of administration; the age, health and body weight of the recipient; the nature and extent of the symptoms; the frequency of treatment; the administration of other therapies; and the effect desired.
- a typical daily dose will be from about 5 to about 250 milligrams per kilogram of body weight by oral administration and from about 1 to about 100 milligrams per kilogram of body weight by parenteral administration.
- the compounds of the present invention can be administered in conventional solid or liquid pharmaceutical administration forms, for example, uncoated or (film-)coated tablets, capsules, powders, granules, suppositories or solutions. These are produced in a conventional manner.
- the active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, sustained release compositions, antioxidants and/or propellant gases (cf. H. Sücker et al.: Pharmazeutician Technologie , Thieme-Verlag, Stuttgart, 1978).
- the administration forms obtained in this way typically contain from about 1 to about 90% by weight of the active substance.
- the compounds of the present invention are synthesized by classical solution synthesis using standard Z- and Boc-methodology as discussed above or by standard methods of solid-phase synthesis on a model 431A synthesizer supplied by APPLIED BIOSYSTEMS.
- This apparatus uses different synthetic cycles for the Boc and Fmoc protective group techniques, as described below.
- Synthetic cycle for the Boc protecting group technique 1. 30% trifluoroacetic acid in DCM 1 ⁇ 3 min 2. 50% trifluoroacetic acid in DCM 1 ⁇ 1 min 3.
- DCM washing 5 ⁇ 1 min 4. 5% diisopropylethylamine in DCM 1 ⁇ 1 min 5. 5% diisopropylethylamine in NMP 1 ⁇ 1 min 6.
- BOP-Cl and PyBrop were used as reagents for coupling an amino acid to an N-methylamino acid. The reaction times were correspondingly increased.
- Synthetic cycle for the Fmoc protective group technique 1. DMF washing 1 ⁇ 1 min 2. 20% piperidine in DMF 1 ⁇ 4 min 3. 20% piperidine in DMF 1 ⁇ 16 min 4.
- BOP-Cl and PyBrop were used as reagents for coupling an amino acid to an N-methylamino acid. The reaction times were correspondingly increased.
- the hydrogen fluoride was then stripped off under reduced pressure, and the residue was washed with ethyl acetate to remove any remaining scavenger.
- the peptide was extracted with 30% acetic acid and filtered, and the filtrate was lyophilized.
- the peptide-resin formed by the Fmoc protecting group method was dried under reduced pressure and then subjected to one of the following cleavage procedures, depending upon the amino-acid composition (Wade, Tregear, Howard Florey Fmoc Workshop Manual, Melbourne 1985).
- the suspension of the peptide-resin in the suitable TFA mixture was stirred at room temperature for the stated time and then the resin was filtered off and washed with TFA and DCM.
- the filtrate and the washings were concentrated, and the peptide was precipitated by addition of diethyl ether. After cooling in an ice bath, the precipitate was filtered off, taken up in 30% acetic acid and lyophilized.
- polypeptides were characterized by amino-acid analysis and fast atom bombardment mass spectroscopy.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula II F and the group —C( ⁇ O)-G is in position 2 relative to the nitrogen atom.
- G is of Formula II g or, III g or IV g . No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula II f
- the group —C(O)-G is in position 3 relative to the nitrogen atom and G is of Formula II g , III g or IV g . No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula II f
- the substituent —(C ⁇ O)-G is in position 4 relative to the nitrogen.
- G is of Formula II g , III g or IV g . No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula II f
- the substituent —(C ⁇ O)-G is in position 2 relative to the nitrogen.
- G is of Formula V g , VI g , VII g , VIII g or IX g . No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula II f
- the substituent —(C ⁇ O)-G is in position 3 relative to the nitrogen.
- G is of Formula V g , VI g , VII g , VIII g or IX g . No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula II f
- the substituent —(C ⁇ O)-G is in position 4 relative to the nitrogen.
- G is of Formula V g , VI g , VII g , VIII g or IX g . No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula III f
- the substituent —(C ⁇ O)-G is in position 2 relative to the nitrogen and a f is 1.
- G is of Formula II g or III g .
- the compounds are mixtures of diasteromers, configuration in F is R, S (cis) or S,R (cis). No.
- A is Me 2 Val
- B is Val
- D is MeVal
- E is Pro
- F is of Formula III f
- the substituent —(C ⁇ O)-G is in position 2 relative to the nitrogen and a f is 1.
- G is of Formula II g or III g .
- the compounds are mixtures of diasteromers, configuration in F is either R, R (trans) or S,S (trans).
- FAB-MS 706 (M + H + ) I-79 2-(Me 2 Val-Val-MeVal-Pro-NH)—C 6 H 4 —CO—N(CH 2 C 6 H 5 ) 2
- Cytotoxicity was measured using a standard methodology for adherent cell lines, such as the microculture tetrazolium assay (MTT). Details of this assay have been published (Alley, M. C. et al., Cancer Research 48: 589-601, 1988). Exponentially growing cultures of tumor cells such as the HT-29 colon carcinoma or LX-1 lung tumor were used to make microtiter plate cultures. Cells were seeded at 5000-20,000 cells per well in 96-well plates (in 150 mL of media), and grown overnight at 37° C. Test compounds were added, in 10-fold dilutions varying from 10 ⁇ 4 M to 10 ⁇ 10 M. Cells were then incubated for 48 hours.
- MTT microculture tetrazolium assay
- the MTT dye was added (50 mL of a 3 mg/mL solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in saline). This mixture was incubated at 37° C. for 5 hours, and then 50 mL of 25% SDS, pH 2, was added to each well. After an overnight incubation, the absorbance of each well at 550 nm was read using an ELISA reader. The values for the mean+/ ⁇ SD of data from replicated wells were calculated, using the formula % T/C (% viable cells treated/control). The concentration of test compound which gives a T/C of 50% growth inhibition was designated as the IC 50 .
- Compounds of this invention may be further tested in any of the various preclinical assays for in vivo activity which are indicative of clinical utility. Such assays are conducted with nude mice into which tumor tissue, preferably of human origin, has been transplanted (“xenografted”), as is well known in this field. Test compounds are evaluated for their anti-tumor efficacy following administration to the xenograft-bearing mice.
- human tumors which have been grown in athymic nude mice are transplanted into new recipient animals, using tumor fragments which are about 50 mg in size.
- the day of transplantation is designated as day 0.
- the mice are treated with the test compounds given as an intravenous or intraperitoneal injection, in groups of 5-10 mice at each dose.
- Compounds are given daily for 5 days, 10 days or 15 days, at doses from 10-100 mg/kg body weight.
- Tumor diameters and body weights are measured twice weekly. Tumor masses are calculated using the diameters measured with Vernier calipers, and the formula:
- Mean tumor weights are calculated for each treatment group, and T/C values determined for each group relative to the untreated control tumors.
- novel compounds of the present invention show good in vitro activity in the above-mentioned assay system.
Abstract
Compounds of the present invention include cell growth inhibitors which are peptides of Formula I
A-B-D-E-F-G (I)
and acid salts thereof, wherein A, D, and E are α-amino acid residues, B is an α-amino acid residue or an α-hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sultoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
Description
- This application is a continuation of International Application No. PCT/US99/14099, which designated the United States and was filed on Jun. 23, 1999, published in English, which is a continuation of, and claims priority to, Ser. No. 09/112,249, filed Jul. 8, 1998, the teachings of which are incorporated herein by reference in their entirety.
- A number of short peptides with significant activity as inhibitors of cell growth have been isolated from the Indian Ocean sea hareDolabella auricularia (Bai, et al., Biochem. Pharmacology 40: 1859-1864 (1990); Beckwith et al., J. Natl. Cancer Inst. 85: 483-488 (1993) and references cited therein). These include Dolastatins 1-10 (U.S. Pat. No. 4,816,444, issued to Pettit et al.) and Dolastatin-15 (European Patent Application No. 398558). Dolastatin 15, for example, markedly inhibits the growth of the National Cancer Institute's P388 lymphocytic leukemia (PS system) cell line, a strong predictor of efficacy against various types of human malignancies.
- The exceedingly small amounts of the various Dolastatin peptides present inDolabella auricularia (about 1 mg each per 100 kg sea hare) and the consequent difficulties in purifying amounts sufficient for evaluation and use, have motivated efforts toward the synthesis of these compounds (Roux et al., Tetrahedron 50: 5345-5360 (1994); Shioiri et al., Tetrahedron 49: 1913-24 (1993); Patino et al., Tetrahedron 48: 4115-4122 (1992) and references cited therein). Synthetic Dolastatin 15, however, suffers from drawbacks which include poor solubility in aqueous systems and the need for expensive starting materials for its synthesis. These, in turn, have led to the synthesis and evaluation of structurally modified Dolastatin 15 derivatives (see, for example, Bioorg. Med. Chem. Lett. 4: 1947-50 (1994); WO 93 03054; JP-A-06234790).
- However, there is a need for synthetic compounds with the biological activity of Dolastatin 15 which have useful aqueous solubility and can be produced efficiently and economically.
- Compounds of the present invention include cell growth inhibitors which are peptides of Formula I
- A-B-D-E-F-G (I)
- and acid salts thereof, wherein A, D, and E are α-amino acid residues, B is an α-amino acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone.
- Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.
- An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.
- The present invention provides compounds with antineoplastic activity as well as increased metabolic stability relative to Dolastatin 15.
- The present invention relates to peptides having antineoplastic activity. It also includes pharmaceutical compositions comprising these compounds and methods for treating cancer in a mammal, including a human, by administration of these compositions to the mammal.
- The invention is based on the discovery that Dolastatin 15, a peptide isolated from the sea hareDolabella auricularia, is a potent inhibitor of cell growth. This compound, however, is present in trace quantities in the sea hare, and is, thus, difficult to isolate and expensive to synthesize and suffers from poor aqueous solubility. As shown herein, however, Dolastatin 15 can serve as a starting point for the development of compounds which overcome these disadvantages while retaining antineoplastic activity or exhibiting greater antineoplastic activity than the natural product. Applicants have discovered that certain structural modifications of Dolastatin 15 provide compounds with a surprisingly improved therapeutic potential for the treatment of neoplastic diseases as compared to Dolastatins-10 and -15. The Dolastatin-15 derivatives exhibit activity even in multiple drug-resistant tumor systems and an unpredicted high solubility in aqueous solvents. Furthermore, the compounds of the present invention can be conveniently synthesized, as described below in detail.
- For the purposes of the present invention, the term “monovalent radical” is intended to mean an electrically neutral molecular fragment capable of forming one covalent bond with a second neutral molecular fragment. Monovalent radicals include the hydrogen atom, alkyl groups, such as methyl, ethyl and propyl groups, halogen atoms, such as fluorine, chlorine and bromine atoms, aryl groups, such as phenyl and naphthyl groups, and alkoxy groups, such as methoxy and ethoxy groups. Two monovalent radicals on adjacent sigma-bonded atoms can also together form a pi bond between the adjacent atoms. Two monovalent radicals may also be linked together, for example, by a polymethylene unit, to form a cyclic structure. For example, in the unit —N(R)R′, R and R′ are each a monovalent radical, and can, together with the nitrogen atom, form a heterocyclic ring. In addition, two monovalent radicals bonded to the same atom can also together form a divalent radical, such as an alkylidene group, for example, a propylidene group, or an oxygen atom.
- For the purposes of the present invention, the term “residue” refers to the molecular fragment remaining after the removal of the elements of a water molecule (one oxygen atom, two hydrogen atoms) from a molecule, such as an amino acid or a hydroxy acid.
- For the purposes of the present invention the term “normal alkyl” refers to an unbranched, or straight chain, alkyl group, for example, normal propyl (n-propyl, —CH2CH2CH3).
- The compounds of the present invention can be represented by Formula I,
- A-B-D-E-F-G (I),
- wherein A, D and E are α-amino acid residues; B is an α -amino acid residue or an α-hydroxy acid residue; F is an aminobenzoic acid residue, or an aminocycloalkanecarboxylic acid residue, such as an aminocyclobutanecarboxylic acid residue, an aminocylopentanecarboxylic acid residue, or an aminocyclohexanecarboxylic acid residue; and G is a monovalent radical.
- The peptides of Formula I are generally composed of L-amino acids but they can contain one or more D-amino acids. They can also be present as salts with physiologically-compatible acids, including hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.
- The following is a description of the present invention, including a detailed description of individual components and of methods of using the claimed compounds.
- Identity of A
-
- where na is an integer, preferably 0, 1, 2, or 3. Ra is a monovalent radical, such as a hydrogen atom or a C1-C3-alkyl group which can be normal, branched or cyclic and can be substituted by one or more, preferably 1 to about 3, fluorine atoms; suitable examples include methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-2-fluoroethyl, 1-fluoromethyl-2-fluoroethyl or cyclopropyl; methyl, ethyl or isopropyl are preferred;
- In this embodiment, R1 a is a monovalent radical, such as a hydrogen atom or a methyl, ethyl, propyl or phenyl group. The phenyl group can be substituted; suitable substituents include one or more halogen atoms, with fluorine, chlorine and bromine being preferred, C1-C4-alkyl groups, methoxy, ethoxy, trifluoromethyl or nitro groups.
- R2 a, R3 a, R4 a and R5 a are each, independently, a monovalent radical, such as a hydrogen atom or a methyl group. Ra and R1 a together can also form a propylene bridge.
-
- where Ra has the meaning stated for Formula IIa, R1 a is a monovalent radical, for example, a hydrogen atom or a lower alkyl group, preferably a methyl, ethyl or propyl group.
- In this embodiment, R6 a is a monovalent radical, such as a hydrogen atom, a normal or branched C1-C8-alkyl group, which can he substituted by one or more halogen, preferably fluorine, atoms, or a C3-C8-cycloalkyl or C3-C8-cycloalkyl-C 1-C4-alkyl group, a C1-C4-oxoalkyl group such as a methoxymethyl, 1-methoxyethyl or 1,1-dimethylhydroxymethyl group, a C2-C5 alkenyl group, such as a vinyl or 1-methylvinyl group, or a substituted or unsubstituted phenyl group. Suitable phenyl substituents include one or more halogen atoms, preferably fluorine, chlorine or bromine atoms, and alkyl, methoxy, ethoxy, trifluoromethyl, or nitro groups. R7 a is a monovalent radical, preferably a methyl group or an ethyl group.
-
- where ma is an integer, preferably 1 or 2. Ra and R7 a have the meanings stated for Ra and R7 a in Formula IIIa.
-
- where Ra and R7 a have the meanings stated for Ra and R7 a in Formula IIIa.
-
- where Ra and R1 a have the meanings stated for Ra and R1 a in Formula IIa, and Xa is a monovalent radical, preferably a hydroxyl, methoxy or ethoxy group or a fluorine atom.
-
- where Ra, R1 a, R2 a, R3 a, R4 a and R5 a have the meanings stated for these variables in Formula IIa.
-
- where Ra has the meaning stated for Ra in Formula IIa.
-
- where Za is a single or double bond and Ra has the meaning stated for this variable in Formula IIa. The 3-carbonyl substituent can have either the exo or endo orientation.
- Identity of B
-
- wherein R1 b and R2 b are each a monovalent radical. R1 b is, preferably, a hydrogen atom and R2 b is, for example, a cyclopropyl group, a normal or branched butyl, preferably tertiary-butyl, group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group. Additionally, R1 b and R2 b together can be an isopropylidene group.
- Identity of D
- D is an N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkyl-2-tert-butylglycyl, N-alkyl-norleucyl, N-alkyl-isoleucyl, N-alkyl-allo-isoleucyl or N-alkyl-norvalyl residue, where the alkyl group is preferably methyl or ethyl.
-
- where Rd has the meaning stated for Ra in Formula IIIa, R1 d is a monovalent radical, preferably a hydrogen atom, and R2 is a monovalent radical such as a cyclopropyl group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group. Additionally, R1 d and R2 d together can form an isopropylidene group.
-
- where nd is an integer, for example, 1 or 2. and R3 d has the meaning stated for R1 a in Formula IIIa. Xd is a monovalent radical, preferably a hydrogen atom, and, in the case where nd equals 1, can also be a hydroxyl, methoxy or ethoxy group or a fluorine atom.
- Identity of E
-
- where ne is an integer, preferably 0, 1 or 2. R1 e has the meaning stated for R1 a in Formula IIIa. R2 e and R3 e are each a monovalent radical, and can be, independently, a hydrogen atom or a methyl group. R4 e is a monovalent radical, preferably a hydrogen atom, a hydroxyl, methoxy or ethoxy group or a fluorine atom. R5 e is a monovalent radical, preferably a hydrogen atom. In the case where ne has the value 1, R3 e and R4 e together can form a double bond or R4 e and R5 e can together be a double-bonded oxygen radical. In the case where ne has the value 1 or 2, R1 e and R2 e can together form a double bond.
-
- where Re is a monovalent radical, such as a methyl or ethyl group and R1 e has the meaning stated for R1 a in Formula IIIa.
- Identity of F
-
- where Rf is a hydrogen atom or an alkyl group, preferably a methyl, ethyl or propyl group. The carbonyl group can be in position 1 (ortho), 2 (meta), or 3 (para) of the phenyl ring relative to the nitrogen atom. R1 f and R2 f are each, independently, a hydrogen atom; a halogen atom, for example, a fluorine, chlorine, bromine, or iodine atom; a C1-C4-alkyl group; a methoxy, ethoxy, trifluoromethyl, nitro, cyano, amino or dimethyalmino group. Additionally, R1 f and R2 f can together form a dioxymethylene group.
-
- where Rf is a monovalent radical, such as a hydrogen atom or a lower alkyl group, preferably a methyl, ethyl or propyl group. af is an integer, for example, 0, 1 or 2. The carbonyl group is in position 2 or position 3 of the cycloalkane ring relative to the nitrogen atom at position 1. The stereogenic centers can be, independently of each other, R or S. For a five-membered ring (af=1) , the combinations R1,S2 and S1,R2 would be referred to as cis-pentacin derivatives, while the combinations R1,R2 and S1,S2 are trans-pentacin derivatives.
- Identity of G
-
- where R1 l is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated C1-C18-alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryl-C1-C6-alkoxy group, or a substituted or unsubstituted aryloxy-C1-C6-alkoxy or heteroaryl-C1-C6-alkoxy group. The aryl group is preferably a phenyl or naphthyl group. The heteroaryl group is a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system, such as, for example, imidazolyl, isoxazolyl, isothiazolyl, thiazolyl, oxazolyl, pyrazolyl, thiophenyl, furanyl, pyrrolyl, 1,2,4- or 1,2,3-triazolyl, pyrazinyl, indolyl, benzofuranyl, benzothiophenyl, isoindolyl, indazolyl, quinolinyl, pyridazinyl, pyrimidinyl, benzimidazolyl, benzopyranyl, benzothiazolyl, oxadiazolyl, thiadiazolyl or pyridinyl group. Suitable aryl or heteroaryl substituents include one or more halogen atoms, preferably fluorine, bromine or chlorine; C1-C4-alkyl groups; methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group or a nitro group.
- R2 l is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated C1-C18-alkyl group, a C3-C10-cycloalkyl group, a substituted or unsubstituted aryl group, where aryl is preferably phenyl or naphthyl. Suitable aryl substituents include one or more halogen, preferably fluorine, chlorine or bromine, atoms, C1-C4-alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group, nitro or cyano groups, a C1-C7-alkoxycarbonyl group, a C1-C7-alkylsulfonyl group, an amino or C1-C7-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle, or an unsubstituted or substituted heteroaryl group. The heteroaryl group can be a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system which can be fused to a benzene ring, such as, for example, imidazolyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, oxazolyl, pyrazolyl, 1,2,4- or 1,2,3-triazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzopyranyl, indolyl, isoindolyl, indazolyl or quinolinyl group, with preferred substituents being C1-C6-alkyl groups, or hydroxyl or phenyl groups.
-
- wherein al is an integer, preferably 0, 1, 2, 3, 4, or 5. R3 l is a monovalent radical, such as a lower alkyl group, for example, a methyl, ethyl, propyl or isopropyl group. R4 l is a saturated or partially unsaturated carbocyclic group containing from 3 to about 10 carbon atoms, or a substituted or unsubstituted aryl or heteroaryl group, where the preferred aryl and heteroaryl groups and suitable substituents are as stated for R2 l in Formula IIg.
-
- wherein Wl is an oxygen or sulfur atom or an N—R6 l group. R5 l is a monovalent radical, such as a hydrogen atom, a C1-C4-alkyl or C3-C7-cycloalkyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R2 l from Formula IIg. R6 l is a monovalent radical, preferably a hydrogen atom, a C1-C4-alkyl group or a C3-C7-cycloalkyl group, a C1-C18-alkanoyl group, a benzoyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R2 l in Formula IIg,
-
- where bl is an integer, preferably 2, 3 or 4. Zl is a monovalent radical, such as a formyl, aminocarbonyl or hydrazinocarbonyl group, or a cyclic or acyclic acetal or thioacetal group.
-
- in which bl is an integer, preferably 2, 3 or 4. R7 l is a monovalent radical, such as a glycol oligomer of the formula
- —O(CH2CH2O)dl—CH3,
- where dl is an integer, preferably in the range from about 2 to about 4 or from about 40 to about 90.
-
- where R8 l is a monovalent radical, such as a hydrogen atom, a C1-C4-alkanoyl or alkyl group, a benzoyl group or a benzyl group.
-
- where R9 l is a monovalent radical such as a hydrogen atom, a C1-C6-alkyl group or a substituted or unsubstituted aryl group, with aryl and its preferred substituents having the meaning stated for R2 l in Formula IIg. R10 l is a monovalent radical, preferably a hydrogen atom, alkyl, for example, methyl, or a phenyl group.
-
- where R11 l and R12 l are each, independently, a monovalent radical such as a hydrogen atom, a normal or branched C1-C8-alkyl group, a C3-C8- cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group or a substituted or unsubstituted aryl, heteroaryl, aryl-C1-C4-alkyl or heteroaryl-C1-C4-alkyl group, where aryl, heteroaryl and their preferred substituents can be selected from among the options listed for R2 1 in Formula IIg. R11 l and R12 l can also together form a propylene or butylene bridge.
- Another subclass of compounds of this invention includes peptides of Formula I wherein G is a monovalent radical of the formula —O—R13 l or —S—R13 l, where R13 l is a monovalent radical, such as a C3-C10-cycloalkyl group, a normal or branched C2-C16-alkenylmethyl group or a C1-C16-alkyl group which can be substituted by from 1 to about 5 halogen, preferably fluorine, atoms.
- R13 l can also be the radical —(CH2)el—R14 l where el is an integer, preferably 1, 2 or 3. R14 l is a monovalent radical, preferably a saturated or partially unsaturated C3-C10-carbocycle.
- R13 l can further be the radical
- —[CH2—CH═C(CH3)—CH2]fl—H,
- where fl is an integer, preferably 1, 2, 3 or 4.
- R13 l can also be the radical
- —[CH2—CH2—O]gl—CH3,
- where gl is an integer, preferably from about 2 to about 4, or from about 40 to about 90.
- R13 l can also be the radical
- —(CH2)hl-aryl or —(CH2)hl-heteroaryl,
- where aryl and heteroaryl can also be substituted and, along with their preferred substituents, can be selected from the group listed for R2 l in Formula IIg. hl is an integer, preferably 0, 1, 2 or 3.
- R13 l can further be the radical
- —(CH2)bl-Wl-R5 l,
- where bl, Wl and R5 l are each selected from among the options described for Formula IIIl.
- Another subclass of compounds of this invention includes peptides of Formula I in which G is an aminoxy group of the formula
- —O—N(R15 l)(R16 l),
- where R15 l and R16 l are each a monovalent radical, and can independently be a hydrogen atom, a normal or branched C1-C8-alkyl group, which can be substituted by halogen, preferably fluorine, atoms, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl or heteroaryl group or a substituted or unsubstituted aryl-C1-C4-alkyl group. Aryl and heteroaryl groups and the preferred substituents thereof can be selected from the options listed for R2 l in Formula IIg. Additionally, R15 l and R16 l can together form a 5-, 6- or 7-membered heterocycle.
- Another subclass of compounds of this invention includes peptides of Formula I wherein G is an oximato group of the formula
- —O—N═C(R15 l)(R16 l),
-
- A further subclass of compounds of this invention includes peptides of Formula I wherein G is a hydrogen atom, a normal or branched C1-C8-alkyl group, which can be substituted by up to six halogen, preferably fluorine, atoms, a C3-C8-cycloalkyl group or a C3-C8-cycloalkyl-C 1-C4-alkyl group.
- G can also be an arylalkyl, heteroarylalkyl, aryl or heteroaryl group of Formula Vg,
- —(CH2)ag—R17 l (Vg)
- where ag is an integer, such as 0, 1 or 2. R17 l is a substituted or unsubstituted aryl or heteroaryl group. Preferred aryl groups include phenyl and naphthyl groups. Suitable aryl substituents include halogen, preferably fluorine, bromine or chlorine, atoms, C1-C4-alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group, a nitro or cyano group, a C1-C7-alkoxycarbonyl group, a C1-C7- alkylsulfonyl group, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle. R17 l can also be a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfur-containing, ring system which can be fused to a benzene ring. Suitable heteroaryl groups include imidazolyl, pyrrolyl, thiophenyl, furanyl, thiazolyl, oxazolyl, pyrazolyl, 1,2,4- or 1,2,3-triazolyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzothiazolyl, benzopyranyl, indolyl, isoindolyl, indazolyl and quinolinyl groups. Preferred heteroaryl substituents are C1-C6-alkyl groups, a hydroxyl group or a phenyl group.
- Another subclass of compounds of this invention includes compounds of Formula I wherein G is a monovalent radical of Formula VIg,
- —(CH2)bg—(C═O)cg—OR18 l (VIg),
- where bg is an integer, preferably 0, 1, 2 or 3, and cg is an integer, preferably 0 or 1. bg and cg are not both simultaneously 0. R18 l is a monovalent radical, such as a hydrogen atom, a straight-chain or branched C1-C8-alkyl group which can be substituted by halogen, preferably fluorine, atoms, especially a CF2-moiety, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl, group. Suitable aryl substituents are halogen, preferably fluorine, bromine or chlorine, atoms, C1-C4-alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C1-C7-alkoxycarbonyl moiety, a C1-C7-alkylsulfonyl moiety, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
-
- where dg is an integer, preferably 0, 1, 2 or 3, and eg is an integer such as 0 or 1. dg and eg cannot both simultaneously take the value 0. R19 l and R20 l are each, independently, a monovalent radical, such as a hydrogen atom, a straight-chain or branched C1-C8-alkyl group, which can further be substituted by halogen, preferably fluorine, atoms, especially a CF2-moiety, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl group. Suitable aryl substituents include one or more halogen, referably fluorine, bromine or chlorine, atoms, C1-C4-alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C1-C7-alkoxycarbonyl moiety, a C1-C 7-alkylsulfonyl group, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle. N(R19 l)R20 l can additionally form a ring system of the formula N(CH2)fg, where fg is an integer selected from among 4, 5 or 6.
- Another subclass of compounds of this invention includes peptides of Formula I, wherein G is a monovalent radical of Formula VIIIg,
- —(CH2)gg—S(O)hg—R21 l (VIIIg),
- where gg is an integer, for example, 1 or 2, and hg is 1 or 2. R21 l is a monovalent radical, preferably a methyl group, a trifluoromethyl group, an ethyl group or a phenyl group.
- G can also be an alkyl- or arylcarbonylalkyl group of Formula IXg,
- —(CH2)ig—(C═O)—R22 l (IXg),
- where R22 l is a monovalent radical, such as a hydrogen atom, a straight-chain or branched C1-C8-alkyl group which can be substituted by up to six halogen, preferably fluorine, atoms, especially a CF2-moiety, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, a substituted or unsubstituted aryl, preferably phenyl or naphthyl, group. Suitable aryl substituents are halogen, preferably fluorine, bromine or chlorine, atoms, C1-C4-alkoxy, trifluoromethyl, nitro or cyano groups, a dioxymethylene moiety, a C1-C7-alkoxycarbonyl moiety, a C1-C7-alkylsulfonyl moiety, an amino group or a C1-C6-dialkylamino group, where the alkyl groups can, together with the nitrogen atom, also form a 5- or 6-membered heterocycle.
- Synthetic Methods
- The compounds of the present invention can be prepared by known methods of peptide synthesis. Thus, the peptides can be assembled sequentially from individual amino acids or by linking suitable small peptide fragments. In sequential assemblage, the peptide chain is extended stepwise, starting at the C-terminus, by one amino acid per step. In fragment coupling, fragments of different lengths can be linked together, and the fragments in turn can be obtained by sequential assembly from amino acids or by fragment coupling of still shorter peptides.
- In both sequential assemblage and fragment coupling it is necessary to link the units by forming an amide linkage, which can be accomplished via a variety of enzymatic and chemical methods. Chemical methods for forming the amide linkage are described in detail in standard references on peptide chemistry, including Müller,Methoden der organischen Chemie Vol. XV/2, pages 1-364, Thieme Verlag, Stuttgart, Germany (1974); Stewart and Young, Solid Phase Peptide Synthesis, pages 31-34 and 71-82, Pierce Chemical Company, Rockford, Ill. (1984); Bodanszky et al., Peptide Synthesis, pages 85-128, John Wiley & Sons, New York, (1976). Preferred methods include the azide method, the symmetric and mixed anhydride method, the use of in situ generated or preformed active esters, the use of urethane protected N-carboxy anhydrides of amino acids and the formation of the amide linkage using coupling reagents, such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloyl chloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propane-phosphonic anhydride (PPA), N,N-bis(2-oxo-oxazolidinyl)imido-phosphoryl chloride (BOP-Cl), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop), diphenyl-phosphoryl azide (DPPA), Castro's reagent (BOP, PyBop), O-benzotriazolyl-N,N,N′, N′-tetramethyluronium salts (HBTU), diethylphosphoryl cyanide (DEPCN), 2,5-diphenyl-2,3-dihydro-3-oxo-4-hydroxy-thiophene dioxide (Steglich's reagent; HOTDO), and 1,1′-carbonyl-diimidazole (CDI). The coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.
- Although the use of protecting groups is generally not necessary in enzymatic peptide synthesis, reversible protection of reactive groups not involved in formation of the amide linkage is necessary for both reactants in chemical synthesis. Three conventional protective group techniques are preferred for chemical peptide synthesis: the benzyloxycarbonyl (Z), the t-butoxycarbonyl (Boc) and the 9-fluorenylmethoxycarbonyl (Fmoc) techniques. Identified in each case is the protective group on the α-amino group of the chain-extending unit. A detailed review of amino-acid protective groups is given by Müller,Methoden der organischen Chemie Vol. XV/1, pp 20-906, Thieme Verlag, Stuttgart (1974). The units employed for assembling the peptide chain can be reacted in solution, in suspension or by a method similar to that described by Merrifield (J. Am. Chem. Soc. 85: 2149 (1963)). Particularly preferred methods are those in which peptides are assembled sequentially or by fragment coupling using the Z, Boc or Fmoc protective group technique, with one of the reactants in the said Merrifield technique being bonded to an insoluble polymeric support (also called resin hereinafter). This typically entails assembling the peptide sequentially on the polymeric support using the Boc or Fmoc protective group technique, with the growing peptide chain covalently bonded at the C terminus to the insoluble resin particles. This procedure allows the removal of reagents and byproducts by filtration, eliminating the need to recrystallize intermediates.
- The protected amino acids can be linked to any suitable polymer, which must be insoluble in the solvents used and have a stable physical form which permits filtration. The polymer must contain a functional group to which the first protected amino acid can be covalently attached. A wide variety of polymers are suitable for this purpose, including cellulose, polyvinyl alcohol, polymethacrylate, sulfonated polystyrene, chloromethylated styrene/divinylbenzene copolymer (Merrifield resin), 4-methylbenzhydrylamine resin (MBHA-resin), phenylacetamidomethyl resin (Pam-resin), p-benzyloxy-benzyl-alcohol-resin, benzhydryl-amine-resin (BHA-resin), 4-(hydroxymethyl)-benzoyl-oxymethyl-resin, the resin of Breipohl et al. (Tetrahedron Letters 28 (1987) 565; supplied by BACHEM), 4-(2,4-dimethoxyphenylaminomethyl) phenoxy resin (supplied by Novabiochem) or o-chlorotrityl-resin (supplied by Biohellas).
- Solvents suitable for peptide synthesis include any solvent which is inert under the reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of these solvents.
- Peptide synthesis on the polymeric support can be carried out in a suitable inert organic solvent in which the amino acid derivatives starting materials are soluble. However, preferred solvents additionally have resin-swelling properties and include DMF, DCM, NMP, acetonitrile, DMSO, and mixtures of these solvents. Following synthesis, the peptide is removed from the polymeric support. The conditions under which this cleavage is accomplished for various resin types are disclosed in the literature. The cleavage reactions most commonly used are acid- or palladium-catalyzed, the former being conducted in, for example, liquid anhydrous hydrogen fluoride, anhydrous trifluoromethanesulfonic acid, dilute or concentrated trifluoroacetic acid, and acetic acid/dichloromethane/trifluoroethanol mixtures. The latter can be carried out in THF or THF-DCM-mixtures in the presence of a weak base such as morpholine. Certain protecting groups are also cleaved off under these conditions.
- Partial deprotection of the peptide may also be necessary prior to certain derivatization reactions. For example, peptides dialkylated at the N-terminus can be prepared either by coupling the appropriate N,N-di-alkylamino acid to the peptide in solution or on the polymeric support or by reductive alkylation of the resin-bound peptide in DMF/1% acetic acid with NaCNBH3 and the appropriate aldehyde.
-
-
- Here, the N-terminal protected tetrapeptide A′-B-D-E-OH is coupled with an amino-derivative F-G to give an intermediate compound A′-B-D-E-F-G using the methods for peptide coupling as described above. Then, the N-protecting group is removed by conventional methods as described above. The groups RA and R7 A can then be attached to the amino terminus via reductive alkylation as described above.
- Building blocks of use in the synthesis of the claimed compounds (described in scheme I and II as F-G) can be prepared by the following general methods:
- a) Synthesis of Amino-phenyl-ketones
-
-
-
- 2-Amino-phenyl ketones can be obtained by reaction of the corresponding 2-fluorophenyl-ketone with sodium azide in a polar solvent, such as N,N-dimethylformamide, and subsequent reduction of the intermediate benzisoxazole (see scheme III.3). For example, the synthesis of 2-aminophenyl-(4-pyridazinyl)-ketone has been described by N. Haider et al. (Arch. Pharm. 325: 119-122 (1992)).
- b) Synthesis of Amino-benzamides
-
- In scheme IV.1, the steps are described starting from nitrobenzoic acids or substituted nitrobenzoic acids. These acids are coupled with primary or secondary amines (HNR1R2) by using coupling reagents. Preferred method is the use of coupling reagents such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), pivaloylchloride, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propane-phosphonic anhydride (PPA), N,N-bis(2-oxo-3oxazolidinyl)-imidophosphoryl chloride (BOP-Cl), bromo-tris-pyrrolidinophosphonium hexafluorophosphate (PyBrop), diphenylphosphoryl azide (DPPA), Castro's reagent (BOP, PyBop), O-benzotriazolyl-N,N,N′,N′-tetramethyluronium salts (HBTU), diethylphosphoryl cyanide (DEPCN), 2,5-diphenyl 2,3-dihydro-3-oxo-4-hydroxythiophene dioxide (Steglich's reagent; HOTDO) and 1,1′-carbonyldiimidazole (CDI). The coupling reagents can be employed alone or in combination with additives such as N,N-dimethyl-4-aminopyridine (DMAP), N-hydroxy-benzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), azabenzotriazole, N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.
- In place of the acids, the corresponding nitro-benzoyl chloride can be used. These are either commercially available or could be synthesized from the corresponding acids with thionyl chloride. The amines react with the nitrobenzoylchlorides in the presence of a base such as pyridine, which can also be used as the solvent (N. S. Cho et al.,J. Heterocycl. Chem. 33, 1201-1206 (1996)). The nitro-benzamides are then reduced to the corresponding amino-benzamides by reducing agents such as metal salts in presence of hydrochloride acids or by metal-catalysed hydrogenation using palladium on a solid such as palladium on charcoal as catalyst. This route is described in Example 1.
- Another method involves transforming the amine to the trifluoroacetamide by treatment with trifluoroacetic anhydride. The amide is deprotonated with a base such as sodium hydride or potassium t-butanolate and then treated with the corresponding alkyl halide such as methyl iodide, ethyl iodide or isopropyl iodide. The trifluoroacetamide is easily cleaved in basic alcoholic solution such as potassium carbonate in methanol.
- In scheme IV.2. the starting materials for the synthesis of amino-benzamides are the N-protected aminobenzoic acids. Different protecting groups for the nitrogen are compatible such as the above mentioned Z-, Boc- or Fmoc-protecting groups. The N-protected amino-benzoic acids are coupled with amines as described above for the nitro-benzoic acids using the above mentioned coupling conditions. This route is exemplified in Example 2.
- A route for the preparation of 2-aminobenzamides is described in scheme IV.3. Opening of isatoic anhydride (substituted or unsubstituted at the nitrogen) by amines with evolution of carbon dioxide led to the corresponding 2-amino-benzamides, as described by Clark et al.,J. Org. Chem. 9: 55-64 (1944).
- c) Amino-cyclopentane- or Aminocyclohexane-carboxamides
- Different routes have been described to the synthesis of cis-2-amino-cyclopentylcarboxylic acid (cispentacin) in racemic form or as pure enantiomer. Using an intramolecular nitrone-olefin cycloaddition cis-2-(t-butoxycarbonylamino)cyclopentane-1-carboxylic acid could be prepared in a few synthetic steps (Konosu et al.,Chem. Pharm. Bull. 41: 1012 (1993)). Another route to enantiomerically pure cis-(1R, 2S)-2-amino-cyclopentylcarboxylic acid is the addition of chiral lithium (S)-(-methylbenzyl)benzylamide to t-butyl-1-cyclopentene-1-carboxylate with subsequent removal of the benzyl groups by hydogenation and removal of the t-butyl group by acid treatment (Davies et al., Synlett 1993, p. 461). The corresponding trans-epimer could be obtained by isomerisation with a base such as potassium t-butoxide. By using the lithium (R)-(-methylbenzyl)benzylamide in the Michael addition (1S, 2R)-2-amino-cyclopentylcarboxylic acid and (1S, 2S)-2-amino-cyclopentylcarboxylic acid can be obtained. This method is also applicable to the synthesis of cis-and trans-aminocyclohexane-1-carboxylic acid.
- Resolution of racemic Boc-protected cis-2-aminocyclopentane carboxylic acid (Bernath et al.,Acta Chim. 74: 479 (1972); Nativ et al., Isr. J. Chem. 10: 55 (1972)) can be achieved with (+)- and (−)-ephedrine in high enantiomeric excess (Nöteberg et al., Tetrahedron 53: 7975 (1997)). In this paper also the synthesis of the trans-enantiomers of Boc-protected trans-2-aminocyclopentane carboxylic methyl ester was described, starting with either trans-(3R, 4R)-bis(methoxycarbonyl)cyclopentanone or trans(3S,4S)-bis(methoxycarbonyl)-cyclopentanone.
- Amides of Boc-protected 2-aminocyclopentylcarboxylic acid can be obtained by coupling the acid with the corresponding amine using the standard procedures as described above for the coupling of nitrobenzoic acid with amines or as described in D. Nöteberg et al.,Tetrahedron 53: 7975 (1997). Deprotection of the amine function can be achieved by using Lewis acids, for example, a mineral acid such as hydrochloric acid in ether or dioxane or an organic acid, such as trifluoroacetic acid in methylene chloride.
- Methods of Use of the Claimed Compounds
- In another embodiment, the present invention comprises a method for partially or totally inhibiting formation of, or otherwise treating (e.g., reversing or inhibiting the further development of) solid tumors (e.g., tumors of the lung, breast, colon, prostate, bladder, rectum, or endometrial tumors) or hematological malignancies (e.g., leukemias, lymphomas) in a mammal, for example, a human, by administering to the mammal a therapeutically effective amount of a compound or a combination of compounds of Formula I. The agent may be administered alone or in a pharmaceutical composition comprising the agent and an acceptable carrier or diluent. Administration may be by any of the means which are conventional for pharmaceutical, preferably oncological, agents, including oral and parenteral means such as subcutaneously, intravenously, intramuscularly and intraperitoneally, nasally or rectally. The compounds may be administered alone or in the form of pharmaceutical compositions containing a compound of Formula I together with a pharmaceutically accepted carrier appropriate for the desired route of administration. Such pharmaceutical compositions may be combination products, i.e., they may also contain other therapeutically active ingredients.
- The dosage to be administered to the mammal, such as a human, will contain a therapeutically effective amount of a compound described herein. As used herein, “therapeutically effective amount” is an amount sufficient to inhibit (partially or totally) formation of a tumor or a hematological malignancy or to reverse development of a solid tumor or other malignancy or prevent or reduce its further progression. For a particular condition or method of treatment, the dosage is determined empirically, using known methods, and will depend upon factors such as the biological activity of the particular compound employed; the means of administration; the age, health and body weight of the recipient; the nature and extent of the symptoms; the frequency of treatment; the administration of other therapies; and the effect desired. A typical daily dose will be from about 5 to about 250 milligrams per kilogram of body weight by oral administration and from about 1 to about 100 milligrams per kilogram of body weight by parenteral administration.
- The compounds of the present invention can be administered in conventional solid or liquid pharmaceutical administration forms, for example, uncoated or (film-)coated tablets, capsules, powders, granules, suppositories or solutions. These are produced in a conventional manner. The active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, sustained release compositions, antioxidants and/or propellant gases (cf. H. Sücker et al.:Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978). The administration forms obtained in this way typically contain from about 1 to about 90% by weight of the active substance.
- The following examples are intended to illustrate the invention but are not to be considered limitations of the invention.
- The proteinogenous amino acids are abbreviated in the examples using the known three-letter code. Other abbreviations employed are: TFA=trifluoroacetic acid, Ac= acetic acid, DCM=dichloromethane, DMSO= dimethylsulfoxide, Bu=butyl, Et=ethyl, Me=methyl, Bn= benzyl. In the compounds listed, all proteinogenous amino acids are L-amino acids unless otherwise noted.
- General Materials and Methods
- The compounds of the present invention are synthesized by classical solution synthesis using standard Z- and Boc-methodology as discussed above or by standard methods of solid-phase synthesis on a model 431A synthesizer supplied by APPLIED BIOSYSTEMS. This apparatus uses different synthetic cycles for the Boc and Fmoc protective group techniques, as described below.
Synthetic cycle for the Boc protecting group technique 1. 30% trifluoroacetic acid in DCM 1 × 3 min 2. 50% trifluoroacetic acid in DCM 1 × 1 min 3. DCM washing 5 × 1 min 4. 5% diisopropylethylamine in DCM 1 × 1 min 5. 5% diisopropylethylamine in NMP 1 × 1 min 6. NMP washing 5 × 1 min 7. Addition of preactivated 1 × 30 min protected amino acid (activation with 1 equivalent of DCC and 1 equivalent of HOBt in NMP/DCM); Peptide coupling (1st part) 8. Addition of DMSO to the reaction mixture until it contains 20% DMSO by volume 9. Peptide coupling (2nd part) 1 × 16 min 10. Addition of 3.8 equivalents of diisopropylethylamine to the reaction mixture 11. Peptide coupling (3rd part) 1 × 7 min 12. DCM washing 3 × 1 min 13. if conversion is incomplete, repetition of coupling (back to step 5) 14. 10% acetic anhydride, 5% diisopropylethylamine in DCM 1 × 2 min 15. 10% acetic anhydride in DCM 1 × 4 min 16. DCM washing 4 × 1 min 17. back to step 1. - BOP-Cl and PyBrop were used as reagents for coupling an amino acid to an N-methylamino acid. The reaction times were correspondingly increased. In solution synthesis, the use of either Boc-protected amino acid NCAs (N-tert-butyloxycarbonyl-amino acid-N-carboxy-anhydrides) or Z-protected amino acid NCAs (N-benzyloxycarbonyl-amino acid-N-carboxy-anhydrides) respectively is most preferable for this type of coupling.
Synthetic cycle for the Fmoc protective group technique 1. DMF washing 1 × 1 min 2. 20% piperidine in DMF 1 × 4 min 3. 20% piperidine in DMF 1 × 16 min 4. DMF washing 5 × 1 min 5. Addition of the preactivated 1 × 61 min protected amino acid (activation by 1 equivalent of TBTU and 1.5 equivalent of DIPEA in DMF); Peptide coupling 6. DMF washing 3 × 1 min 7. If conversion is incomplete, repetition of coupling (back to 5.) 8. 10% acetic anhydride in DMF 1 × 8 min 9. DMF washing 3 × 1 min 10. back to 2. - BOP-Cl and PyBrop were used as reagents for coupling an amino acid to an N-methylamino acid. The reaction times were correspondingly increased.
- Reductive Alkylation of the N Terminus
- The peptide-resin prepared as described above was deprotected at the N terminus and then reacted with a 3-fold molar excess of aldehyde or ketone in DMF/1% acetic acid with addition of 3 equivalents of NaCNBH3. After reaction was complete (negative Kaiser test), the resin was washed several times with water, isopropanol, DMF and dichloromethane.
- Workup of the Peptide-Resins
- The peptide-resin obtained via the Boc protecting group technique was dried under reduced pressure and transferred into a reaction vessel of a TEFLON HF apparatus (supplied by PENINSULA). A scavenger, usually anisole (1 mL/g of resin), was then added and additionally, in the case of tryptophan-containing peptides, a thiol (0.5 mL/g of resin), preferably ethanedithiol, to remove the indolic formyl group. This was followed by condensing in hydrogen fluoride (10 mL/g of resin) in a bath of liquid N2. The mixture was allowed to warm to 0° C. and stirred at this temperature for 45 min. The hydrogen fluoride was then stripped off under reduced pressure, and the residue was washed with ethyl acetate to remove any remaining scavenger. The peptide was extracted with 30% acetic acid and filtered, and the filtrate was lyophilized.
- The peptide-resin formed by the Fmoc protecting group method was dried under reduced pressure and then subjected to one of the following cleavage procedures, depending upon the amino-acid composition (Wade, Tregear, Howard Florey Fmoc Workshop Manual, Melbourne 1985). The suspension of the peptide-resin in the suitable TFA mixture was stirred at room temperature for the stated time and then the resin was filtered off and washed with TFA and DCM. The filtrate and the washings were concentrated, and the peptide was precipitated by addition of diethyl ether. After cooling in an ice bath, the precipitate was filtered off, taken up in 30% acetic acid and lyophilized.
- When an o-chlorotrityl-resin (supplied by Biohellas) was used, the suspension of the peptide-resin in an acetic acid/trifluoroethanol/dichloromethane mixture (1:1:3) was stirred at room temperature for 1 h. The suspension was then filtered with suction and the peptide-resin was thoroughly washed with the cleavage solution. The combined filtrates were concentrated in vacuo and treated with water. The precipitated solid was removed by filtration or centrifugation, washed with diethyl ether and dried under reduced pressure.
- Purification and Characterization of the Peptides
- Purification was carried out by gel chromatography (SEPHADEX G-10, G-15/10% HOAc, SEPHADEX LH20/MeOH) with or without subsequent medium pressure chromatography (stationary phase: HD-SIL C-18, 20-45 m, 100 Å; mobile phase: gradient with A=0.1% TFA/MeOH, B=0.1% TFA/H2O). The purity of the resulting products was determined by analytical HPLC (stationary phase: 100 2.1 mm VYDAC C-18, 5 l, 300 Å; mobile phase: CH3CN/H2O gradient, buffered with 0.1% TFA, 40%C).
- The polypeptides were characterized by amino-acid analysis and fast atom bombardment mass spectroscopy.
- Me2Val-Val-MeVal-Pro-OH and Z-Val-Val-MeVal-Pro-OH were prepared by the method disclosed in patent applications DE 4415998 and DE 19527575, the contents of which are incorporated herein by reference.
-
- To a solution of 2.0 g 2-nitrobenzoic acid and 0.98 g dimethylammonium chloride in dichloromethane at 0° C. were added 2.29 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1.62 g N-hydroxy-benzotriazol and 6.05 g N-methyl-morpholine. The resulting mixture was stirred at room temperature overnight. The reaction mixture was then washed sequentially with saturated sodium hydrogen carbonate, a 5% aqueous solution of citric acid and brine. The organic phase was dried over sodium sulfate. After filteration the solvent was removed in vacuo yielding N,N-dimethyl-2-nitrobenzamide (2.13 g).
-
-
- Palladium on charcoal (0.54 g, 10% Pd by weight) was added to a solution of 2.1 g N,N-dimethyl-2-nitrobenzamide in 150 mL methanol. The resulting suspension was hydrogenated at room temperature at atmospheric pressure for three hours. After filtration of the catalyst, the solvent was removed in vacuo affording N,N-dimethyl-2-aminobenzamide (1.8 g).
-
-
- To a solution of 2.0 g Z-Val-Val-MeVal-Pro-OH and 0.53 g N,N-dimethyl-2-amino-benzamide in dichloromethane was added 1.66 g bromo-tris-pyrrolidinophosphonium hexafluoro-phosphate (PyBrop) and 0.77 g N-ethyldiisopropylamine at 0° C. The mixture was stirred at room temperature overnight, and then washed sequentially with saturated sodium hydrogen carbonate, a 5% aqueous solution of citric acid, and brine. The organic phase was dried over sodium sulfate. After filtration, the solvent was removed in vacuo. The residue was purified by silica gel chromatography (1:3 dichloromethane:ethyl acetate) to provide (2)-(Z-Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)2 (1.8 g).
- FAB-MS 707.0 (M+H+d)
-
- Palladium on charcoal (58 mg, 10% Pd by weight) was added to a solution of 1.8 g 2-(Z-Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)2 in 150 mL methanol. The resulting suspension was hydrogenated at room temperature at atmospheric pressure for three hours, then 1.5 mL of an aqueous formaldehyde solution (37% formaldehyde by weight) and 341 mg of palladium on charcoal were added. The mixture was hydrogenated at room temperature at atmospheric pressure overnight. After filtration over celite the solvent was removed in vacuo to give 1.30 g 2-(Me2Val-Val-MeVal-Pro-NH)—C 6H4—CON(CH3)2.
- FAB-MS: 601.0 (M+H+)
-
-
- To a solution of 1.5 g 2-N-t-butoxy-carbonyl anthranilic acid and 0.68 g N,O-dimethylhydroxylamine hydrochloride in dichloromethane at 0° C., 1.33 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 0.94 g N-hydroxybenzotriazol and 3.20 g N-methylmorpholine were added. The mixture was stirred at room temperature overnight. The reaction mixture was washed sequentially with saturated aqueous sodium hydrogen carbonate, a 5% aqueous solution of citric acid and brine. The organic phase was dried over sodium sulfate. After filtration the solvent was removed in vacuo. Flash chromatography (silica gel, heptane:ethyl acetate 10:1) afforded N,O-dimethyl-(2-N-tert.Butoxycarbonyl-amino)benzohydroxylamide (1.18 g).
-
-
- To a solution of 0.5 g N,O-dimethyl-(2-N-tert.butoxycarbonyl-amino)benzohydroxylamide in 15 mL dichloromethane at 0° C. was added 17 mL of a hydrogen chloride solution in ether and the resulting solution was stirred for 2 hours. The solvent was evaporated to give 0.41 g N,O-dimethyl-(2-amino)benzohydroxylamide hydrochloride.
-
-
- To a solution of 0.892 g Me2Val-Val-MeVal-Pro-OH and 0.234 g triethylamine in 10 mL dichloromethane at 0° C. was added 0.218 g formate. After stirring the resulting mixture for two hours, 0.41 g N,O-dimethyl-(2-amino)benzohydroxylamide hydrochloride and 0.234 g triethylamine were added and the mixture was stirred overnight at room temperature. The reaction mixture was washed sequentially with saturated sodium hydrogen carbonate solution and brine. The organic phase was dried over sodium sulfate. After filtration the solvent was removed in vacuo. The residue was purified by chromatography (silica gel treated with 1% triethylamine, solvent: dichloromethane/3% isopropanol) to provide 0.28 g (2)-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CON(CH3)(OCH3).
- FAB-MS: 617.5 (M+H+)
-
-
- 8.4 g (44.3 mmol) of commercially available cyclopentane-trans-1,2-dicarboxylic acid was refluxed for 20 h in 75 ml of acetic acid anhydride, then evaporated and the obtained residue distilled in a “Kugelrohr-apparatus” at 1.0 mbar. The fraction boiling at 165° was collected, yielding 5.8 g of the product as an oil.
-
-
- 1.1 g (7.85 mmol) of cyclopentane-cis-1,2-dicarboxylic acid anhydride were added to 8 ml of an aqueous NH3-solution and stirred until dissolution of the educt. The excess of ammonia was then evaporated, the remaining solution cooled to 0° C. and acidified with conc. HCl. The resulting precipitate was filtered off, washed with cold water and dried, yielding 0.7 g of cis-2-carbamoylcyclopentanecarboxylic acid with a melting point of 132-133° C. (lit.: 126-128° C.).
-
- Under stirring at 0° C. 0.41 g (2.6 mmol) of Br2 were added to an aqueous solution (1.8 mL) of 0.48 g (12 mmol) NaOH. The mixture was cooled again and then 0.34 g (2.16 mmol) of cis-2-carbamoylcyclopentanecarboxylic acid added. After stirring for about 10 minutes again 0.35 g (8.65 mmol) NaOH—dissolved in 1.35 ml of water—were added, and then the whole mixture warmed to 75° C. for about 5 minutes. The mixture then was cooled again, neutralized by addition of conc. HCl, acidified with acetic acid and evaporated to dryness. The residue obtained was extracted five times with refluxing ethanol, and the combined ethanol-fractions evaporated again yielding 1.1 g of a white solid.
- Purification was achieved by filtration of this residue over a column with Dowex 50 ion exchange resin. Therefore the column was washed with a solution of the solid in water, and then the product eluted by treatment with solid was dissolved in water and the column, absorbed on by washing the column with aqueous diluted NH3. After evaporation of the water the remaining crude product was recristallized from acetone yielding 0.14 g of pure cis-2-aminocyclopentanecarboxylic acid with a melting point of 200-202° C.
-
- To a solution of 1.5 g (11.6 mmol) of cis-2-aminocyclopentanecarboxylic acid in a mixture of acetonitrile/water 3:1 were added 3.3 g (15.1 mmol) of ditbutyldicarbonate, 0.5 g (12.2 mmol) of NaOH dissolved in 12 ml of H2O and 0.1 g (0.82 mmol) of DMAP. The mixture was stirred at ambient temperature for about 3 days, then diluted with water, extracted with ethylacetate. The combined organic phases were washed with a saturated aqueous NaCl-solution, dried over MgSO4 and evaporated to dryness leaving 1.3 g of the Boc-protected compound as an oil. A solution of the crude product and 0.65 g (6.1 mmol) benzylamine in a mixture of THF/DMF 10:1 was cooled to −10° C., then were added subsequently 0.9 g (5.86 mmol) of HOBT, 1.12 g (5.86 mmol) of EDC×HCl and 3 ml of NMM. The mixture was stirred for 2 h at −10° C., for 3 h at 0° C. and was then allowed to warm up to room temperature. After evaporation to dryness the remaining residue was dissolved in ethylacetate, washed with aqueous solutions of 5% citric acid, NaHCO3 and NaCl and dried over MgSO4. Evaporation yielded 1.3 g of cis-2-t-butyloxycarbonylaminocyclo-pentanecarboxylic acid benzylamide as an oil.
- HPLC (gradient 2): Rt 10.5 min.
- (Column: Machery & Nagel Nucleosil C18 PPN, 100×2.1, 5 m/100 A, acetonitrile/H2O+0.1% TFA; flow: 0.2 ml/min; temp. 40° C.).
-
-
- To a solution of 0.7 g (2.2 mmol) of of cis-2-tert.butyloxycarbonylaminocyclo-pentanecarboxylic acid benzylamide in 30 ml CH2Cl2 were added 25 ml of saturated HCl in diethylether; the mixture was then stirred for 2 h at ambient temperature. Evaporation to dryness and coevaporation with toluene yielded 0.6 g of the deprotected amine as hydrochloride salt.
-
- To a solution of 0.86 g (1.9 mmol) of the tetrapeptide Me2Val-Val-MeVal-Pro-OH and 0.56 g (2.2 mmol) aminocyclo-pentanecarboxylic acid benzylamide hydrochloride in 30 ml of THF/DMF 5:1 were added subsequently at −10° C. 0.29 g (1.9 mmol) of HOBT; 0.37 g (1.9 mmol) of EDC×HCl and 1.2 ml of NMM. The mixture was stirred for another at −10° C., then for 1-2 h at 0° C. and then allowed to warm up to ambient temperature. After evaporation the remaining residue was diluted with ethyl acetate, washed with an aqueous solution of NaCl, dried over MgSO4 and evaporated again. The remaining crude product (1.2 g) was purified by flash cromatography on silica gel (CH2Cl2/CH3OH) yielding 0.37 g of Me2Val-Val-MeVal-Pro-[cis-2-aminocyclopentanecarboxylic acid]-NHBn.
- FAB-MS: 655 (M+H+).
- The following compounds can be prepared as outlined in Schemes I-III and according to the above examples.
- Table 1:
- A is Me2Val, B is Val, D is MeVal, E is Pro, F is of Formula IIF and the group —C(═O)-G is in position 2 relative to the nitrogen atom. G is of Formula IIg or, IIIg or IVg.
No. RF R1 F R2 F —C(═O)—G I-1 H H H —NH—CH3 I-2 H H H —NH—CH2—C6H5 I-3 H H H —NH-isoC3H5 I-4 H H H —NH—C6H5 I-5 H H H 1,3-Thiazol-2-yl-amide I-6 H 4-OCH3 5-OCH3 —NH—CH3 I-7 H 3-cycloC5H9 H —NH—CH3 I-8 H H H —NH—C2H5 I-9 H H H —NH-nC3H7 I-10 H H H —NH-nC4H9 I-11 H H H —NH-tertC4H9 I-12 H H H —NH-cycloC3H5 I-13 H H H —NH-cycloC4H7 I-14 H H H —NH-cycloC5H9 I-15 H H H —NH-cycloC6H11 I-16 H H H —NH-cycloC7H12 I-17 H H H —NH—CH3—O—CH3 I-18 H H H —NH—CH2—CH2—O—CH3 I-19 H H H —NH-1-adamantyl I-20 H H H —NH-(4-HO-C6H5) I-21 H H H —NH-(2-CF3—C6H4) I-22 H H H —NH-(3-CF3—C6H4) I-23 H H H —NH-(4-CF3—C6H4) I-24 H H H —NH-(2-OCH3—C6H4) I-25 H H H —NH-(3-OCH3—C6H4) I-26 H H H —NH-(4-OCH3—C6H4) I-27 H H H —NH-(2-SCH3—C6H4) I-28 H H H —NH-(3-SCH3—C6H4) I-29 H H H —NH-(4-SCH3—C6H4) I-30 H H H —NH-(2-N(CH3)2—C6H4) I-31 H H H —NH-(3-N(CH3)2—C6H4) I-32 H H H —NH-(4-N(CH3)2—C6H4) I-33 H H H —NH-(4-CN-C6H4) I-34 H H H —NH-(4-Cl-C6H4) I-35 H H H —NH-(4-Br-C6H4] I-36 H H H —NH-(4-F-C6H4] I-37 H H H —NH-(4-CH3—C6H4) I-33 H H H —NH-(2-NO2—C6H4) I-39 H H H —NH-(3-NO2—C6H4) I-40 H H H —NH-(4-NO2—C6H4) I-41 H H H —NH-(2,4-OCH3—C6H3) I-42 H H H —NH-(3,4-OCH3—C6H3) I-43 H H H —NH-(3,4,5-OCH3—C6H2) I-44 H H H —NH-(3,4-CH2OCH2—C6H3) I-45 H H H —NH-(2,3-CH2OCH2—C6H3) I-46 H H H —NH-2-pyridinyl I-47 H H H —NH-2-furanyl I-48 H H H —NH-2-thienyl I-49 H H H —NH-3-pyridinyl I-50 H H H —NH-3-furanyl I-51 H H H —NH-3-thienyl I-52 H H H —NH-4-pyridinyl I-53 H H H —NH-2-oxazolyl I-54 H H H —NH-3-isoxazolyl I-55 H H H —NH-4-isoxazolyl I-56 H H H —NH-5-isoxazloyl I-57 H H H —NH-2R-(but-2-yl) I-58 H H H —NH-2S-(but-2-yl) I-59 H H H —NH—O—CH3 I-60 H H H —N(CH3) (OCH3) I-61 H H H —N(—(CH2)3—O—) I-62 H H H —NH—O—CH2—C6H5 I-63 H H H —N(CH3)(O—CH2—C6H5) I-64 H H H —N(—(CH2)2—CH(C6H5)—O—) I-65 H H H —NH—O—C2H5 I-66 H H H —N(C2H5)(OC2H5) I-67 H H H —N(CH2)(OC2H5) I-58 H H H —NH—O-isoC3H7 I-69 H H H —N(CH3)(O-isoC3H7) I-70 H H H —NH—O—nC3H7 I-71 H H H —N(CH3)(O—nC3H7) I-72 H H H —NH—O—nC4H9 I-73 H H H —N(CH2)(O—nC4H9) I-74 H H H —NH-O-tertC4H9 I-75 H H H —N(CH3)(O-tertC4H9) I-76 H H H —NH—O—C6H5 I-77 H H H —N(CH3)(O—C6H5) I-78 H H H —N(CH3)2 I-79 H H H —N(CH2—C6H5)2 I-80 H H H —N(C2H5)2 I-81 H H H —N(isoC3H7)2 I-82 H H H —N(nC3H7)2 I-83 H H H —N(nC4H9)2 I-84 H H H —N(C6H5)2 I-85 H H H —NH—CH2—CH2—OH I-86 H H H —NH—(CH2)3—OH I-87 H H H —NH(—(CH2)2CH(C6H5)OH) I-88 H H H —NH—(CH2)4—OH I-89 H H H —NH(—CH(CH3)—CH2—OH) I-90 H H H —NH(—CH2—CH(CH3)—OH) I-91 H H H —NH(CH(CH3)(CH2)2OH) I-92 H H H —NH(—(CH2)2CH(CH3)OH) I-93 H 4-CH3 H —NH—CH3 I-94 H 4-CH3 H —NH—CH2—C6H5 I-95 H 4-CH3 H —NH—isoC3H7 I-96 H 4-CH3 H —NH—C6H5 I-97 H 4-CH3 H —NH—C2H5 I-98 H 4-CH3 H —NH-nC3H7 I-99 H 4-CH3 H —NH—nC4H9 I-100 H 4-CH3 H —NH-tertC4H9 I-101 H 4-CH3 H —NH-cycloC3H5 I-102 H 4-CH3 H —NH- cycloC4H7 I-103 H 4-CH3 H —NH-cycloC5H9 I-104 H 4-CH3 H —NH-cycloC6H11 I-105 H 4-CH3 H —NH-1-adamantyl I-106 H 4-CH3 H —NH-2R-(but-2-yl) I-107 H 4-CH3 H —NH-2S-(but-2-yl) I-108 H 4-CH3 H —NH—O—CH3 I-109 H 4-CH3 H —N(CH3)(OCH3) I-110 H 4-CH3 H —N(—(CH3—O—) I-111 H 4-CH3 H —N(CH3)2 I-112 H 4-CH3 H —N(CH2—C6H5)2 I-113 H 4-CH3 H —N(C2H5)2 I-114 H 4-CH3 H —N(isoC3H7)2 I-115 H 4-CH3 H —N(nC3H7)2 I-116 H 4-CH3 H —N(nC4H9)2 I-117 H 4-CH3 H —N(C6H5)2 I-118 H 5-CH3 H —NH—CH3 I-119 H 5-CH3 H —NH—CH2—C6H5 I-120 H 5-CH3 H —NH-isoC3H7 I-121 H 5-CH3 H —NH-C6H5 I-122 H 5-CH3 H —NH-C2H5 I-123 H 5-CH3 H —NH-nC3H7 I-124 H 5-CH3 H —NH-nC4H9 I-125 H 5-CH3 H —NH-tertC4H9 I-126 H 5-CH3 H —NH-cycloC3H5 I-127 H 5-CH3 H —NH-cycloC4H7 I-128 H 5-CH3 H —NH-cycloC5H9 I-129 H 5-CH3 H —NH-cycloC6H11 I-130 H 5-CH3 H —NH-1-adamantyl I-131 H 5-CH3 H —NH-2R-(but-2-yl) I-132 H 5-CH3 H —NH-2S-(but-2-yl) I-133 H 5-CH3 H —NH—O—CH3 I-134 H 5-CH3 H —N(CH3)(OCH3) I-135 H 5-CH3 H —N(—(CH3)3—O—) I-136 H 5-CH3 H —N(CH3)2 I-137 H 5-CH3 H —N(CH2—C6H5)2 I-138 H 5-CH3 H —N(C2H5)2 I-139 H 5-CH3 H —N(isoC3H7)2 I-140 H 5-CH3 H —N(nC3H7)2 I-141 H 5-CH3 H —N(nC4H9)2 I-142 H 5-CH3 H —N(C6H5)2 I-143 CH3 H H —NH—CH3 I-144 CH3 H H —NH—CH2—C6H5 I-145 CH3 H H —NH—isoC3H7 I-146 CH3 H H —NH-C6H5 I-147 CH3 H H —NH-C2H5 I-148 CH3 H H —NH-nC3H7 I-149 CH3 H H —NH-nC4H9 I-150 CH3 H H —NH-tertC4H9 I-151 CH3 H H —NH-cycloC3H5 I-152 CH3 H H —NH-cycloC4H7 I-153 CH3 H H —NH-cycloC5H9 I-154 CH3 H H —NH-cycloC6H11 I-155 CH3 H H —NH-1-adamantyl I-156 CH3 H H —NH-2R-(but-2-yl) I-157 CH3 H H —NH-2S-(but-2-yl) I-158 CH3 H H —NH—O—CH3 I-159 CH3 H H —N(CH3)(OCH3) I-160 CH3 H H —N(—(CH2)3—O—) I-161 CH3 H H —N(CH3)2 I-162 CH3 H H —N(CH2—C6H5)3 I-163 CH3 H H —N(C2H5)2 I-164 CH3 H H —N(isoC3H7)2 I-165 CH3 H H —N(nC3H7)2 I-155 CH3 H H —N(nC4H9)2 I-167 CH3 H H —N(C6H5)2 I-168 H 4-OCH3 H —NH—CH3 I-159 H 4-OCH3 H —NH—CH2—C6H5 I-170 H 4-OCH3 H —NH-isoC3H7 I-171 H 4-OCH3 H —NH-C6H5 I-172 H 4-OCH3 H —NH-C2H5 I-173 H 4-OCH3 H —NH-nC4H7 I-174 H 4-OCH3 H —NH-nC5H9 I-175 H 4-OCH3 H —NH-tertC4H9 I-176 H 4-OCH3 H —NH-cycloC3H5 I-177 H 4-OCH3 H —NH-cycloC4H7 I-178 H 4-OCH3 H —NH-cycloC5H9 I-179 H 4-OCH3 H —NH-cycloC6H11 I-180 H 4-OCH3 H —NH-1-adamantyl I-181 H 4-OCH3 H —NH-2R-(but-2-yl) I-182 H 4-OCH3 H —NH-2S-(but-2-yl) I-183 H 4-OCH3 H —NH—O—CH3 I-184 H 4-OCH3 H —N(CH3)(OCH3) I-185 H 4-OCH3 H —N(—(CH2)3—O—) I-186 H 4-OCH3 H —N(CH3)2 I-187 H 4-OCH3 H —N(CH2—C6H5)2 I-188 H 4-OCH3 H —N(C2H5)2 I-189 H 4-OCH3 H —N(isoC3H7)2 I-190 H 4-OCH3 H —N(nC3H7)2 I-191 H 4-OCH3 H —N(nC4H9)2 I-192 H 4-CH3 H —N(C6H5)2 I-193 H 5-OCH3 H —NH—CH3 I-194 H 5-OCH3 H —NH—CH2—C6H5 I-195 H 5-OCH3 H —NH-isoC3H7 I-196 H 5-OCH3 H —NH—C6H5 I-197 H 5-OCH3 H —NH—C2H5 I-198 H 5-OCH3 H —NH-nC3H7 I-199 H 5-OCH3 H —NH-nC4H9 I-200 H 5-OCH3 H —NH-tertC4H9 I-201 H 5-OCH3 H —NH-cycloC3H5 I-202 H 5-OCH3 H —NH-cycloC4H7 I-203 H 5-OCH3 H —NH-cycloC5H9 I-204 H 5-OCH3 H —NH-cycloC6H11 I-205 H 5-OCH3 H —NH-1-adamantyl I-206 H 5-OCH3 H —NH-2R-(but-2-y1) I-207 H 5-OCH3 H —NH-2S-(but-2-yl) I-208 H 5-OCH3 H —NH—O—CH3 I-209 H 5-OCH3 H —N(CH3)(OCH3) I-210 H 5-OCH3 H —N(—(CH2)3—O—) I-211 H 5-OCH3 H —N(CH3)2 I-212 H 5-OCH3 H —N(CH2—C6H5)2 I-213 H 5-OCH3 H —N(C2H5)2 I-214 H 5-OCH3 H —N(isoC3H7)2 I-215 H 5-OCH3 H —N(nC4H9)2 I-216 H 5-OCH3 H —N(nC4H9)2 I-217 H 5-OCH3 H —N(C6H5)2 - Table 2:
- A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the group —C(O)-G is in position 3 relative to the nitrogen atom and G is of Formula IIg, IIIg or IVg.
No. RF R1 F R2 F —G II-1 H H H —NH—CH3 II-2 H H H —NH—CH2—C6H5 II-3 H H H —NH-isoC3H5 II-4 H H H —NH—C6H5 II-5 H H H 1,3-Thiazol-2-yl-amide II-6 H 4-OCH3 5-OCH3 —NH—CH3 II-7 H 3-cycloC5H9 H —NH—CH3 II-8 H H H —NH—C2H5 II-9 H H H —NH-nC3H7 II-10 H H H —NH-nC4H9 II-11 H H H —NH-tertC4H9 II-12 H H H —NH-cycloC3H5 II-13 H H H —NH-cycloC4H7 II-14 H H H —NH-cycloC5H9 II-15 H H H —NH-cycloC6H11 II-16 H H H —NH-cycloC7H12 II-17 H H H —NH—CH3—O—CH3 II-18 H H H —NH—CH2—CH2—O—CH3 II-19 H H H —NH-1-adamantyl II-20 H H H —NH-(4-HO-C6H5) II-21 H H H —NH-(2-CF3—C6H4) II-22 H H H —NH-(3-CF3—C6H4) II-23 H H H —NH-(4-CF3—C6H4) II-24 H H H —NH-(2-OCH3—C6H4) II-25 H H H —NH-(3-OCH3—C6H4) II-26 H H H —NH-(4-OCH3—C6H4) II-27 H H H —NH-(2-SCH3—C6H4) II-28 H H H —NH-(3-SCH3—C6H4) II-29 H H H —NH-(4-SCH3—C6H4) II-30 H H H —NH-(2-N(CH3)2—C6H4) II-31 H H H —NH-(3-N(CH3)2—C6H4) II-32 H H H —NH-(4-N(CH3)2—C6H4) II-33 H H H —NH-(4-CN-C6H4) II-34 H H H —NH-(4-Cl-C6H4) II-35 H H H —NH-(4-Br-C6H4] II-36 H H H —NH-(4-F-C6H4] II-37 H H H —NH-(4-CH3—C6H4) II-33 H H H —NH-(2-NO2—C6H4) II-39 H H H —NH-(3-NO2—C6H4) II-40 H H H —NH-(4-NO2—C6H4) II-41 H H H —NH-(2,4-OCH3—C6H3) II-42 H H H —NH-(3,4-OCH3—C6H3) II-43 H H H —NH-(3,4,5-OCH3—C6H2) II-44 H H H —NH-(3,4-CH2OCH2—C6H3) II-45 H H H —NH-(2,3-CH2OCH2—C6H3) II-46 H H H —NH-2-pyridinyl II-47 H H H —NH-2-furanyl II-48 H H H —NH-2-thienyl II-49 H H H —NH-3-pyridinyl II-50 H H H —NH-3-furanyl II-51 H H H —NH-3-thienyl II-52 H H H —NH-4-pyridinyl II-53 H H H —NH-2-oxazolyl II-54 H H H —NH-3-isoxazolyl II-55 H H H —NH-4-isoxazolyl II-56 H H H —NH-5-isoxazloyl II-57 H H H —NH-2R-(but-2-yl) II-58 H H H —NH-2S-(but-2-yl) II-59 H H H —NH—O—CH3 II-60 H H H —N(CH3) (OCH3) II-61 H H H —N(—(CH2)3—O—) II-62 H H H —NH—O—CH2—C6H5 II-63 H H H —N(CH3)(O—CH2—C6H5) II-64 H H H —N(—(CH2)2—CH(C6H5)—O—) II-65 H H H —NH—O—C2H5 II-66 H H H —N(C2H5)(OC2H5) II-67 H H H —N(CH2)(OC2H5) II-68 H H H —NH—O-isoC3H7 II-69 H H H —N(CH3)(O-isoC3H7) II-70 H H H —NH—O—nC3H7 II-71 H H H —N(CH3)(O—nC3H7) II-72 H H H —NH—O—nC4H9 II-73 H H H —N(CH2)(O—nC4H9) II-74 H H H —NH-O-tertC4H9 II-75 H H H —N(CH3)(O-tertC4H9) II-76 H H H —NH—O—C6H5 II-77 H H H —N(CH3)(O—C6H5) II-78 H H H —N(CH3)2 II-79 H H H —N(CH2—C6H5)2 II-80 H H H —N(C2H5)2 II-81 H H H —N(isoC3H7)2 II-82 H H H —N(nC3H7)2 II-83 H H H —N(nC4H9)2 II-84 H H H —N(C6H5)2 II-85 H H H —NH—CH2—CH2—OH II-86 H H H —NH—(CH2)3—OH II-87 H H H —NH(—(CH2)2CH(C6H5)OH) II-88 H H H —NH—(CH2)4—OH II-89 H H H —NH(—CH(CH3)—CH2—OH) II-90 H H H —NH(—CH2—CH(CH3)—OH) II-91 H H H —NH(CH(CH3)(CH2)2OH) II-92 H H H —NH(—(CH2)2CH(CH3)OH) II-93 H 4-CH3 H —NH—CH3 II-94 H 4-CH3 H —NH—CH2—C6H5 II-95 H 4-CH3 H —NH—isoC3H7 II-96 H 4-CH3 H —NH—C6H5 II-97 H 4-CH3 H —NH—C2H5 II-98 H 4-CH3 H —NH-nC3H7 II-99 H 4-CH3 H —NH—nC4H9 II-100 H 4-CH3 H —NH-tertC4H9 II-101 H 4-CH3 H —NH-cycloC3H5 II-102 H 4-CH3 H —NH- cycloC4H7 II-103 H 4-CH3 H —NH-cycloC5H9 II-104 H 4-CH3 H —NH-cycloC6H11 II-105 H 4-CH3 H —NH-1-adamantyl II-106 H 4-CH3 H —NH-2R-(but-2-yl) II-107 H 4-CH3 H —NH-2S-(but-2-yl) II-108 H 4-CH3 H —NH—O—CH3 II-109 H 4-CH3 H —N(CH3)(OCH3) II-110 H 4-CH3 H —N(—(CH3—O—) II-111 H 4-CH3 H —N(CH3)2 II-112 H 4-CH3 H —N(CH2—C6H5)2 II-113 H 4-CH3 H —N(C2H5)2 II-114 H 4-CH3 H —N(isoC3H7)2 II-115 H 4-CH3 H —N(nC3H7)2 II-116 H 4-CH3 H —N(nC4H9)2 II-117 H 4-CH3 H —N(C6H5)2 II-118 H 5-CH3 H —NH—CH3 II-119 H 5-CH3 H —NH—CH2—C6H5 II-120 H 5-CH3 H —NH-isoC3H7 II-121 H 5-CH3 H —NH-C6H5 II-122 H 5-CH3 H —NH-C2H5 II-123 H 5-CH3 H —NH-nC3H7 II-124 H 5-CH3 H —NH-nC4H9 II-125 H 5-CH3 H —NH-tertC4H9 II-126 H 5-CH3 H —NH-cycloC3H5 II-127 H 5-CH3 H —NH-cycloC4H7 II-128 H 5-CH3 H —NH-cycloC5H9 II-129 H 5-CH3 H —NH-cycloC6H11 II-130 H 5-CH3 H —NH-1-adamantyl II-131 H 5-CH3 H —NH-2R-(but-2-yl) II-132 H 5-CH3 H —NH-2S-(but-2-yl) II-133 H 5-CH3 H —NH—O—CH3 II-134 H 5-CH3 H —N(CH3)(OCH3) II-135 H 5-CH3 H —N(—(CH3)3—O—) II-136 H 5-CH3 H —N(CH3)2 II-137 H 5-CH3 H —N(CH2—C6H5)2 II-138 H 5-CH3 H —N(C2H5)2 II-139 H 5-CH3 H —N(isoC3H7)2 II-140 H 5-CH3 H —N(nC3H7)2 II-141 H 5-CH3 H —N(nC4H9)2 II-142 H 5-CH3 H —N(C6H5)2 II-143 CH3 H H —NH—CH3 II-144 CH3 H H —NH—CH2—C6H5 II-145 CH3 H H —NH—isoC3H7 II-146 CH3 H H —NH-C6H5 II-147 CH3 H H —NH-C2H5 II-148 CH3 H H —NH-nC3H7 II-149 CH3 H H —NH-nC4H9 II-150 CH3 H H —NH-tertC4H9 II-151 CH3 H H —NH-cycloC3H5 II-152 CH3 H H —NH-cycloC4H7 II-153 CH3 H H —NH-cycloC5H9 II-154 CH3 H H —NH-cycloC6H11 II-155 CH3 H H —NH-1-adamantyl II-156 CH3 H H —NH-2R-(but-2-yl) II-157 CH3 H H —NH-2S-(but-2-yl) II-158 CH3 H H —NH—O—CH3 II-159 CH3 H H —N(CH3)(OCH3) II-160 CH3 H H —N(—(CH2)3—O—) II-161 CH3 H H —N(CH3)2 II-162 CH3 H H —N(CH2—C6H5)3 II-163 CH3 H H —N(C2H5)2 II-164 CH3 H H —N(isoC3H7)2 II-165 CH3 H H —N(nC3H7)2 II-155 CH3 H H —N(nC4H9)2 II-167 CH3 H H —N(C6H5)2 II-168 H 4-OCH3 H —NH—CH3 II-159 H 4-OCH3 H —NH—CH2—C6H5 II-170 H 4-OCH3 H —NH-isoC3H7 II-171 H 4-OCH3 H —NH-C6H5 II-172 H 4-OCH3 H —NH-C2H5 II-173 H 4-OCH3 H —NH-nC4H7 II-174 H 4-OCH3 H —NH-nC5H9 II-175 H 4-OCH3 H —NH-tertC4H9 II-176 H 4-OCH3 H —NH-cycloC3H5 II-177 H 4-OCH3 H —NH-cycloC4H7 II-178 H 4-OCH3 H —NH-cycloC5H9 II-179 H 4-OCH3 H —NH-cycloC6H11 II-180 H 4-OCH3 H —NH-1-adamantyl II-181 H 4-OCH3 H —NH-2R-(but-2-yl) II-182 H 4-OCH3 H —NH-2S-(but-2-yl) II-183 H 4-OCH3 H —NH—O—CH3 II-184 H 4-OCH3 H —N(CH3)(OCH3) II-185 H 4-OCH3 H —N(—(CH2)3—O—) II-186 H 4-OCH3 H —N(CH3)2 II-187 H 4-OCH3 H —N(CH2—C6H5)2 II-188 H 4-OCH3 H —N(C2H5)2 II-189 H 4-OCH3 H —N(isoC3H7)2 II-190 H 4-OCH3 H —N(nC3H7)2 II-191 H 4-OCH3 H —N(nC4H9)2 II-192 H 4-OCH3 H —N(C6H5)2 II-193 H 5-OCH3 H —NH—CH3 II-194 H 5-OCH3 H —NH—CH2—C6H5 II-195 H 5-OCH3 H —NH-isoC3H7 II-196 H 5-OCH3 H —NH—C6H5 II-197 H 5-OCH3 H —NH—C2H5 II-198 H 5-OCH3 H —NH-nC3H7 II-199 H 5-OCH3 H —NH-nC4H9 II-200 H 5-OCH3 H —NH-tertC4H9 II-201 H 5-OCH3 H —NH-cycloC3H5 II-202 H 5-OCH3 H —NH-cycloC4H7 II-203 H 5-OCH3 H —NH-cycloC5H9 II-204 H 5-OCH3 H —NH-cycloC6H11 II-205 H 5-OCH3 H —NH-1-adamantyl II-206 H 5-OCH3 H —NH-2R-(but-2-y1) II-207 H 5-OCH3 H —NH-2S-(but-2-yl) II-208 H 5-OCH3 H —NH—O—CH3 II-209 H 5-OCH3 H —N(CH3)(OCH3) II-210 H 5-OCH3 H —N(—(CH2)3—O—) II-211 H 5-OCH3 H —N(CH3)2 II-212 H 5-OCH3 H —N(CH2—C6H5)2 II-213 H 5-OCH3 H —N(C2H5)2 II-214 H 5-OCH3 H —N(isoC3H7)2 II-215 H 5-OCH3 H —N(nC4H9)2 II-216 H 5-OCH3 H —N(nC4H9)2 II-217 H 5-OCH3 H —N(C6H5)2 - Table 3:
- A is Me2Val, B is Val, D is MeVal, E is Pro, F is of Formula IIf, the substituent —(C═O)-G is in position 4 relative to the nitrogen. G is of Formula IIg, IIIg or IVg.
No. RF R1 F R2 F —G III-1 H H H —NH—CH3 III-2 H H H —NH—CH2—C6H5 III-3 H H H —NH-isoC3H5 III-4 H H H —NH—C6H5 III-5 H H H 1,3-Thiazol-2-yl-amide III-6 H 4-OCH3 5-OCH3 —NH—CH3 III-7 H 3-cycloC5H9 H —NH—CH3 III-8 H H H —NH—C2H5 III-9 H H H —NH-nC3H7 III-10 H H H —NH-nC4H9 III-11 H H H —NH-tertC4H9 III-12 H H H —NH-cycloC3H5 III-13 H H H —NH-cycloC4H7 III-14 H H H —NH-cycloC5H9 III-15 H H H —NH-cycloC6H11 III-16 H H H —NH-cycloC7H12 III-17 H H H —NH—CH3—O—CH3 III-18 H H H —NH—CH2—CH2—O—CH3 III-19 H H H —NH-1-adamantyl III-20 H H H —NH-(4-HO-C6H5) III-21 H H H —NH-(2-CF3—C6H4) III-22 H H H —NH-(3-CF3—C6H4) III-23 H H H —NH-(4-CF3—C6H4) III-24 H H H —NH-(2-OCH3—C6H4) III-25 H H H —NH-(3-OCH3—C6H4) III-26 H H H —NH-(4-OCH3—C6H4) III-27 H H H —NH-(2-SCH3—C6H4) III-28 H H H —NH-(3-SCH3—C6H4) III-29 H H H —NH-(4-SCH3—C6H4) III-30 H H H —NH-(2-N(CH3)2—C6H4) III-31 H H H —NH-(3-N(CH3)2—C6H4) III-32 H H H —NH-(4-N(CH3)2—C6H4) III-33 H H H —NH-(4-CN-C6H4) III-34 H H H —NH-(4-Cl-C6H4) III-35 H H H —NH-(4-Br-C6H4] III-36 H H H —NH-(4-F-C6H4] III-37 H H H —NH-(4-CH3—C6H4) III-33 H H H —NH-(2-NO2—C6H4) III-39 H H H —NH-(3-NO2—C6H4) III-40 H H H —NH-(4-NO2—C6H4) III-41 H H H —NH-(2,4-OCH3—C6H3) III-42 H H H —NH-(3,4-OCH3—C6H3) III-43 H H H —NH-(3,4,5-OCH3—C6H2) III-44 H H H —NH-(3,4-CH2OCH2—C6H3) III-45 H H H —NH-(2,3-CH2OCH2—C6H3) III-46 H H H —NH-2-pyridinyl III-47 H H H —NH-2-furanyl III-48 H H H —NH-2-thienyl III-49 H H H —NH-3-pyridinyl III-50 H H H —NH-3-furanyl III-51 H H H —NH-3-thienyl III-52 H H H —NH-4-pyridinyl III-53 H H H —NH-2-oxazolyl III-54 H H H —NH-3-isoxazolyl III-55 H H H —NH-4-isoxazolyl III-56 H H H —NH-5-isoxazloyl III-57 H H H —NH-2R-(but-2-yl) III-58 H H H —NH-2S-(but-2-yl) III-59 H H H —NH—O—CH3 III-60 H H H —N(CH3) (OCH3) III-61 H H H —N(—(CH2)3—O—) III-62 H H H —NH—O—CH2—C6H5 III-63 H H H —N(CH3)(O—CH2—C6H5) III-64 H H H —N(—(CH2)2—CH(C6H5)—O—) III-65 H H H —NH—O—C2H5 III-66 H H H —N(C2H5)(OC2H5) III-67 H H H —N(CH2)(OC2H5) III-58 H H H —NH—O-isoC3H7 III-69 H H H —N(CH3)(O-isoC3H7) III-70 H H H —NH—O—nC3H7 III-71 H H H —N(CH3)(O—nC3H7) III-72 H H H —NH—O—nC4H9 III-73 H H H —N(CH2)(O—nC4H9) III-74 H H H —NH-O-tertC4H9 III-75 H H H —N(CH3)(O-tertC4H9) III-76 H H H —NH—O—C6H5 III-77 H H H —N(CH3)(O—C6H5) III-78 H H H —N(CH3)2 III-79 H H H —N(CH2—C6H5)2 III-80 H H H —N(C2H5)2 III-81 H H H —N(isoC3H7)2 III-82 H H H —N(nC3H7)2 III-83 H H H —N(nC4H9)2 III-84 H H H —N(C6H5)2 III-85 H H H —NH—CH2—CH2—OH III-86 H H H —NH—(CH2)3—OH III-87 H H H —NH(—(CH2)2CH(C6H5)OH) III-88 H H H —NH—(CH2)4—OH III-89 H H H —NH(—CH(CH3)—CH2—OH) III-90 H H H —NH(—CH2—CH(CH3)—OH) III-91 H H H —NH(CH(CH3)(CH2)2OH) III-92 H H H —NH(—(CH2)2CH(CH3)OH) III-93 H 2-CH3 H —NH—CH3 III-94 H 2-CH3 H —NH—CH2—C6H5 III-95 H 2-CH3 H —NH—isoC3H7 III-96 H 2-CH3 H —NH—C6H5 III-97 H 2-CH3 H —NH—C2H5 III-98 H 2-CH3 H —NH-nC3H7 III-99 H 2-CH3 H —NH—nC4H9 III-100 H 2-CH3 H —NH-tertC4H9 III-101 H 2-CH3 H —NH-cycloC3H5 III-102 H 2-CH3 H —NH- cycloC4H7 III-103 H 2-CH3 H —NH-cycloC5H9 III-104 H 2-CH3 H —NH-cycloC6H11 III-105 H 2-CH3 H —NH-1-adamantyl III-106 H 2-CH3 H —NH-2R-(but-2-yl) III-107 H 2-CH3 H —NH-2S-(but-2-yl) III-108 H 2-CH3 H —NH—O—CH3 III-109 H 2-CH3 H —N(CH3)(OCH3) III-110 H 2-CH3 H —N(—(CH3—O—) III-111 H 2-CH3 H —N(CH3)2 III-112 H 2-CH3 H —N(CH2—C6H5)2 III-113 H 2-CH3 H —N(C2H5)2 III-114 H 2-CH3 H —N(isoC3H7)2 III-115 H 2-CH3 H —N(nC3H7)2 III-116 H 2-CH3 H —N(nC4H9)2 III-117 H 2-CH3 H —N(C6H5)2 III-118 H 3-CH3 H —NH—CH3 III-119 H 3-CH3 H —NH—CH2—C6H5 III-120 H 3-CH3 H —NH-isoC3H7 III-121 H 3-CH3 H —NH-C6H5 III-122 H 3-CH3 H —NH-C2H5 III-123 H 3-CH3 H —NH-nC3H7 III-124 H 3-CH3 H —NH-nC4H9 III-125 H 3-CH3 H —NH-tertC4H9 III-126 H 3-CH3 H —NH-cycloC3H5 III-127 H 3-CH3 H —NH-cycloC4H7 III-128 H 3-CH3 H —NH-cycloC5H9 III-129 H 3-CH3 H —NH-cycloC6H11 III-130 H 3-CH3 H —NH-1-adamantyl III-131 H 3-CH3 H —NH-2R-(but-2-yl) III-132 H 3-CH3 H —NH-2S-(but-2-yl) III-133 H 3-CH3 H —NH—O—CH3 III-134 H 3-CH3 H —N(CH3)(OCH3) III-135 H 3-CH3 H —N(—(CH3)3—O—) III-136 H 3-CH3 H —N(CH3)2 III-137 H 3-CH3 H —N(CH2—C6H5)2 III-138 H 3-CH3 H —N(C2H5)2 III-139 H 3-CH3 H —N(isoC3H7)2 III-140 H 3-CH3 H —N(nC3H7)2 III-141 H 3-CH3 H —N(nC4H9)2 III-142 H 3-CH3 H —N(C6H5)2 III-143 CH3 H H —NH—CH3 III-144 CH3 H H —NH—CH2—C6H5 III-145 CH3 H H —NH—isoC3H7 III-146 CH3 H H —NH-C6H5 III-147 CH3 H H —NH-C2H5 III-148 CH3 H H —NH-nC3H7 III-149 CH3 H H —NH-nC4H9 III-150 CH3 H H —NH-tertC4H9 III-151 CH3 H H —NH-cycloC3H5 III-152 CH3 H H —NH-cycloC4H7 III-153 CH3 H H —NH-cycloC5H9 III-154 CH3 H H —NH-cycloC6H11 III-155 CH3 H H —NH-1-adamantyl III-156 CH3 H H —NH-2R-(but-2-yl) III-157 CH3 H H —NH-2S-(but-2-yl) III-158 CH3 H H —NH—O—CH3 III-159 CH3 H H —N(CH3)(OCH3) III-160 CH3 H H —N(—(CH2)3—O—) III-161 CH3 H H —N(CH3)2 III-162 CH3 H H —N(CH2—C6H5)3 III-163 CH3 H H —N(C2H5)2 III-164 CH3 H H —N(isoC3H7)2 III-165 CH3 H H —N(nC3H7)2 III-166 CH3 H H —N(nC4H9)2 III-167 CH3 H H —N(C6H5)2 III-168 H 2-OCH3 H —NH—CH3 III-169 H 2-OCH3 H —NH—CH2—C6H5 III-170 H 2-OCH3 H —NH-isoC3H7 III-171 H 2-OCH3 H —NH-C6H5 III-172 H 2-OCH3 H —NH-C2H5 III-173 H 2-OCH3 H —NH-nC4H7 III-174 H 2-OCH3 H —NH-nC5H9 III-175 H 2-OCH3 H —NH-tertC4H9 III-176 H 2-OCH3 H —NH-cycloC3H5 III-177 H 2-OCH3 H —NH-cycloC4H7 III-178 H 2-OCH3 H —NH-cycloC5H9 III-179 H 2-OCH3 H —NH-cycloC6H11 III-180 H 2-OCH3 H —NH-1-adamantyl III-181 H 2-OCH3 H —NH-2R-(but-2-yl) III-182 H 2-OCH3 H —NH-2S-(but-2-yl) III-183 H 2-OCH3 H —NH—O—CH3 III-184 H 2-OCH3 H —N(CH3)(OCH3) III-185 H 2-OCH3 H —N(—(CH2)3—O—) III-186 H 2-OCH3 H —N(CH3)2 III-187 H 2-OCH3 H —N(CH2—C6H5)2 III-188 H 2-OCH3 H —N(C2H5)2 III-189 H 2-OCH3 H —N(isoC3H7)2 III-190 H 2-OCH3 H —N(nC3H7)2 III-191 H 2-OCH3 H —N(nC4H9)2 III-192 H 2-OCH3 H —N(C6H5)2 III-193 H 3-OCH3 H —NH—CH3 III-194 H 3-OCH3 H —NH—CH2—C6H5 III-195 H 3-OCH3 H —NH-isoC3H7 III-196 H 3-OCH3 H —NH—C6H5 III-197 H 3-OCH3 H —NH—C2H5 III-198 H 3-OCH3 H —NH-nC3H7 III-199 H 3-OCH3 H —NH-nC4H9 III-200 H 3-OCH3 H —NH-tertC4H9 III-201 H 3-OCH3 H —NH-cycloC3H5 III-202 H 3-OCH3 H —NH-cycloC4H7 III-203 H 3-OCH3 H —NH-cycloC5H9 III-204 H 3-OCH3 H —NH-cycloC6H11 III-205 H 3-OCH3 H —NH-1-adamantyl III-206 H 3-OCH3 H —NH-2R-(but-2-y1) III-207 H 3-OCH3 H —NH-2S-(but-2-yl) III-208 H 3-OCH3 H —NH—O—CH3 III-209 H 3-OCH3 H —N(CH3)(OCH3) III-210 H 3-OCH3 H —N(—(CH2)3—O—) III-211 H 3-OCH3 H —N(CH3)2 III-212 H 3-OCH3 H —N(CH2—C6H5)2 III-213 H 3-OCH3 H —N(C2H5)2 III-214 H 3-OCH3 H —N(isoC3H7)2 III-215 H 3-OCH3 H —N(nC4H9)2 III-216 H 3-OCH3 H —N(nC4H9)2 III-217 H 3-OCH3 H —N(C6H5)2 - Table 4:
- A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the substituent —(C═O)-G is in position 2 relative to the nitrogen. G is of Formula Vg, VIg, VIIg, VIIIg or IXg.
No. RF R1F R2F -G IV-1 H H H —CH3 IV-2 H H H —C2H5 IV-3 H H H -nC3H7 IV-4 H H H -isoC3H7 IV-5 H H H -nC4H9 IV-6 H H H -tertC4H9 IV-7 H H H -cycloC3H5 IV-8 H H H -cycloC4H7 IV-9 H H H -cycloC5H9 IV-10 H H H -cycloC6H11 IV-11 H H H -cycloC7H12 IV-12 H H H —CH2—O—CH3 IV-13 H H H —CH2—CH2—O—CH3 IV-14 H H H —CH2—C6H5 IV-15 H H H —C6H5 IV-16 H H H -(4-HO—C6H5) IV-17 H H H -(2-CF3—C6H4) IV-18 H H H -(3-CF3—C6H4) IV-19 H H H -(4-CF3—C6H4) IV-20 H H H -(2-OCH3—C6H4) IV-21 H H H -(3-OCH3—C6H4) IV-22 H H H -(4-OCH3—C6H4) IV-23 H H H -(2-SCH3—C6H4) IV-24 H H H -(3-SCH3—C6H4) IV-25 H H H -(4-SCH3—C6H4) IV-26 H H H -(2-N(CH3)2—C6H4) IV-27 H H H -(3-N(CH3)2—C6H4) IV-28 H H H -(4-N(CH3)2—C6H4) IV-29 H H H -(4-CN—C6H4) IV-30 H H H -(4-Cl—C6H4) IV-31 H H H -(4-Br—C6H4] IV-32 H H H -(4-F—C6H4] IV-33 H H H -(4-CH3—C6H4) IV-34 H H H -(2-NO2—C6H4) IV-35 H H H -(3-NO2—C6H4) IV-36 H H H -(4-NO2—C6H4] IV-37 H H H -(2,4-OCH3—C6H3) IV-38 H H H -(3,4-OCH3—C6H3) IV-39 H H H -(3,4,5-OCH3—C6H2) IV-40 H H H -(3,4-CH2OCH2—C6H3) IV-41 H H H -(2,3-CH2OCH2—C6H3) IV-42 H H H -2-pyridinyl IV-43 H H H -2-furanyl IV-44 H H H -2-thienyl IV-45 H H H -3-pyridinyl IV-46 H H H -3-furanyl IV-47 H H H -3-thienyl IV-48 H H H -4-pyridinyl IV-49 H H H -2-thiazolyl IV-50 H H H -2-oxazolyl IV-51 H H H -3-isoxazolyl IV-52 H H H -4-isoxazolyl IV-53 H H H -5-isoxazolyl IV-54 H H H —CF3 IV-55 H H H —C2F5 IV-56 H H H —CH3 IV-57 H H H —C2H5 IV-58 H H H -nC3H7 IV-59 H H H -tertC4H9 IV-60 H H H —CH2—C6H5 IV-61 H H H —C6H5 IV-62 H H H —CH2—COOCH3 IV-63 H H H —CH2—COOC2H5 IV-64 H H H —CF2—COOCH3 IV-65 H H H —CF2—COOC2H5 IV-66 H H H —CH2—CONH2 IV-67 H H H —CH2—CONHCH3 IV-68 H H H —CH2—CON(CH3)2 IV-69 H H H —CH2—CONH—CH2—C6H5 IV-70 H H H —CH2—CONH—C6H5 IV-71 H H H —CH2—CONH(CH2—C6H5)2 IV-72 H H H —CH2—CON(—CH2—CH2— CH2—CH2—) IV-73 H H H —CH2—CON(—CH2—CH2— CH2—CH2—CH2) IV-74 H H H —CH2—CH2—COOCH3 IV-75 H H H —CH2—CH2—COOC2H5 IV-76 H H H —CH2—CH2—CONH2 IV-77 H H H —CH2—CH2—CONHCH3 IV-78 H H H —CH2—CH2—CON(CH3)2 IV-79 H H H —CH2—CH2—CONH—CH2—C6H5 IV-80 H H H —CH2—CH2—CONH—C6H5 IV-81 H H H —CH2—CH2—CONH(CH2—C6H5)2 IV-82 H H H —CH2—CH2—CON(—CH2—CH2— CH2—CH2—) IV-83 H H H —CH2—CH2—CON(—CH2— (CH2)3—CH2) IV-84 H H H —CH2—COCH3 IV-85 H H H —CH2—CH2—COCH3 IV-86 H H H —CH2—COC2H5 IV-87 H H H —CH2—CH2—COC2H5 IV-88 H H H —CH2—CO—C6H5 IV-89 H H H —CH2—CH2—CO—C6H5 IV-90 H H H —CH2—CO—CH2—C6H5 IV-91 H H H —CH2—CH2—CO—CH2—C6H5 IV-92 H H H —CH2—SOC6H5 IV-93 H H H —CH2—SOCH3 IV-94 H H H —CH2SO(4-CH3—C6H4) IV-95 H H H —CH2—SO2C6H5 IV-96 H H H —CH2—SO2CH3 IV-97 H H H —CH2—SO2(4-CH3—C6H4) IV-98 H H H —CH2—CH2—SOC6H5 IV-99 H H H —CH2—CH2—SOCH3 IV-100 H H H —CH2—CH2—SO(4-CH3—C6H4) IV-101 H H H —CH2—CH2—SO2C6H5 IV-102 H H H —CH2—CH2—SO2CH3 IV-103 H H H —CH2—CH2—SO3(4-CH3—C6H4) IV-104 CH3 H H —CH3 IV-105 CH3 H H —C2H5 IV-106 CH3 H H -nC3H7 IV-107 CH3 H H -isoC3H7 IV-108 CH3 H H -nC4H9 IV-109 CH3 H H -tertC4H9 IV-110 CH3 H H -cycloC3H5 IV-111 CH3 H H -cycloC4H7 IV-112 CH3 H H -cycloC5H9 IV-113 CH3 H H -cycloC6H11 IV-114 CH3 H H -cycloC7H12 IV-115 CH3 H H —CH2—O—CH3 IV-116 CH3 H H —CH2—CH3—O—CH3 IV-117 CH3 H H —CH2—C6H5 IV-118 CH3 H H —C6H5 IV-119 CH3 H H -(4-HO-C6H5) IV-120 CH3 H H -(2-CF3—C6H4) IV-121 CH3 H H -(3-CF3—C6H4) IV-122 CH3 H H -(4-CF3—C6H4) IV-123 CH3 H H -(2-OCH3—C6H4) IV-124 CH3 H H -(3-OCH3—C6H4) IV-125 CH3 H H -(4-OCH3—C6H4) IV-126 CH3 H H -(2-SCH3—C6H4) IV-127 CH3 H H -(3-SCH3—C6H4) IV-128 CH3 H H -(4-SCH3—C6H4) IV-129 CH3 H H -(2-N(CH3)2—C6H4) IV-130 CH3 H H -(3-N(CH3)2—C6H4) IV-131 CH3 H H -(4-N(CH3)2—C6H4) IV-132 CH3 H H -(4-CN-C6H4) IV-133 CH3 H H -(4-Cl—C6H4) IV-134 CH3 H H -(4-Br—C6H4] IV-135 CH3 H H -(4-F—C6H4] IV-136 CH3 H H -(4-CH3—C6H4) IV-137 CH3 H H -(2-NO2—C6H4) IV-138 CH3 H H -(3-NO2—C6H4) IV-139 CH3 H H -(4-NO2—C6H4] IV-140 CH3 H H -(2,4-OCH3—C6H3) IV-141 CH3 H H -(3,4-OCH3—C6H3) IV-142 CH3 H H -(3,4,5-OCH3—C6H2) IV-143 CH3 H H -(3,4-CH2OCH2—C6H3) IV-144 CH3 H H -(2,3-CH2OCH2—C6H3) IV-145 CH3 H H -2-pyridinyl IV-146 CH3 H H -2-furanyl IV-147 CH3 H H -2-thienyl IV-148 CH3 H H -3-pyridinyl IV-149 CH3 H H -3-furanyl IV-150 CH3 H H -3-thienyl IV-151 CH3 H H -4-pyridinyl IV-152 CH3 H H -2-thiazolyl IV-153 CH3 H H -2-oxazolyl IV-154 CH3 H H -3-isoxazolyl IV-155 CH3 H H -4-isoxazolyl IV-156 CH3 H H -5-isoxazoyl IV-157 CH3 H H —CF3 IV-158 CH3 H H —C2F5 IV-159 CH3 H H —CH3 IV-160 CH3 H H —C2H5 IV-161 CH3 H H -nC3H7 IV-162 CH3 H H -tertC4H9 IV-163 CH3 H H —CH2—C6H5 IV-164 CH3 H H —C6H5 IV-165 CH3 H H —CH2—COOCH3 IV-166 CH3 H H —CH2—COOC2H5 IV-167 CH3 H H —CF2—COOCH3 IV-168 CH3 H H —CF2—COOC2H5 IV-169 CH3 H H —CH2—CONH2 IV-170 CH3 H H —CH2—CONHCH3 IV-171 CH3 H H —CH2—CON(CH3)2 IV-172 CH3 H H —CH2—CONH—CH2—C6H5 IV-173 CH3 H H —CH2—CONH—C6H5 IV-174 CH3 H H —CH2—CONH(CH2—C6H5)2 IV-175 CH3 H H —CH2—CON(—CH2—CH2— CH2—CH2—) IV-176 CH3 H H —CH2—CON(—CH2—CH2—CH2— CH2—CH2) IV-177 CH3 H H —CH2—CH2—COOCH3 IV-178 CH3 H H —CH2—CH2—COOC2H5 IV-179 CH3 H H —CH2—CH2—CONH2 IV-180 CH3 H H —CH2—CH2—CONHCH3 IV-181 CH3 H H —CH2—CH2—CON(CH3)2 IV-182 CH3 H H —CH2—CH2—CONH—CH2—C6H5 IV-183 CH3 H H —CH2—CH2—CONH—C6H5 IV-184 CH3 H H —CH2—CH2—CONH(CH2—C6H5)2 IV-185 CH3 H H —CH2—CH2—CON(— CH2—CH2—CH2—CH2—) IV-186 CH3 H H —CH2—CH2—CON(—CH2— (CH2)3—CH2) IV-187 CH3 H H —CH2—COCH3 IV-188 CH3 H H —CH2—CH2—COCH3 IV-189 CH3 H H —CH2—COC2H5 IV-190 CH3 H H —CH2—CH2—COC2H5 IV-191 CH3 H H —CH2—CO—C6H5 IV-192 CH3 H H —CH2—CH2—CO—C6H5 IV-193 CH3 H H —CH2—CO—CH2—C6H5 IV-194 CH3 H H —CH2—CH2—CO—CH2—C6H5 IV-195 CH3 H H —CH2—SOC6H5 IV-196 CH3 H H —CH2—SOCH3 IV-197 CH3 H H —CH2—SO(4-CH3—C6H4) IV-198 CH3 H H —CH2—SO2C6H5 IV-199 CH3 H H —CH2—SO2CH3 IV-200 CH3 H H —CH2—SO2(4-CH3—C6H4) IV-201 CH3 H H —CH2—CH2—SOC6H5 IV-202 CH3 H H —CH2—CH2—SOCH3 IV-203 CH3 H H —CH2—CH2—SO(4-CH3—C6H4) IV-204 CH3 H H —CH2—CH2—SO2C6H5 IV-205 CH3 H H —CH2—CH2—SO2CH3 IV-206 CH3 H H —CH2—CH2—SO2(4-CH3—C6H4) - Table 5:
- A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the substituent —(C═O)-G is in position 3 relative to the nitrogen. G is of Formula Vg, VIg, VIIg, VIIIg or IXg.
No. RF R1F R2F -G V-1 H H H —CH3 V-2 H H H —C2H5 V-3 H H H -nC3H7 V-4 H H H -isoC3H7 V-5 H H H -nC4H9 V-6 H H H -tertC4H9 V-7 H H H -cycloC3H5 V-8 H H H -cycloC4H7 V-9 H H H -cycloC5H9 V-10 H H H -cycloC6H11 V-11 H H H -cycloC7H12 V-12 H H H —CH2—O—CH3 V-13 H H H —CH2—CH2—O—CH3 V-14 H H H —CH2—C6H5 V-15 H H H —C6H5 V-16 H H H -(4-HO—C6H5) V-17 H H H -(2-CF3—C6H4) V-18 H H H -(3-CF3—C6H4) V-19 H H H -(4-CF3—C6H4) V-20 H H H -(2-OCH3—C6H4) V-21 H H H -(3-OCH3—C6H4) V-22 H H H -(4-OCH3—C6H4) V-23 H H H -(2-SCH3—C6H4) V-24 H H H -(3-SCH3—C6H4) V-25 H H H -(4-SCH3—C6H4) V-26 H H H -(2-N(CH3)2—C6H4) V-27 H H H -(3-N(CH3)2—C6H4) V-28 H H H -(4-N(CH3)2—C6H4) V-29 H H H -(4-CN—C6H4) V-30 H H H -(4-Cl—C6H4) V-31 H H H -(4-Br—C6H4] V-32 H H H -(4-F—C6H4] V-33 H H H -(4-CH3—C6H4) V-34 H H H -(2-NO2—C6H4) V-35 H H H -(3-NO2—C6H4) V-36 H H H -(4-NO2—C6H4] V-37 H H H -(2,4-OCH3—C6H3) V-38 H H H -(3,4-OCH3—C6H3) V-39 H H H -(3,4,5-OCH3—C6H2) V-40 H H H -(3,4-CH2OCH2—C6H3) V-41 H H H -(2,3-CH2OCH2—C6H3) V-42 H H H -2-pyridinyl V-43 H H H -2-furanyl V-44 H H H -2-thienyl V-45 H H H -3-pyridinyl V-46 H H H -3-furanyl V-47 H H H -3-thienyl V-48 H H H -4-pyridinyl V-49 H H H -2-thiazolyl V-50 H H H -2-oxazolyl V-51 H H H -3-isoxazolyl V-52 H H H -4-isoxazolyl V-53 H H H -5-isoxazolyl V-54 H H H —CF3 V-55 H H H —C2F5 V-56 H H H —CH3 V-57 H H H —C2H5 V-58 H H H -nC3H7 V-59 H H H -tertC4H9 V-60 H H H —CH2—C6H5 V-61 H H H —C6H5 V-62 H H H —CH2—COOCH3 V-63 H H H —CH2—COOC2H5 V-64 H H H —CF2—COOCH3 V-65 H H H —CF2—COOC2H5 V-66 H H H —CH2—CONH2 V-67 H H H —CH2—CONHCH3 V-68 H H H —CH2—CON(CH3)2 V-69 H H H —CH2—CONH—CH2—C6H5 V-70 H H H —CH2—CONH—C6H5 V-71 H H H —CH2—CONH(CH2—C6H5)2 V-72 H H H —CH2—CON(—CH2—CH2— CH2—CH2—) V-73 H H H —CH2—CON(—CH2—CH2— CH2—CH2—CH2) V-74 H H H —CH2—CH2—COOCH3 V-75 H H H —CH2—CH2—COOC2H5 V-76 H H H —CH2—CH2—CONH2 V-77 H H H —CH2—CH2—CONHCH3 V-78 H H H —CH2—CH2—CON(CH3)2 V-79 H H H —CH2—CH2—CONH—CH2—C6H5 V-80 H H H —CH2—CH2—CONH—C6H5 V-81 H H H —CH2—CH2—CONH(CH2—C6H5)2 V-82 H H H —CH2—CH2—CON(—CH2—CH2— CH2—CH2—) V-83 H H H —CH2—CH2—CON(—CH2— (CH2)3—CH2) V-84 H H H —CH2—COCH3 V-85 H H H —CH2—CH2—COCH3 V-86 H H H —CH2—COC2H5 V-87 H H H —CH2—CH2—COC2H5 V-88 H H H —CH2—CO—C6H5 V-89 H H H —CH2—CH2—CO—C6H5 V-90 H H H —CH2—CO—CH2—C6H5 V-91 H H H —CH2—CH2—CO—CH2—C6H5 V-92 H H H —CH2—SOC6H5 V-93 H H H —CH2—SOCH3 V-94 H H H —CH2SO(4-CH3—C6H4) V-95 H H H —CH2—SO2C6H5 V-96 H H H —CH2—SO2CH3 V-97 H H H —CH2—SO2(4-CH3—C6H4) V-98 H H H —CH2—CH2—SOC6H5 V-99 H H H —CH2—CH2—SOCH3 V-100 H H H —CH2—CH2—SO(4-CH3—C6H4) V-101 H H H —CH2—CH2—SO2C6H5 V-102 H H H —CH2—CH2—SO2CH3 V-103 H H H —CH2—CH2—SO3(4-CH3—C6H4) V-104 CH3 H H —CH3 V-105 CH3 H H —C2H5 V-106 CH3 H H -nC3H7 V-107 CH3 H H -isoC3H7 V-108 CH3 H H -nC4H9 V-109 CH3 H H -tertC4H9 V-110 CH3 H H -cycloC3H5 V-111 CH3 H H -cycloC4H7 V-112 CH3 H H -cycloC5H9 V-113 CH3 H H -cycloC6H11 V-114 CH3 H H -cycloC7H12 V-115 CH3 H H —CH2—O—CH3 V-116 CH3 H H —CH2—CH3—O—CH3 V-117 CH3 H H —CH2—C6H5 V-118 CH3 H H —C6H5 V-119 CH3 H H -(4-HO-C6H5) V-120 CH3 H H -(2-CF3—C6H4) V-121 CH3 H H -(3-CF3—C6H4) V-122 CH3 H H -(4-CF3—C6H4) V-123 CH3 H H -(2-OCH3—C6H4) V-124 CH3 H H -(3-OCH3—C6H4) V-125 CH3 H H -(4-OCH3—C6H4) V-126 CH3 H H -(2-SCH3—C6H4) V-127 CH3 H H -(3-SCH3—C6H4) V-128 CH3 H H -(4-SCH3—C6H4) V-129 CH3 H H -(2-N(CH3)2—C6H4) V-130 CH3 H H -(3-N(CH3)2—C6H4) V-131 CH3 H H -(4-N(CH3)2—C6H4) V-132 CH3 H H -(4-CN-C6H4) V-133 CH3 H H -(4-Cl—C6H4) V-134 CH3 H H -(4-Br—C6H4] V-135 CH3 H H -(4-F—C6H4] V-136 CH3 H H -(4-CH3—C6H4) V-137 CH3 H H -(2-NO2—C6H4) V-138 CH3 H H -(3-NO2—C6H4) V-139 CH3 H H -(4-NO2—C6H4] V-140 CH3 H H -(2,4-OCH3—C6H3) V-141 CH3 H H -(3,4-OCH3—C6H3) V-142 CH3 H H -(3,4,5-OCH3—C6H2) V-143 CH3 H H -(3,4-CH2OCH2—C6H3) V-144 CH3 H H -(2,3-CH2OCH2—C6H3) V-145 CH3 H H -2-pyridinyl V-146 CH3 H H -2-furanyl V-147 CH3 H H -2-thienyl V-148 CH3 H H -3-pyridinyl V-149 CH3 H H -3-furanyl V-150 CH3 H H -3-thienyl V-151 CH3 H H -4-pyridinyl V-152 CH3 H H -2-thiazolyl V-153 CH3 H H -2-oxazolyl V-154 CH3 H H -3-isoxazolyl V-155 CH3 H H -4-isoxazolyl V-156 CH3 H H -5-isoxazoyl V-157 CH3 H H —CF3 V-158 CH3 H H —C2F5 V-159 CH3 H H —CH3 V-160 CH3 H H —C2H5 V-161 CH3 H H -nC3H7 V-162 CH3 H H -tertC4H9 V-163 CH3 H H —CH2—C6H5 V-164 CH3 H H —C6H5 V-165 CH3 H H —CH2—COOCH3 V-166 CH3 H H —CH2—COOC2H5 V-167 CH3 H H —CF2—COOCH3 V-168 CH3 H H —CF2—COOC2H5 V-169 CH3 H H —CH2—CONH2 V-170 CH3 H H —CH2—CONHCH3 V-171 CH3 H H —CH2—CON(CH3)2 V-172 CH3 H H —CH2—CONH—CH2—C6H5 V-173 CH3 H H —CH2—CONH—C6H5 V-174 CH3 H H —CH2—CONH(CH2—C6H5)2 V-175 CH3 H H —CH2—CON(—CH2—CH2— CH2—CH2—) V-176 CH3 H H —CH2—CON(—CH2—CH2—CH2— CH2—CH2) V-177 CH3 H H —CH2—CH2—COOCH3 V-178 CH3 H H —CH2—CH2—COOC2H5 V-179 CH3 H H —CH2—CH2—CONH2 V-180 CH3 H H —CH2—CH2—CONHCH3 V-181 CH3 H H —CH2—CH2—CON(CH3)2 V-182 CH3 H H —CH2—CH2—CONH—CH2—C6H5 V-183 CH3 H H —CH2—CH2—CONH—C6H5 V-184 CH3 H H —CH2—CH2—CONH(CH2—C6H5)2 V-185 CH3 H H —CH2—CH2—CON(— CH2—CH2—CH2—CH2—) V-186 CH3 H H —CH2—CH2—CON(—CH2— (CH2)3—CH2) V-187 CH3 H H —CH2—COCH3 V-188 CH3 H H —CH2—CH2—COCH3 V-189 CH3 H H —CH2—COC2H5 V-190 CH3 H H —CH2—CH2—COC2H5 V-191 CH3 H H —CH2—CO—C6H5 V-192 CH3 H H —CH2—CH2—CO—C6H5 V-193 CH3 H H —CH2—CO—CH2—C6H5 V-194 CH3 H H —CH2—CH2—CO—CH2—C6H5 V-195 CH3 H H —CH2—SOC6H5 V-196 CH3 H H —CH2—SOCH3 V-197 CH3 H H —CH2—SO(4-CH3—C6H4) V-198 CH3 H H —CH2—SO2C6H5 V-199 CH3 H H —CH2—SO2CH3 V-200 CH3 H H —CH2—SO2(4-CH3—C6H4) V-201 CH3 H H —CH2—CH2—SOC6H5 V-202 CH3 H H —CH2—CH2—SOCH3 V-203 CH3 H H —CH2—CH2—SO(4-CH3—C6H4) V-204 CH3 H H —CH2—CH2—SO2C6H5 V-205 CH3 H H —CH2—CH2—SO2CH3 V-206 CH3 H H —CH2—CH2—SO2(4-CH3—C6H4) - Table 6:
- A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIf, the substituent —(C═O)-G is in position 4 relative to the nitrogen. G is of Formula Vg, VIg, VIIg, VIIIg or IXg.
No. RF R1F R2F -G VI-1 H H H —CH3 VI-2 H H H —C2H5 VI-3 H H H -nC3H7 VI-4 H H H -isoC3H7 VI-5 H H H -nC4H9 VI-6 H H H -tertC4H9 VI-7 H H H -cycloC3H5 VI-8 H H H -cycloC4H7 VI-9 H H H -cycloC5H9 VI-10 H H H -cycloC6H11 VI-11 H H H -cycloC7H12 VI-12 H H H —CH2—O—CH3 VI-13 H H H —CH2—CH2—O—CH3 VI-14 H H H —CH2—C6H5 VI-15 H H H —C6H5 VI-16 H H H -(4-HO—C6H5) VI-17 H H H -(2-CF3—C6H4) VI-18 H H H -(3-CF3—C6H4) VI-19 H H H -(4-CF3—C6H4) VI-20 H H H -(2-OCH3—C6H4) VI-21 H H H -(3-OCH3—C6H4) VI-22 H H H -(4-OCH3—C6H4) VI-23 H H H -(2-SCH3—C6H4) VI-24 H H H -(3-SCH3—C6H4) VI-25 H H H -(4-SCH3—C6H4) VI-26 H H H -(2-N(CH3)2—C6H4) VI-27 H H H -(3-N(CH3)2—C6H4) VI-28 H H H -(4-N(CH3)2—C6H4) VI-29 H H H -(4-CN—C6H4) VI-30 H H H -(4-Cl—C6H4) VI-31 H H H -(4-Br—C6H4] VI-32 H H H -(4-F—C6H4] VI-33 H H H -(4-CH3—C6H4) VI-34 H H H -(2-NO2—C6H4) VI-35 H H H -(3-NO2—C6H4) VI-36 H H H -(4-NO2—C6H4] VI-37 H H H -(2,4-OCH3—C6H3) VI-38 H H H -(3,4-OCH3—C6H3) VI-39 H H H -(3,4,5-OCH3—C6H2) VI-40 H H H -(3,4-CH2OCH2—C6H3) VI-41 H H H -(2,3-CH2OCH2—C6H3) VI-42 H H H -2-pyridinyl VI-43 H H H -2-furanyl VI-44 H H H -2-thienyl VI-45 H H H -3-pyridinyl VI-46 H H H -3-furanyl VI-47 H H H -3-thienyl VI-48 H H H -4-pyridinyl VI-49 H H H -2-thiazolyl VI-50 H H H -2-oxazolyl VI-51 H H H -3-isoxazolyl VI-52 H H H -4-isoxazolyl VI-53 H H H -5-isoxazolyl VI-54 H H H —CF3 VI-55 H H H —C2F5 VI-56 H H H —CH3 VI-57 H H H —C2H5 VI-58 H H H -nC3H7 VI-59 H H H -tertC4H9 VI-60 H H H —CH2—C6H5 VI-61 H H H —C6H5 VI-62 H H H —CH2—COOCH3 VI-63 H H H —CH2—COOC2H5 VI-64 H H H —CF2—COOCH3 VI-65 H H H —CF2—COOC2H5 VI-66 H H H —CH2—CONH2 VI-67 H H H —CH2—CONHCH3 VI-68 H H H —CH2—CON(CH3)2 VI-69 H H H —CH2—CONH—CH2—C6H5 VI-70 H H H —CH2—CONH—C6H5 VI-71 H H H —CH2—CONH(CH2—C6H5)2 VI-72 H H H —CH2—CON(—CH2—CH2— CH2—CH2—) VI-73 H H H —CH2—CON(—CH2—CH2— CH2—CH2—CH2) VI-74 H H H —CH2—CH2—COOCH3 VI-75 H H H —CH2—CH2—COOC2H5 VI-76 H H H —CH2—CH2—CONH2 VI-77 H H H —CH2—CH2—CONHCH3 VI-78 H H H —CH2—CH2—CON(CH3)2 VI-79 H H H —CH2—CH2—CONH—CH2—C6H5 VI-80 H H H —CH2—CH2—CONH—C6H5 VI-81 H H H —CH2—CH2—CONH(CH2—C6H5)2 VI-82 H H H —CH2—CH2—CON(—CH2— CH2—CH2—CH2—) VI-83 H H H —CH2—CH2—CON(—CH2— (CH2)3—CH2) VI-84 H H H —CH2—COCH3 VI-85 H H H —CH2—CH2—COCH3 VI-86 H H H —CH2—COC2H5 VI-87 H H H —CH2—CH2—COC2H5 VI-88 H H H —CH2—CO—C6H5 VI-89 H H H —CH2—CH2—CO—C6H5 VI-90 H H H —CH2—CO—CH2—C6H5 VI-91 H H H —CH2—CH2—CO—CH2—C6H5 VI-92 H H H —CH2—SOC6H5 VI-93 H H H —CH2—SOCH3 VI-94 H H H —CH2SO(4-CH3—C6H4) VI-95 H H H —CH2—SO2C6H5 VI-96 H H H —CH2—SO2CH3 VI-97 H H H —CH2—SO2(4-CH3—C6H4) VI-98 H H H —CH2—CH2—SOC6H5 VI-99 H H H —CH2—CH2—SOCH3 VI-100 H H H —CH2—CH2—SO(4-CH3—C6H4) VI-101 H H H —CH2—CH2—SO2C6H5 VI-102 H H H —CH2—CH2—SO2CH3 VI-103 H H H —CH2—CH2—SO3(4-CH3—C6H4) VI-104 CH3 H H —CH3 VI-105 CH3 H H —C2H5 VI-106 CH3 H H -nC3H7 VI-107 CH3 H H -isoC3H7 VI-108 CH3 H H -nC4H9 VI-109 CH3 H H -tertC4H9 VI-110 CH3 H H -cycloC3H5 VI-111 CH3 H H -cycloC4H7 VI-112 CH3 H H -cycloC5H9 VI-113 CH3 H H -cycloC6H11 VI-114 CH3 H H -cycloC7H12 VI-115 CH3 H H —CH2—O—CH3 VI-116 CH3 H H —CH2—CH3—O—CH3 VI-117 CH3 H H —CH2—C6H5 VI-118 CH3 H H —C6H5 VI-119 CH3 H H -(4-HO-C6H5) VI-120 CH3 H H -(2-CF3—C6H4) VI-121 CH3 H H -(3-CF3—C6H4) VI-122 CH3 H H -(4-CF3—C6H4) VI-123 CH3 H H -(2-OCH3—C6H4) VI-124 CH3 H H -(3-OCH3—C6H4) VI-125 CH3 H H -(4-OCH3—C6H4) VI-126 CH3 H H -(2-SCH3—C6H4) VI-127 CH3 H H -(3-SCH3—C6H4) VI-128 CH3 H H -(4-SCH3—C6H4) VI-129 CH3 H H -(2-N(CH3)2—C6H4) VI-130 CH3 H H -(3-N(CH3)2—C6H4) VI-131 CH3 H H -(4-N(CH3)2—C6H4) VI-132 CH3 H H -(4-CN-C6H4) VI-133 CH3 H H -(4-Cl—C6H4) VI-134 CH3 H H -(4-Br—C6H4] VI-135 CH3 H H -(4-F—C6H4] VI-136 CH3 H H -(4-CH3—C6H4) VI-137 CH3 H H -(2-NO2—C6H4) VI-138 CH3 H H -(3-NO2—C6H4) VI-139 CH3 H H -(4-NO2—C6H4] VI-140 CH3 H H -(2,4-OCH3—C6H3) VI-141 CH3 H H -(3,4-OCH3—C6H3) VI-142 CH3 H H -(3,4,5-OCH3—C6H2) VI-143 CH3 H H -(3,4-CH2OCH2—C6H3) VI-144 CH3 H H -(2,3-CH2OCH2—C6H3) VI-145 CH3 H H -2-pyridinyl VI-146 CH3 H H -2-furanyl VI-147 CH3 H H -2-thienyl VI-148 CH3 H H -3-pyridinyl VI-149 CH3 H H -3-furanyl VI-150 CH3 H H -3-thienyl VI-151 CH3 H H -4-pyridinyl VI-152 CH3 H H -2-thiazolyl VI-153 CH3 H H -2-oxazolyl VI-154 CH3 H H -3-isoxazolyl VI-155 CH3 H H -4-isoxazolyl VI-156 CH3 H H -5-isoxazoyl VI-157 CH3 H H —CF3 VI-158 CH3 H H —C2F5 VI-159 CH3 H H —CH3 VI-160 CH3 H H —C2H5 VI-161 CH3 H H -nC3H7 VI-162 CH3 H H -tertC4H9 VI-163 CH3 H H —CH2—C6H5 VI-164 CH3 H H —C6H5 VI-165 CH3 H H —CH2—COOCH3 VI-166 CH3 H H —CH2—COOC2H5 VI-167 CH3 H H —CF2—COOCH3 VI-168 CH3 H H —CF2—COOC2H5 VI-169 CH3 H H —CH2—CONH2 VI-170 CH3 H H —CH2—CONHCH3 VI-171 CH3 H H —CH2—CON(CH3)2 VI-172 CH3 H H —CH2—CONH—CH2—C6H5 VI-173 CH3 H H —CH2—CONH—C6H5 VI-174 CH3 H H —CH2—CONH(CH2—C6H5)2 VI-175 CH3 H H —CH2—CON(—CH2—CH2— CH2—CH2—) VI-176 CH3 H H —CH2—CON(—CH2—CH2—CH2— CH2—CH2) VI-177 CH3 H H —CH2—CH2—COOCH3 VI-178 CH3 H H —CH2—CH2—COOC2H5 VI-179 CH3 H H —CH2—CH2—CONH2 VI-180 CH3 H H —CH2—CH2—CONHCH3 VI-181 CH3 H H —CH2—CH2—CON(CH3)2 VI-182 CH3 H H —CH2—CH2—CONH—CH2—C6H5 VI-183 CH3 H H —CH2—CH2—CONH—C6H5 VI-184 CH3 H H —CH2—CH2—CONH(CH2—C6H5)2 VI-185 CH3 H H —CH2—CH2—CON(— CH2—CH2—CH2—CH2—) VI-186 CH3 H H —CH2—CH2—CON(—CH2— (CH2)3—CH2) VI-187 CH3 H H —CH2—COCH3 VI-188 CH3 H H —CH2—CH2—COCH3 VI-189 CH3 H H —CH2—COC2H5 VI-190 CH3 H H —CH2—CH2—COC2H5 VI-191 CH3 H H —CH2—CO—C6H5 VI-192 CH3 H H —CH2—CH2—CO—C6H5 VI-193 CH3 H H —CH2—CO—CH2—C6H5 VI-194 CH3 H H —CH2—CH2—CO—CH2—C6H5 VI-195 CH3 H H —CH2—SOC6H5 VI-196 CH3 H H —CH2—SOCH3 VI-197 CH3 H H —CH2—SO(4-CH3—C6H4) VI-198 CH3 H H —CH2—SO2C6H5 VI-199 CH3 H H —CH2—SO2CH3 VI-200 CH3 H H —CH2—SO2(4-CH3—C6H4) VI-201 CH3 H H —CH2—CH2—SOC6H5 VI-202 CH3 H H —CH2—CH2—SOCH3 VI-203 CH3 H H —CH2—CH2—SO(4-CH3—C6H4) VI-204 CH3 H H —CH2—CH2—SO2C6H5 VI-205 CH3 H H —CH2—CH2—SO2CH3 VI-206 CH3 H H —CH2—CH2—SO2(4-CH3—C6H4) - Table 7:
- A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIIf, the substituent —(C═O)-G is in position 2 relative to the nitrogen and af is 1. G is of Formula IIg or IIIg. The compounds are mixtures of diasteromers, configuration in F is R, S (cis) or S,R (cis).
No. Rf -G VII-1 H —NH—CH3 VII-2 H —NH—CH2—C6H5 VII-3 H —NH-isoC3H7 VII-4 H —NH—C6H5 VII-5 H 1,3-Thiazol-2-yl-amide VII-6 H —NH—CH3 VII-7 H —NH—CH3 VII-8 H —NH—C2H5 VII-9 H —NH-nC3H7 VII-10 H —NH-nC4H9 VII-11 H —NH-tertC4H9 VII-12 H —NH-cycloC3H5 VII-13 H —NH-cycloC4H7 VII-14 H —NH-cycloC5H9 VII-15 H —NH-cycloC6H11 VII-16 H —NH-cycloC7H12 VII-17 H —NH—CH2—O—CH3 VII-18 H —NH—CH2—CH2—O—CH3 VII-19 H —NH-1-adamantyl VII-20 H —NH-(4-HO—C6H5) VII-21 H —NH-(2-CF3—C6H4) VII-22 H —NH-(3-CF3—C4H4) VII-23 H —NH-(4-CF3—C6H4) VII-24 H —NH-(2-OCH3—C6H4) VII-25 H —NH-(3-OCH3—C6H4) VII-26 H —NH-(4-OCH3—C6H4) VII-27 H —NH-(2-SCH3—C6H4) VII-28 H —NH-(3-SCH3—C6H4) VII-29 H —NH-(4-SCH3—C6H4) VII-30 H —NH-(2-N(CH3)2—C6H4) VII-31 H —NH-(3-N(CH3)2—C6H4) VII-32 H —NH-(4-N(CH3)2—C6H4) VII-33 H —NH-(4-CN—C6H4) VII-34 H —NH-(4-Cl—C6H4) VII-35 H —NH-(4-Br—C6H4] VII-36 H —NH-(4-F—C6H4] VII-37 H —NH-(4-CH3—C6H4) VII-38 H —NH-(2-NO2—C6H4) VII-39 H —NH-(3-NO2—C6H4) VII-40 H —NH-(4-NO2—C6H4] VII-41 H —NH-(2,4-OCH3—C6H3) VII-42 H —NH-(3,4-OCH3—C6H3) VII-43 H —NH-(3,4,5-OCH3—C6H2) VII-44 H —NH-(3,4-CH2OCH2—C6H3) VII-45 H —NH-(2,3-CH2OCH2—C6H3) VII-46 H —NH-2-pyridinyl VII-47 H —NH-2-furanyl VII-48 H —NH-2-thienyl VII-49 H —NH-3-pyridinyl VII-50 H —NH-3-furanyl VII-51 H —NH-3-thienyl VII-52 H —NH-4-pyridinyl VII-53 H —NH-2-oxazolyl VII-54 H —NH-3-isoxazolyl VII-55 H —NH-4-isoxazolyl VII-56 H —NH-5-isoxazoyl VII-57 H —NH-2R-(but-2-yl) VII-58 H —NH-2S-(but-2-yl) VII-59 H —NH—O—CH3 VII-60 H —N(CH3)(OCH3) VII-61 H —N(—(CH2)3—O—) VII-62 H —NH—O—CH2—C6H5 VII-63 H —N(CH3)(O—CH2—C6H5) VII-64 H —N(—(CH2)2—CH(C6H5)—O—) VII-65 H —NH—O—C2H5 VII-66 H —N(C2H5)(OC2H5) VII-67 H —N(CH3)(OC2H5) VII-68 H —NH—O-isoC3H7 VII-69 H —N(CH3)(O-isoC3H7) VII-70 H —NH—O-nC3H7 VII-71 H —N(CH3)(O-nC3H7) VII-72 H —NH—O-nC4H9 VII-73 H —N(CH3)(O-nC4H9) VII-74 H —NH—O-tertC4H9 VII-75 H —N(CH3)(O-tertC4H9) VII-76 H —NH—O—C6H5 VII-77 H —N(CH3)(O—C6H5) VII-78 H —N(CH3)2 VII-79 H —N(CH2—C6H5)2 VII-80 H —N(C2H5)2 VII-81 H —N(isoC3H7)2 VII-82 H —N(nC3H7)2 VII-83 H —N(nC4H9)2 VII-84 H —N(C6H5)2 VII-85 H —NH—CH2—CH2—OH VII-86 H —NH—(CH2)3—OH VII-87 H —NH(—(CH2)2—CH(C6H5)—OH) VII-88 H —NH—(CH2)4—OH VII-89 H —NH(—CH(CH3)—CH2—OH) VII-90 H —NH(—CH2—CH(CH3)—OH) VII-91 H —NH(—CH(CH3)—(CH2)2—OH) VII-92 H —NH(—(CH2)2—CH(CH3)—OH) VII-93 CH3 —NH—CH3 VII-94 CH3 —NH—CH2—C6H5 VII-95 CH3 —NH-isoC3H7 VII-96 CH3 —NH—C6H5 VII-97 CH3 —NH—C2H5 VII-98 CH3 —NH-nC3H7 VII-99 CH3 —NH-nC4H9 VII-100 CH3 —NH-tertC4H9 VII-101 CH3 —NH-cycloC3H5 VII-102 CH3 —NH-cycloC4H7 VII-103 CH3 —NH-cycloC5H9 VII-104 CH3 —NH-cycloC6H11 VII-105 CH3 —NH-1-adamantyl VII-106 CH3 —NH-2R-(but-2-yl) VII-107 CH3 —NH-2S-(but-2-yl) VII-108 CH3 —NH—O—CH3 VII-109 CH3 —N(CH3)(OCH3) VII-110 CH3 —N(—(CH2)3—O—) VII-111 CH3 —N(CH3)2 VII-112 CH3 —N(CH2—C6H5)2 VII-113 CH3 —N(C2H5)2 VII-114 CH3 —N(isoC3H7)2 VII-115 CH3 —N(nC3H7)2 VII-116 CH3 —N(nC4H9)2 VII-117 CH3 —N(C6H5)2 - Table 8:
- A is Me2Val, B is Val, D is MeVal, E is Pro and F is of Formula IIIf, the substituent —(C═O)-G is in position 2 relative to the nitrogen and af is 1. G is of Formula IIg or IIIg.
- The compounds are mixtures of diasteromers, configuration in F is either R, R (trans) or S,S (trans).
No. Rf -G VIII-1 H —NH—CH3 VIII-2 H —NH—CH2—C6H5 VIII-3 H —NH-isoC3H7 VIII-4 H —NH—C6H5 VIII-5 H 1,3-Thiazol-2-yl-amide VIII-6 H —NH—CH3 VIII-7 H —NH—CH3 VIII-8 H —NH—C2H5 VIII-9 H —NH-nC3H7 VIII-10 H —NH-nC4H9 VIII-11 H —NH-tertC4H9 VIII-12 H —NH-cycloC3H5 VIII-13 H —NH-cycloC4H7 VIII-14 H —NH-cycloC5H9 VIII-15 H —NH-cycloC6H11 VIII-16 H —NH-cycloC7H12 VIII-17 H —NH—CH2-O-CH3 VIII-18 H —NH—CH2—CH2—O-CH3 VIII-19 H —NH-1-adamantyl VIII-20 H —NH-(4-HO-C6H5) VIII-21 H —NH-(2-CF3—C6H4) VIII-22 H —NH-(3-CF3—C6H4) VIII-23 H —NH-(4-CF3—C6H4) VIII-24 H —NH-(2-OCH3—C6H4) VIII-25 H —NH-(3-OCH3—C6H4) VIII-26 H —NH-(4-OCH3—C6H4) VIII-27 H —NH-(2-SCH3—C6H4) VIII-28 H —NH-(3-SCH3—C6H4) VIII-29 H —NH-(4-SCH3—C6H4) VIII-30 H —NH-(2-N(CH3)2—C6H4) VIII-31 H —NH-(3-N(CH3)2-C6H4) VIII-32 H —NH-(4-N(CH3)2-C6H4) VIII-33 H —NH-(4-CN-C6H4) VIII-34 H —NH-(4-Cl-C6H4) VIII-35 H —NH-(4-Br-C6H4] VIII-36 H —NH-(4-F-C-6H4] VIII-37 H —NH-(4-CH3-C6H4) VIII-38 H —NH-(2-NO2-C4H4) VIII-39 H —NH-(3-NO2-C6H4) VIII-40 H —NH-(4-NO2-C6H4] VIII-41 H —NH-(2,4-OCH3-C6H3) VIII-42 H —NH-(3,4-OCH3-C6H3) VIII-43 H —NH-(3,4,5-OCH3-C6H2) VIII-44 H —NH-(3,4-CH2OCH2-C6H3) VIII-45 H —NH-(2,3-CH2OCH2-C6H3) VIII-46 H —NH-2-pyridinyl VIII-47 H —NH-2-furanyl VIII-48 H —NH-2-thienyl VIII-49 H —NH-3-pyridinyl VIII-50 H —NH-3-furanyl VIII-51 H —NH-3-thienyl VIII-52 H —NH-4-pyridinyl VIII-53 H —NH-2-oxazolyl VIII-54 H —NH-3-isoxazolyl VIII-55 H —NH-4-isoxazolyl VIII-56 H —NH-5-isoxazoyl VIII-57 H —NH-2R-(but-2-yl) VIII-58 H —NH-2S-(but-2-yl) VIII-59 H —NH—O—CH3 VIII-60 H —N(CH3) (OCH3) VIII-61 H —N(—(CH2)3—O—) VIII-62 H —NH—O—CH2—C6H5 VIII-63 H —N(CH3) (O—CH2—C6H5) VIII-64 H —N(—(CH2)2—CH(C6H5)—O—) VIII-65 H —NH—O—C2H5 VIII-66 H —N(C2H5) (OC2H5) VIII-67 H —N(CH3) (OC2H5) VIII-68 H NH—O-isoC3H7 VIII-69 H —N(CH3) (O-isoC3H7) VIII-70 H —NH—O-nC3H7 VIII-71 H —N(CH3) (O-nC3H7) VIII-72 H —NH—O-nC4H9 VIII-73 H —N(CH3) (O-nC4H9) VIII-74 H —NH—O-tertC4H9 VIII-75 H —N(CH3) (O-tertC4H9) VIII-76 H —NH—O—C6H5 VIII-77 H —N(CH3) (O—C6H5) VIII-78 H —N(CH3)2 VIII-79 H —N(CH2—C6H5)2 VIII-80 H —N(C2H5)2 VIII-81 H —N(isoC3H7)2 VIII-82 H —N(nC3H7)2 VIII-83 H —N(nC4H9)2 VIII-84 H —N(C6H5)2 VIII-85 H —NH—CH2—CH2—OH VIII-86 H —NH—(CH2)3—OH VIII-87 H —NH(—(CH2)2—CH(C6H5) —OH) VIII-88 H —NH—(CH2)4—OH VIII-89 H —NH(—CH(CH3)—CH2—OH) VIII-90 H —NH(—CH2CH(CH3) —OH) VIII-91 H —NH(—CH(CH3)—(CH2)2OH) VIII-92 H —NH(—(CH2)2—CH(CH3)—OH) VIII-93 CH3 —NH—CH3 VIII-94 CH3 —NH—CH2—C6H5 VIII-95 CH3 —NH-isoC3H7 VIII-96 CH3 —NH—C6H5 VIII-97 CH3 —NH—C2H5 VIII-98 CH3 —NH-nC3H7 VIII-99 CH3 —NH-nC4H9 VIII-100 CH3 —NH-tertC4H9 VIII-101 CH3 —NH-cycloC3H5 VIII-102 CH3 —NH-cycloC4H7 VIII-103 CH3 —NH-cycloC5H9 VIII-104 CH3 —NH-cycloC6H11 VIII-105 CH3 —NH-1-adamantyl VIII-106 CH3 —NH-2R-(but-2-yl) VIII-107 CH3 —NH-2S-(but-2-yl) VIII-108 CH3 —NH—O—CH3 VIII-109 CH3 —N(CH3) (OCH3) VIII-110 CH3 —N(—(CH2)3—O—) VIII-111 CH3 —N(CH3)2 VIII-112 CH3 —N(CH2—C6H5)2 VIII-113 CH3 —N(C2H5)2 VIII-114 CH3 —N(isoC3H7)2 VIII-115 CH3 —N(nC3H7)2 VIII-116 CH3 —N(nC4H9)2 VIII-117 CH3 —N(C6H5)2 - Mass spectrometry data of selected examples:
I-1 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHCH3 FAB-MS: 588 (M + H+) I-2 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHCH2C6H5 FAB-MS: 664 (M + H+) I-3 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHCH(CH3)2 FAB-MS: 616 (M + H+) I-4 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NHC6H5 FAB-MS: 650 (M + H+) I-5 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NH(thiazol-2-yl) FAB-MS: 657 (M + H+) I-6 2(Me2Val-Val-MeVal-ProNH)-4, 5-bis(methoxy)C6H2C(O)NHCH3 FAB-MS: 649 (M + H+) I-7 2-(Me2ValVal-MeVal-ProNH)-3-cyclopentanyl-C6H3C(O)NHCH3 FAB-MS: 656 (M + H+) I-64 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—N(—(CH2)2— CH(C6H5)O—) (mix. of diastereomers) FAB-MS: 706 (M + H+) I-79 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—N(CH2C6H5)2 FAB-MS: 754 (M +H+) I-86 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—NH—(—(CH2)3 — OH) FAB-MS: 632 (M + H+) I-87 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4C(O)NH((CH2)2CH(C6H5) OH) FAB-MS: 708 (M + H+) I-143 2-(Me2Val-Val-MeVal-Pro-N(CH3))—C6H4—CONHCH3 FAB-MS: 601 (M + H+) II-1 3-(Ne2Val-Val-MeVal-Pro-NH)—C6H4—CO—NHCH3 FAB-MS: 588 (M + H+) II-2 3-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—NH CH2C6H5 FAB-MS: 664 (M + H+) IV-1 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—CH3 FAB-MS: 609 (M + H+) IV-15 2-(Me2Val-Val-MeVal-Pro-NH)—C6H4—CO—C6H5 FAB-MS: 635 (M + H+) - In Vitro Methodology
- Cytotoxicity was measured using a standard methodology for adherent cell lines, such as the microculture tetrazolium assay (MTT). Details of this assay have been published (Alley, M. C. et al., Cancer Research 48: 589-601, 1988). Exponentially growing cultures of tumor cells such as the HT-29 colon carcinoma or LX-1 lung tumor were used to make microtiter plate cultures. Cells were seeded at 5000-20,000 cells per well in 96-well plates (in 150 mL of media), and grown overnight at 37° C. Test compounds were added, in 10-fold dilutions varying from 10−4 M to 10−10 M. Cells were then incubated for 48 hours. To determine the number of viable cells in each well, the MTT dye was added (50 mL of a 3 mg/mL solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in saline). This mixture was incubated at 37° C. for 5 hours, and then 50 mL of 25% SDS, pH 2, was added to each well. After an overnight incubation, the absorbance of each well at 550 nm was read using an ELISA reader. The values for the mean+/−SD of data from replicated wells were calculated, using the formula % T/C (% viable cells treated/control). The concentration of test compound which gives a T/C of 50% growth inhibition was designated as the IC50.
Compound No. IC50 (mol/l) I-1 4 × 10−7 I-2 >10−6 I-3 5 × 10−7 I-4 4 × 10−7 I-5 1.5 × 10−7 I-6 2 × 10−7 I-7 4 × 10−7 I-60 4 × 10−7 I-64 2.5 × 10−7 I-86 6 × 10−7 I-87 2 × 10−7 II-1 >10−6 II-2 >10−6 IV-1 >10−6 IV-15 7 × 10−8 VII-2 >10−6 - In Vivo Methodology
- Compounds of this invention may be further tested in any of the various preclinical assays for in vivo activity which are indicative of clinical utility. Such assays are conducted with nude mice into which tumor tissue, preferably of human origin, has been transplanted (“xenografted”), as is well known in this field. Test compounds are evaluated for their anti-tumor efficacy following administration to the xenograft-bearing mice.
- More specifically, human tumors which have been grown in athymic nude mice are transplanted into new recipient animals, using tumor fragments which are about 50 mg in size. The day of transplantation is designated as day 0. Six to ten days later, the mice are treated with the test compounds given as an intravenous or intraperitoneal injection, in groups of 5-10 mice at each dose. Compounds are given daily for 5 days, 10 days or 15 days, at doses from 10-100 mg/kg body weight. Tumor diameters and body weights are measured twice weekly. Tumor masses are calculated using the diameters measured with Vernier calipers, and the formula:
- (length×width2)/2=mg of tumor weight
- Mean tumor weights are calculated for each treatment group, and T/C values determined for each group relative to the untreated control tumors.
- The novel compounds of the present invention show good in vitro activity in the above-mentioned assay system.
- While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.
Claims (21)
1. A compound of the formula
A-B-D-E-F-G,
or a salt thereof with a pharmaceutically acceptable acid, wherein
A is a proline derivative of Formula IIa,
wherein na is 0 to 3; Ra is hydrogen, or unsubstituted or fluorine-substituted normal, branched or cyclic C1-C3-alkyl; R1 a is hydrogen, C1-C 3-alkyl, phenyl, or substituted phenyl; or Ra and R1 a together form a propylene bridge; and R2 a, R3 a, R4 a and R5 a are each, independently, hydrogen or alkyl; or
wherein Ra is hydrogen or unsubstituted or fluorine-substituted C1-C3-alkyl; R1 a is hydrogen or C1-C4-alkyl; R6 a is alkyl, substituted alkyl, alkenyl, phenyl or substituted phenyl; or R1 a is an alkyl group and R6 a is C1-C6-alkyl, cycloalkylmethyl, benzyl or substituted benzyl; and R7 a is hydrogen or alkyl; or
wherein ma is 1 or 2; R7 a is hydrogen or alkyl; Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or
wherein R7 a is hydrogen or alkyl and Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or
wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; R1 a is hydrogen, alkyl, phenyl, or substituted phenyl; or Ra and R1 a together form a propylene bridge; and Xa is hydroxy, alkoxy or fluorine; or
wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; R1 a is hydrogen, alkyl, phenyl, or substituted phenyl; or Ra and R1 a together form a propylene bridge; and R2 a, R3 a, R4 a and R5 a are each, independently, hydrogen or alkyl; or
wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or
wherein the 3-carbonyl moiety is in the endo or exo position, Za is a single bond or a double bond, and Ra is hydrogen or unsubstituted or fluorine-substituted alkyl; or
wherein na is 1, 2 or 3, and R7 a is hydrogen or alkyl and Ra is hydrogen , unsubstituted alkyl or fluorine-substituted alkyl;
B is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2-tert-butylglycyl or 2-ethylglycyl residue; or
wherein R1 b is hydrogen, and R2 b is alkyl or alkenyl; or R1 b and R2 b together form an isopropylidene group;
D is an N-alkylvalyl, N-alkyl-2-ethylglycyl, N-alkyl-2-tert-butylglycyl, N-alkylnorleucyl, N-alkylisoleucyl, N-alkyl-allo-isoleucyl or N-alkylnorvalyl residue; or
wherein Rd is hydrogen, or unsubstituted or fluorine-substituted alkyl; R1 d is hydrogen; and R2 d is alkyl, substituted alkyl or alkenyl; or R1 d and R2 d together form an isopropylidene group; or
wherein nd is 1 or 2; R3 d is hydrogen, alkyl or fluorine-substituted alkyl; and Xd is hydrogen; or nd is 1 and Xd is fluorine, hydroxy, methoxy, or ethoxy;
E is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl,or hydroxyprolyl residue; or
wherein ne is 0, 1 or 2, R1 e is hydrogen, or unsubstituted or fluorine-substituted alkyl; R2 e and R3 e are each, independently, hydrogen or alkyl; R4 e is hydrogen, hydroxy or alkoxy; and R5 e is hydrogen or fluorine; or ne is 1 and R3 e and R4 e together form a double bond; or ne is 1 and R4 e and R5 e together form a double-bonded oxygen diradical; or ne is 1 or 2 and R1 e and R2 e together form a double bond; or
wherein Re is alkyl and R1 e is hydrogen, or unsubstituted or fluorine-substituted alkyl;
F is an aminobenzoyl derivative of Formula IIf,
wherein Rf is a hydrogen atom or an alkyl group; the carbonyl group is ortho, meta, or para to the nitrogen atom; R1 f and R2 f are each, independently, a hydrogen atom; a halogen atom; a C1-C4-alkyl group; a methoxy, ethoxy, trifluoromethyl, nitro, cyano, amino or dimethyalmino group; or R1 f and R2 f can together form a dioxymethylene group; or
F is an aminocycloalkanecarboxylic acid residue of Formula IIIf,
wherein Rf is a hydrogen atom or an alkyl group; af is 0, 1 or 2; and the carbonyl group is in position 2 or position 3 of the cycloalkane ring relative to the nitrogen atom; and
G is a substituted or unsubstituted amino, hydrazido, aminoxy, oximato, arylalkyl, heteroarylalkyl, aryl, heteroaryl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, alkoxycarbonyl, aryloxycarbonyl, aminocarbonylalkyl, aminocarbonyl, alkylcarbonylalkyl, alkylcarbonyl, arylcarbonylalkyl, arylcarbonyl, alkylsulfinylalkyl, alkylsulfinyl, arylsulfinylalkyl, arylsulfinyl, alkylsulfonylalkyl, alkylsulfonyl, arylsulfonylalkyl or arylsulfonyl group.
2. The compound of wherein the pharmaceutically acceptable acid is hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid or acetylglycine.
claim 1
wherein
R1 l is a hydrogen atom, a normal or branched, saturated or unsaturated C1-C18-alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryl-C1-C6-alkoxy group, a substituted or unsubstituted aryloxy-C1-C6-alkoxy group, wherein the aryl substituents comprise one or more halogen atoms or one or more C1-C4-alkyl, methoxy, ethoxy, trifluoromethyl, nitro or dioxymethylene groups; or a heteroaryl-C1-C6-alkoxy group, wherein the heteroaryl group is derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine; and
R2 l is a hydrogen atom, a normal or branched C1-C18-alkyl group, a normal C1-C18 alkenyl group, a C3-C10-cycloalkyl group, an aryl group, or a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms, or one or more alkyl, alkoxy, dioxymethylene, trifluoromethyl or nitro groups; or a heteroaryl or substituted heteroaryl group derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
wherein al is 0, 1, 2, 3, 4, or 5; R3 l is a methyl, ethyl, normal propyl or isopropyl group; R4 l is a saturated or partially unsaturated carbocyclic system which contains from 3 to 10 carbon atoms, an aryl group, or a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, dioxymethylene, trifluoromethyl, nitro, cyanof C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a substituted or unsubstituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline, and the heteroaryl group substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
a monovalent radical of Formula IIIl,
—(CH2)2-Wl-R5 l (IIIl),
wherein Wl is an NR6 l group, an oxygen atom or a sulfur atom, R5 l and R6 l are each, independently, a hydrogen atom or a C1-C4-alkyl, C3-C7-cycloalkyl, aryl, arylmethyl or substituted aryl or arylmethyl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, dioxymethylene, trifluoromethyl, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or R6 l is a C1-C18-alkanoyl or benzoyl group; or
a monovalent radical of Formula IVl,
—(CH2)b l -Zl (IVl),
bl is 2, 3, or 4 and Zl is a formyl, aminocarbonyl, hydrazinocarbonyl, cyclic acetal, cyclic thioacetal, acyclic acetal or acyclic thioacetal group; or
bl is 2, 3, or 4; R7 l is a polyglycol group of the formula —O—(CH2—CH2—O)dl—CH3; and dl is between about 2 and about 4, or between about 40 and about 90; or
wherein R8 l is a hydrogen atom, or a C1-C4 alkanoyl, C1-C4 alkyl, benzoyl, or benzyl group.
4. The compound of wherein G is a β-hydroxy amino group of Formula IIIg,
claim 1
R9 l is a hydrogen atom, or a C1-C6-alkyl, aryl or substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; and R10 l is a hydrogen atom, a methyl group or a phenyl group.
5. The compound of wherein G is a hydrazido group of Formula IVg,
claim 1
wherein R11 l is a hydrogen atom and R12 l is a hydrogen atom, a normal or branched C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4-alkyl group, an aryl-C1-C4-alkyl group, an aryl group, a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a heteroaryl group, a heteroaryl-C1-C4-alkyl group or a substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups.
6. The compound of wherein G is a monovalent radical of the formula —O—R13 l or of the formula —S—R13 l, and R13 l is a C3-C10-cycloalkyl, straight-chain or branched C2-C16-alkenylmethyl, C1-C16-alkyl or halogen-substituted C1-C16-alkyl group; R13 l is a monovalent radical of the formula —(CH2)el—R14 l, el is 1, 2, or 3, and R14 l is a saturated or partially unsaturated C3-C10 carbocyclic group; R13 l is a monovalent radical of the formula —[CH2—CH═C(CH3)— CH2]fl—H, and fl is 1, 2, 3, or 4; R13 l is a monovalent radical of the formula —[CH2—CH2—O]gl—CH3, and gl is between about 2 and about 4, or between about 40 and about 90; R13 l is a monovalent radical of the formula —(CH2)hl—X, hl is 0, 1, 2, or 3; and X is an aryl or substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; R13 l is a monovalent radical of the formula —(CH2)bl-Wl-R5 l, bl is 2, 3, or 4, Wl is an oxygen atom, a sulfur atom or an NR6 l group; R5 l is a saturated carbocyclic system which contains from about 3 to about 10 carbon atoms, a partially unsaturated carbocyclic system containing from about 3 to about 10 carbon atoms, an aryl or substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; and R6 l is a hydrogen atom, or a C1-C4 alkyl, C3-C7 cycloalkyl, C1-C18-alkanoyl, benzoyl, arylmethyl, aryl or substituted aryl or arylmethyl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups.
claim 1
7. The compound of wherein G is an aminoxy group of the formula —O—N(R16 l)(R15 l), wherein
claim 1
R15 l and R16 l are each, independently, a hydrogen atom, a normal or branched C1-C8 alkyl group, a halogen-substituted normal or branched C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4 alkyl group, an aryl-C1-C4-alkyl group, an aryl group or a substituted aryl-C1-C4-alkyl or aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
R15 l and R16 l together with the nitrogen atom form a heterocyclic ring structure comprising 5, 6, or 7 atoms.
8. The compound of wherein G is a oximato group of the formula —O—N═C(R15 l)(R16 l), wherein
claim 1
R15 l and R16 l are each, independently, a hydrogen atom, a normal or branched C1-C8 alkyl group, a halogen-substituted normal or branched C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C1-C4 alkyl group, an aryl-C1-C4-alkyl group, an aryl group or a substituted aryl-C1-C4-alkyl or aryl group, wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or
9. The compound of wherein G is a hydrogen atom, a normal or branched C1-C8-alkyl group, a halogen-substituted normal or branched C1-C8-alkyl group, a C3-C8 cycloalkyl group, or a C3-C8-cycloalkyl-C1-C4-alkyl group.
claim 1
10. The compound of wherein G is a monovalent radical of Formula Vg,
claim 1
—(CH2)a g —R17 l (Vg)
ag is 0, 1, or 2, and R17 l is an aryl group or a substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; or a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups
11. The compound of wherein G is a monovalent radical of Formula VIg,
claim 1
bg is 0, 1, 2, or 3; eg is 0 or 1; R18 l is a hydrogen atom, a normal or branched C1-C8-alkyl group, a halogen substituted normal or branched C1-C 8-alkyl group, a C3-C8-cycloalkyl group, a C3-C8-cycloalkyl-C 1-C4-alkyl group, an aryl group or a substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups.
12. The compound of wherein G is a monovalent radical of Formula VIIg,
claim 1
dg is 0, 1, 2, or 3; eg is 0 or 1; R19 l and R20 l are, independently, a hydrogen atom, a normal or branched C1-C8-alkyl group, a halogen-substituted C1-C8-alkyl group, a C3-C8-cycloalkyl group, a C3-C 8-cycloalkyl-C1-C4-alkyl group, an aryl group or a substituted aryl group wherein the aryl substituents comprise one or more halogen atoms or one or more alkoxy, trifluoromethyl, dioxymethylene, nitro, cyano, C1-C7-alkoxycarbonyl, C1-C7-alkylsulfonyl, amino, or C1-C7-dialkylamino groups; a heteroaryl or substituted heteroaryl group derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more C1-C6-alkyl, hydroxyl or phenyl groups; or R19 l, R20 l and the nitrogen atom form a ring system comprising 6 or fewer carbon atoms.
14. A compound of the formula
A-B-D-E-F-G
wherein A is N,N-dimethylvalyl, B is tertiary-leucyl, D is N-methylvalyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and C is a monovalent radical.
15. A compound of the formula
A-B-D-E-F-G
wherein A is N,N-dimethylvalyl, B is valyl, D is N-methyl-tertiaryleucyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and G is a monovalent radical.
16. A compound of the formula
A-B-D-E-F-G
wherein A is N-methyl-d-prolyl, B is valyl, D is N-methylvalyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and G is a monovalent radical.
17. A compound of the formula
A-B-D-E-F-G
wherein A is N-methylhomoprolyl, B is valyl, D is N-methylvalyl, E is prolyl, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue and G is a monovalent radical.
18. A compound of the formula Me2Val-Val-MeVal-Pro-F-G,
wherein F is of Formula IIf and Rf is a hydrogen atom or a methyl group, R1 f and R2 f are each a hydrogen atom, an alkyl group or an alkoxy group, and G is an amino group, an N-substituted amino group, a hydrazido, an alkyl, cycloalkyl, aryl, or alkylaryl, an alkylene ester, an alkylene amide, an alkylene sulfoxide or an alkylene sulfone group or a monovalent radical of the formula —O—R13 l or —S—R13 l, and R13 l is an alkyl, aryl or alkylaryl group.
19. A compound of the formula Me2Val-Val-MeVal-Pro-F-G,
wherein F is of Formula IIIf, Rf is a hydrogen atom or a methyl group, af is 1 or 2, and G is an amino group, an N-substituted amino group, a hydrazido, an alkyl, cycloalkyl, aryl, or alkylaryl, an alkylene ester, an alkylene amide, an alkylene sulfoxide or an alkylene sulfone group or a monovalent radical of the formula —O—R13 l or —S—R13 l, and R13 l is an alkyl, aryl or alkylaryl group.
20. A method for treating cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of .
claim 1
21. The method of claim 45 wherein the mammal is a human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/756,593 US20010018422A1 (en) | 1998-07-08 | 2001-01-08 | Dolastatin 15 derivatives |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/112,249 US5985837A (en) | 1998-07-08 | 1998-07-08 | Dolastatin 15 derivatives |
PCT/US1999/014099 WO2000002906A1 (en) | 1998-07-08 | 1999-06-23 | Dolastatin 15 derivatives |
US09/756,593 US20010018422A1 (en) | 1998-07-08 | 2001-01-08 | Dolastatin 15 derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/014099 Continuation WO2000002906A1 (en) | 1998-07-08 | 1999-06-23 | Dolastatin 15 derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010018422A1 true US20010018422A1 (en) | 2001-08-30 |
Family
ID=22342878
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/112,249 Expired - Fee Related US5985837A (en) | 1998-07-08 | 1998-07-08 | Dolastatin 15 derivatives |
US09/756,593 Abandoned US20010018422A1 (en) | 1998-07-08 | 2001-01-08 | Dolastatin 15 derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/112,249 Expired - Fee Related US5985837A (en) | 1998-07-08 | 1998-07-08 | Dolastatin 15 derivatives |
Country Status (14)
Country | Link |
---|---|
US (2) | US5985837A (en) |
EP (1) | EP1093460A1 (en) |
JP (1) | JP2002520335A (en) |
KR (1) | KR20010053428A (en) |
CN (1) | CN1312817A (en) |
AU (1) | AU4708199A (en) |
BR (1) | BR9911932A (en) |
CA (1) | CA2332641A1 (en) |
HK (1) | HK1041007A1 (en) |
HU (1) | HUP0103560A3 (en) |
IL (1) | IL140578A0 (en) |
NO (1) | NO20010046L (en) |
WO (1) | WO2000002906A1 (en) |
ZA (1) | ZA200100169B (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004010957A3 (en) * | 2002-07-31 | 2004-06-10 | Seattle Genetics Inc | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004052916A2 (en) * | 2002-12-06 | 2004-06-24 | Adaptive Therapeutics, Inc. | Novel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids |
US20040157782A1 (en) * | 2001-04-30 | 2004-08-12 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US20050009751A1 (en) * | 2001-04-30 | 2005-01-13 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20050107289A1 (en) * | 2001-05-04 | 2005-05-19 | The Scripps Research Institute | Anti-microbial peptides and compositions |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US7745394B2 (en) | 2003-11-06 | 2010-06-29 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4776843B2 (en) | 1999-10-01 | 2011-09-21 | イムノゲン インコーポレーティッド | Cancer composition and method using immunoconjugate and chemotherapeutic agent |
AU2002334192A1 (en) * | 2001-10-17 | 2003-04-28 | Instituto Biomar S.A. | Cytotoxic compounds |
BR0307178A (en) * | 2002-01-22 | 2004-12-07 | Du Pont | Compound, composition and method for invertebrate pest control |
GB0329572D0 (en) * | 2003-12-20 | 2004-01-28 | Astrazeneca Ab | Amide derivatives |
JP4954983B2 (en) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | BIR domain binding compound |
NZ572836A (en) | 2006-05-16 | 2011-12-22 | Pharmascience Inc | Iap bir domain binding compounds |
CA2789629A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc. | Cd20 antibodies and uses thereof |
RU2567544C2 (en) | 2010-02-12 | 2015-11-10 | Фармасайенс Инк. | Bir domain iap binding compounds |
CN102173999A (en) * | 2011-02-28 | 2011-09-07 | 盐城工学院 | Method for synthesizing 2-amino-N,N-dimethylbenzamide |
WO2012145112A2 (en) | 2011-04-18 | 2012-10-26 | Immunogen, Inc. | Novel maytansinoid derivatives with sulfoxide linker |
HUE053589T2 (en) | 2011-11-17 | 2021-07-28 | Pfizer | Cytotoxic peptides and antibody drug conjugates thereof |
RU2015116480A (en) | 2012-11-07 | 2016-12-27 | Пфайзер Инк. | Anti-notch3 antibodies and drug conjugants |
WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
AU2014228822A1 (en) | 2013-03-15 | 2015-10-01 | Memorial Sloan-Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
US10722593B2 (en) | 2015-10-02 | 2020-07-28 | Sirenas Llc | Anti-cancer compounds and conjugates thereof |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5857A (en) * | 1848-10-17 | Flood-fence | ||
US5860A (en) * | 1848-10-17 | peters | ||
US13071A (en) * | 1855-06-12 | Joshua turner | ||
US29177A (en) * | 1860-07-17 | Improvement in planishing copper vessels | ||
US29258A (en) * | 1860-07-24 | Improvement in capstans for ditching-plows | ||
US32091A (en) * | 1861-04-16 | Improvement in corn-planters | ||
US35506A (en) * | 1862-06-10 | Improvement in parlor-stoves | ||
US42772A (en) * | 1864-05-17 | Improvement in apparatus for distilling off gases, and vapors | ||
US49617A (en) * | 1865-08-29 | Inkstand | ||
US49818A (en) * | 1865-09-05 | Improvement in seeding-machines | ||
US52764A (en) * | 1866-02-20 | Improved machine for extracting essential oils | ||
US54115A (en) * | 1866-04-24 | Improved hair-curling fluid | ||
US55861A (en) * | 1866-06-26 | Improvement in machines for fine-cutting tobiacco | ||
US69077A (en) * | 1867-09-24 | Josiah copley | ||
US4346442A (en) * | 1980-07-29 | 1982-08-24 | Merrill Lynch, Pierce, Fenner & Smith Incorporated | Securities brokerage-cash management system |
US4648037A (en) * | 1984-03-15 | 1987-03-03 | Metropolitan Life Insurance Company | Method and apparatus for benefit and financial communication |
US4750121A (en) * | 1985-10-03 | 1988-06-07 | Halley Gustavo M | Pension benefits system |
US4969094A (en) * | 1989-05-22 | 1990-11-06 | Pension Benefits System Trust | Self-implementing pension benefits system |
US5136502A (en) * | 1991-10-02 | 1992-08-04 | Fred Van Remortel | System for funding, analyzing and managing health care liabilities |
US5429506A (en) * | 1993-04-05 | 1995-07-04 | Westport Management Services, Inc. | Method of computerized administration of a life insurance plan using computerized administration supervisory system |
US5590037A (en) * | 1993-09-17 | 1996-12-31 | The Evergreen Group Incorporated | Digital computer system and methods for computing a financial projection and an illustration of a prefunding program for an employee benefit |
US5897620A (en) * | 1997-07-08 | 1999-04-27 | Priceline.Com Inc. | Method and apparatus for the sale of airline-specified flight tickets |
US5913198A (en) * | 1997-09-09 | 1999-06-15 | Sbp Services, Inc. | System and method for designing and administering survivor benefit plans |
US5960411A (en) * | 1997-09-12 | 1999-09-28 | Amazon.Com, Inc. | Method and system for placing a purchase order via a communications network |
US5966693A (en) * | 1996-05-07 | 1999-10-12 | Money Accumulation Programs, Inc. | Method for combining loan with key employee life insurance |
US5970478A (en) * | 1997-03-12 | 1999-10-19 | Walker Asset Management Limited Partnership | Method, apparatus, and program for customizing credit accounts |
US6092047A (en) * | 1997-10-07 | 2000-07-18 | Benefits Technologies, Inc. | Apparatus and method of composing a plan of flexible benefits |
US6154732A (en) * | 1997-07-25 | 2000-11-28 | Guidedchoice.Com | System for providing investment advice and management of pension assets |
US6322125B2 (en) * | 1999-02-09 | 2001-11-27 | Cordell Eric Bauer | Truck bed extension |
US6370571B1 (en) * | 1997-03-05 | 2002-04-09 | At Home Corporation | System and method for delivering high-performance online multimedia services |
US6389457B2 (en) * | 1998-05-29 | 2002-05-14 | Research In Motion Limited | System and method for pushing information from a host system to a mobile data communication device |
US6401079B1 (en) * | 1999-10-01 | 2002-06-04 | Inleague, Inc. | System for web-based payroll and benefits administration |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816444A (en) * | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US4879278A (en) * | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US5091368A (en) * | 1990-08-08 | 1992-02-25 | Harbor Branch Oceanographic Institution, Inc. | Biologically active compounds from blue-green algae |
ES2172069T3 (en) * | 1991-08-09 | 2002-09-16 | Teikoku Hormone Mfg Co Ltd | TETRAPEPTIDIC DERIVATIVE |
IL105651A (en) * | 1992-05-20 | 1998-07-15 | Basf Ag | Dolastatin derivatives their preparation and pharmaceutical compositions containing them |
US5831002A (en) * | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
ATE196296T1 (en) * | 1992-12-16 | 2000-09-15 | Basf Ag | DOLASTATIN ANALOGUE |
US5504191A (en) * | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5530097A (en) * | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) * | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5807984A (en) * | 1995-11-09 | 1998-09-15 | Basf Aktienegesellschaft | Oligopeptides, the preparation and use thereof |
TW474946B (en) * | 1995-12-15 | 2002-02-01 | Basf Ag | Novel compounds, the preparation and use thereof |
-
1998
- 1998-07-08 US US09/112,249 patent/US5985837A/en not_active Expired - Fee Related
-
1999
- 1999-06-23 CA CA002332641A patent/CA2332641A1/en not_active Abandoned
- 1999-06-23 WO PCT/US1999/014099 patent/WO2000002906A1/en not_active Application Discontinuation
- 1999-06-23 BR BR9911932-3A patent/BR9911932A/en not_active IP Right Cessation
- 1999-06-23 CN CN99809741A patent/CN1312817A/en active Pending
- 1999-06-23 AU AU47081/99A patent/AU4708199A/en not_active Abandoned
- 1999-06-23 KR KR1020017000268A patent/KR20010053428A/en not_active Application Discontinuation
- 1999-06-23 IL IL14057899A patent/IL140578A0/en unknown
- 1999-06-23 EP EP99930569A patent/EP1093460A1/en not_active Withdrawn
- 1999-06-23 HU HU0103560A patent/HUP0103560A3/en unknown
- 1999-06-23 JP JP2000559135A patent/JP2002520335A/en not_active Withdrawn
-
2001
- 2001-01-04 NO NO20010046A patent/NO20010046L/en not_active Application Discontinuation
- 2001-01-08 ZA ZA200100169A patent/ZA200100169B/en unknown
- 2001-01-08 US US09/756,593 patent/US20010018422A1/en not_active Abandoned
-
2002
- 2002-03-12 HK HK02101870.1A patent/HK1041007A1/en unknown
Patent Citations (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5857A (en) * | 1848-10-17 | Flood-fence | ||
US5860A (en) * | 1848-10-17 | peters | ||
US13071A (en) * | 1855-06-12 | Joshua turner | ||
US29177A (en) * | 1860-07-17 | Improvement in planishing copper vessels | ||
US29258A (en) * | 1860-07-24 | Improvement in capstans for ditching-plows | ||
US32091A (en) * | 1861-04-16 | Improvement in corn-planters | ||
US35506A (en) * | 1862-06-10 | Improvement in parlor-stoves | ||
US42772A (en) * | 1864-05-17 | Improvement in apparatus for distilling off gases, and vapors | ||
US49617A (en) * | 1865-08-29 | Inkstand | ||
US49818A (en) * | 1865-09-05 | Improvement in seeding-machines | ||
US52764A (en) * | 1866-02-20 | Improved machine for extracting essential oils | ||
US54115A (en) * | 1866-04-24 | Improved hair-curling fluid | ||
US55861A (en) * | 1866-06-26 | Improvement in machines for fine-cutting tobiacco | ||
US69077A (en) * | 1867-09-24 | Josiah copley | ||
US4346442A (en) * | 1980-07-29 | 1982-08-24 | Merrill Lynch, Pierce, Fenner & Smith Incorporated | Securities brokerage-cash management system |
US4648037A (en) * | 1984-03-15 | 1987-03-03 | Metropolitan Life Insurance Company | Method and apparatus for benefit and financial communication |
US4750121A (en) * | 1985-10-03 | 1988-06-07 | Halley Gustavo M | Pension benefits system |
US4969094A (en) * | 1989-05-22 | 1990-11-06 | Pension Benefits System Trust | Self-implementing pension benefits system |
US5136502A (en) * | 1991-10-02 | 1992-08-04 | Fred Van Remortel | System for funding, analyzing and managing health care liabilities |
US5429506A (en) * | 1993-04-05 | 1995-07-04 | Westport Management Services, Inc. | Method of computerized administration of a life insurance plan using computerized administration supervisory system |
US5590037A (en) * | 1993-09-17 | 1996-12-31 | The Evergreen Group Incorporated | Digital computer system and methods for computing a financial projection and an illustration of a prefunding program for an employee benefit |
US5966693A (en) * | 1996-05-07 | 1999-10-12 | Money Accumulation Programs, Inc. | Method for combining loan with key employee life insurance |
US6370571B1 (en) * | 1997-03-05 | 2002-04-09 | At Home Corporation | System and method for delivering high-performance online multimedia services |
US5970478A (en) * | 1997-03-12 | 1999-10-19 | Walker Asset Management Limited Partnership | Method, apparatus, and program for customizing credit accounts |
US5897620A (en) * | 1997-07-08 | 1999-04-27 | Priceline.Com Inc. | Method and apparatus for the sale of airline-specified flight tickets |
US6154732A (en) * | 1997-07-25 | 2000-11-28 | Guidedchoice.Com | System for providing investment advice and management of pension assets |
US5913198A (en) * | 1997-09-09 | 1999-06-15 | Sbp Services, Inc. | System and method for designing and administering survivor benefit plans |
US5960411A (en) * | 1997-09-12 | 1999-09-28 | Amazon.Com, Inc. | Method and system for placing a purchase order via a communications network |
US6092047A (en) * | 1997-10-07 | 2000-07-18 | Benefits Technologies, Inc. | Apparatus and method of composing a plan of flexible benefits |
US6389457B2 (en) * | 1998-05-29 | 2002-05-14 | Research In Motion Limited | System and method for pushing information from a host system to a mobile data communication device |
US6401113B2 (en) * | 1998-05-29 | 2002-06-04 | Research In Motion Limited | System and method for pushing information from a host system to a mobile data communication device |
US6322125B2 (en) * | 1999-02-09 | 2001-11-27 | Cordell Eric Bauer | Truck bed extension |
US6401079B1 (en) * | 1999-10-01 | 2002-06-04 | Inleague, Inc. | System for web-based payroll and benefits administration |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098308B2 (en) | 2001-04-30 | 2006-08-29 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US7423116B2 (en) | 2001-04-30 | 2008-09-09 | Seattle Genetics Inc. | Pentapeptide compounds and uses related thereto |
US20040157782A1 (en) * | 2001-04-30 | 2004-08-12 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20050009751A1 (en) * | 2001-04-30 | 2005-01-13 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20050113308A1 (en) * | 2001-04-30 | 2005-05-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20050107289A1 (en) * | 2001-05-04 | 2005-05-19 | The Scripps Research Institute | Anti-microbial peptides and compositions |
US7700615B2 (en) | 2002-06-04 | 2010-04-20 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US20060128742A1 (en) * | 2002-06-04 | 2006-06-15 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
US20060074008A1 (en) * | 2002-07-31 | 2006-04-06 | Senter Peter D | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20090324621A1 (en) * | 2002-07-31 | 2009-12-31 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7659241B2 (en) | 2002-07-31 | 2010-02-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004010957A3 (en) * | 2002-07-31 | 2004-06-10 | Seattle Genetics Inc | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8906376B2 (en) | 2002-07-31 | 2014-12-09 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7829531B2 (en) | 2002-07-31 | 2010-11-09 | Seattle Genetics Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7851437B2 (en) | 2002-07-31 | 2010-12-14 | Seattle Genetics Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004052916A3 (en) * | 2002-12-06 | 2004-09-16 | Adaptive Therapeutics Inc | Novel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids |
WO2004052916A2 (en) * | 2002-12-06 | 2004-06-24 | Adaptive Therapeutics, Inc. | Novel cyclic peptides comprising cis-3 aminocycloalkanecarboxylic acids |
US8703714B2 (en) | 2003-11-06 | 2014-04-22 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10808039B2 (en) | 2003-11-06 | 2020-10-20 | Seattle Genetics Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US7745394B2 (en) | 2003-11-06 | 2010-06-29 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10414826B2 (en) | 2003-11-06 | 2019-09-17 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US8557780B2 (en) | 2003-11-06 | 2013-10-15 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
US10981987B2 (en) | 2007-07-16 | 2021-04-20 | Genentech, Inc. | Humanized anti-CD79b antibodies and immunoconjugates and methods of use |
US10494432B2 (en) | 2007-07-16 | 2019-12-03 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
USRE48558E1 (en) | 2007-07-16 | 2021-05-18 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US11866496B2 (en) | 2007-07-16 | 2024-01-09 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
US10544218B2 (en) | 2008-01-31 | 2020-01-28 | Genentech, Inc. | Anti-CD79B antibodies and immunoconjugates and methods of use |
US11000510B2 (en) | 2014-09-23 | 2021-05-11 | Genentech, Inc. | Methods of using anti-CD79b immunoconjugates |
WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2023280227A2 (en) | 2021-07-06 | 2023-01-12 | Profoundbio Us Co. | Linkers, drug linkers and conjugates thereof and methods of using the same |
Also Published As
Publication number | Publication date |
---|---|
WO2000002906A1 (en) | 2000-01-20 |
CA2332641A1 (en) | 2000-01-20 |
NO20010046D0 (en) | 2001-01-04 |
EP1093460A1 (en) | 2001-04-25 |
NO20010046L (en) | 2001-03-02 |
BR9911932A (en) | 2001-10-16 |
JP2002520335A (en) | 2002-07-09 |
HUP0103560A3 (en) | 2002-05-28 |
HK1041007A1 (en) | 2002-06-28 |
KR20010053428A (en) | 2001-06-25 |
US5985837A (en) | 1999-11-16 |
ZA200100169B (en) | 2002-01-08 |
CN1312817A (en) | 2001-09-12 |
HUP0103560A2 (en) | 2002-02-28 |
AU4708199A (en) | 2000-02-01 |
IL140578A0 (en) | 2002-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5985837A (en) | Dolastatin 15 derivatives | |
Frérot et al. | PyBOP® and PyBroP: Two reagents for the difficult coupling of the α, α-dialkyl amino acid, Aib. | |
EP0797447B1 (en) | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides | |
US5965537A (en) | Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus | |
AU2020283744A1 (en) | Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications | |
JPH072894A (en) | Drastatin 10 derivative | |
JP5289662B2 (en) | Methods for synthesizing aplidine and novel antitumor derivatives, methods for making and using them. | |
CZ376597A3 (en) | Dolastatin derivative, process of its preparation and use | |
US20240033318A1 (en) | Peptidyl inhibitors of calcineurin-nfat interaction | |
JP2001103993A (en) | Cyclic peptide and serine protease inhibitor | |
Doi | Synthesis of the biologically active natural product cyclodepsipeptides apratoxin A and its analogues | |
US5939527A (en) | Tetrapeptides as antitumor agents | |
GB1577115A (en) | Container closure units | |
AU2005243834A1 (en) | Camptothecin derivatives conjugated in position 20 with integrin antagonists | |
Klein et al. | Design and preparation of cyclopeptamine antifungal agents | |
WO2002050102A2 (en) | Inhibitors of the e2f-1/cyclin interaction for cancer therapy | |
TW200538123A (en) | 7-t-butoxyiminomethylcamptothecin conjugated in position 20 with integrin antagonists | |
Vezenkov et al. | New Derivatives of Galantamine Containing Peptide Fragment | |
WO2023110138A1 (en) | Inhibitors of transglutaminases | |
Kotoku et al. | Absolute stereo-structure of kendarimide A, a novel MDR modulator, from a marine sponge | |
KR101830838B1 (en) | Pharmaceutical composition comprising peptidomimetic compounds for preventing and treating rheumatoid arthritis | |
EP0375058B1 (en) | New retro-inverso analogues of trymopentin, the method for their synthesis and their use in the preparation of pharmaceutical compositions | |
Fauchère et al. | Synthesis, Characterization, and Biological Properties of Five Enkephalin‐like Pentapeptides Containing p‐Nitrophenylalanine | |
US4199568A (en) | Tetrapeptide amides | |
CZ200168A3 (en) | Dolastatin 15 derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- INCOMPLETE APPLICATION (PRE-EXAMINATION) |